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Abstract 
This thesis describes work towards the biomimetic synthesis and understanding the 
biosynthesis of two families of natural products: prodiginines and quartromicins. 
Prodiginines are a large family of red pigmented tripyrrole antibiotics. Although they 
have not been used clinically, the promising anti-cancer, immunosuppressive and anti-
malarial activity they display at non-toxic doses has generated renewed interest in their 
utilisation. The synthesis of an analogue of the proposed pyrrole-2-carboxyl-RedO 
intermediate in prodiginine biosynthesis has been achieved. The resulting NAC 
thioester and analogues of it have been used to investigate the prodiginine biosynthetic 
pathway in Streptomyces coelicolor, and to examine the production of prodiginine 
analogues by mutasynthesis. 
Quartromicins, novel anti-viral antibiotics, are a structurally unIque group of 
spirotetronate natural products produced by Amycolatopsis species. They are unusual 
symmetric macro cyclic compounds which possess a 32-membered carbocyclic structure 
with four spirotetronic acid units connected by enone or dienone linkers in a head-to-tail 
fashion. These macrocyclic compounds are intriguing because they have alternating 
endo- and exo- spirotetronic acid units, with the opposite "comers" being identical. 
Although the quartromicins have therapeutic potential, very little is known about their 
biosynthesis. In this research a biosynthetic pathway to the quartromicins has been 
proposed based on hypothetical pathways to related natural products. The synthesis of 
the two putative key intermediates in quartromicin biosynthesis has been achieved. An 
improved method for the synthesis of exomethylene tetronates has been developed, and 
XVl11 
novel rearrangements have been discovered. The two putative key intermediates have 
been used to investigate the biomimetic synthesis of the carbon skeleton of the 
quartromicin algycone, and mass spectrometric evidence for formation of homo- and 
heterodimers, and a heterotetramer of the key intermediates has been obtained. 
XIX 
List of Abbreviations 
1,3-BPG 1,3-bisphosphoglycerate 
6DeB 6-deoxyerythronolide B 
A adenylation 
ACP acyl carrier protein 
AD asymmetric dihydroxylation 
AIBN 2,2' -azobisisobutyronitrile 
AIDS acquired immune deficiency syndrome 
AMV avian myeloblastosis virus 
AT acyltransferase 
ATP adenosine triphosphate 
AZT 3-azido-2',3' -dideoxythymidine 
B.C. before christ 
BLAST basic local alignment search tool 
BOC tert-butyloxycarbonyl 
BuLi butyl lithium 
C condensation 
CD4+ T cells expressing CD4 protein 
CoA coenzyme A 
COSY correlation spectroscopy 
CPE cytopathic effect 
DBU 1,8-Diazabicyclo[S.4.0]undec-7-ene 
DCC dicyclohexylcarbodiimide 
DCE 1,2-dichloroethane 
xx 
DCM 
DEBS 
DH 
DIBAL-H 
DMAP 
DMF 
DMF-DMA 
DMSO 
DNA 
dppe 
E 
EDCI 
ER 
FAB-MS 
FAD 
FAS 
FMN 
HIV 
HMBC 
HMDS 
HMPA 
HMQC 
HPLC 
HRMS 
HSV-l 
dichloromethane 
6-deoxylerythronolide B synthase 
dehydratase 
diisobutyl aluminum hydride 
4-dimethylaminopyridine 
dimethyl formamide 
dimethyl formamide dimethyl acetyl 
dimethylsulfoxide 
deoxyribonucleic acid 
1 ,2-bis( diphenylphosphino )ethane 
epimerisation 
l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
enoylreductase 
fast atom bombardment mass spectroscopy 
flavin adenine dinucleotide 
fatty acid synthase 
flavin mononucleotide 
human immunodeficiency virus 
heteronuclear multiple bond connectivity 
hexamethyldisilazide 
hexamethylphosphoramide 
heteronuclear multiple quantum coherence 
high performance liquid chromatography 
high resolution mass spectrometry 
herpes simplex virus type 1 
XXI 
HTLV 
IL-2 
IMDA 
IR 
JAK-3 
KAPA 
KR 
KS 
LC-MS 
LDA 
LNKS 
LTMP 
M 
MBC 
MDCK 
Min 
MM 
MOM 
MPS 
MS 
Ms 
NADH 
NADPH 
NMR 
NRPS 
human T -celllymphotrophic virus 
inter-Ieukin-2 
intramolecular Diels-Alder 
infra-red 
Janus Kinase 3 
7 -keto-8-aminopelargonic acid 
ketoreductase 
~-ketoacyl synthase 
liquid chromatography mass spectrometry 
lithium diisopropylamide 
lovastatin nonaketide synthase 
lithium tetramethylpiperidine 
molar 
4-methoxy-2,-2' -bipyrrole-5-carboxaldehyde 
Madin-Darby canine kidney 
minutes 
molecular mechanics 
methoxymethyl 
macrophomate synthase 
mass spectrometry 
mesityl 
nicotinamide adenine dinucleotide 
nicotinamide adenine dinucleotide phosphate 
nuclear magnetic resonance 
non-ribosomal peptide synthetase 
XXll 
OAS 
PCP 
PEPS 
PKS 
PLA2 
PLP 
PPDK 
PPTase 
PPTS 
QM 
r.t. 
SAM 
SAR 
Sat. 
sp. 
TASF 
TBAF 
TBDPS 
TBS 
TE 
t-
Tf 
TFA 
THF 
TMPH 
oxoamine synthase 
peptidyl carrier protein 
phosphoenol pyruvate synthase 
polyketide synthetase 
phospholipase A2 
pyridoxal 5' -phosphate 
phosphate pyruvate dikinase 
phosphopantophenyl transferase 
pyridinium para-toluene sulfonate 
quantum mechanics 
room termperature 
S-Adenosylmethionine 
structure activity relationships 
saturated 
speCIes 
tris( dimethy 1 amino )sulfonium difluorotrimethyl silicate 
tetra-n-butylammonium fluoride 
tert-butyldiphenylsilyl 
tert-butyldimethylsilyl 
thioesterase 
tertiary 
trifluoromethanesulfonyl 
trifluoroacetic acid 
tetrahydrofuran 
2,2,6,6-tetramethylpiperidine 
XXIll 
1NF -(1 and -~ 
Tr 
UP 
r 
tumour necrosis factor 
trityl 
2-undecylpyrrole 
XXIV 
Chapter J: General Introduction 
Chapter 1: General Introduction 
1.1: Natural Products 
Natural products are chemical compounds or substances that are produced by living 
organisms such as plants, animals and micro-organisms. Many of these abundant natural 
products are produced by secondary metabolism and often exhibit biological or 
pharmacological activities. For example, penicillin G is an antibiotic produced by the 
fungus Penicillium notatum which can be used to treat streptococcal, pneumococcal, 
gonococcal and meningococcal infections. 1 An amazing variety and number of natural 
products are found in nature and more than 100,000 secondary metabolites have been 
characterised to date. Natural products fall into several main categories including 
complex polyketides, aromatic polyketides, peptides, terpenes and aminoglycosides and 
alkaloids (Figure 1). 
Complex Polyketides 
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Figure 1: Natural products classes 
Terpenes 
including complex polyketides: erythromycin A 1, aminoglycosides: kan~ycin 2, alkaloi~: ~affine 3, 
aromatic polyketides: chlorotetracycline 4, terpenes: taxol 5, and peptldes: benzyipemcillm 6 
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Erythromycin A 1 (Figure 2), first isolated in 1952 from Saccharopo/yspora erythraea, 
belongs to the class of complex polyketides. Members of this family, which are 
characterised by macrocycles containing 12, 14 or 16 atoms, show an intriguing 
common structural and stereochemical relationship. Erythromycin A is used clinically 
against infections caused by Gram-positive bacteria, pulmonary infections such as 
legionnaires disease and as an alternative for patients allergic to penicillin.2 It is 
biosynthesised by a polyketide synthase (PKS) which catalyses the sequential 
condensation of one unit of propionyl-CoA and six units of methylmalonyl-CoA to give 
6-deoxyerythronolide B (6DeB), then it is elaborated by a series of tailoring enzymes 
which include regiospecific hydroxylases, glycosyl transferases and methyl 
transferases.2 
o 
I"" OH ,.,\\ 
\,., 0 I"., "'O~ 
I , HO NMe2 
o "0 OH 
~OH 
1 
Figure 2: Erythromycin A 
Gramicidin S 7 was first isolated in 1942 from Bacillus brevis. Gramicidin is toxic 
internally to the human body inducing haemolysis at lower concentrations than bacterial 
cell death. It acts on bacterial membranes, increasing permeability resulting in a loss of 
barrier function. It is a mixture of cyclic peptides biosynthesised by a non-ribosomal 
peptide synthetase (NRPS) system, which constructs a pentapeptide by activating and 
condensing in turn L-phenylalanine (which undergoes epimerization to D-phenyalanine 
after activation), L-proline, L-valine, L-omithine and L-Ieucine, and finally catalysing 
I d· . . 13 cyc 0 ImensatlOn. ' 
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Figure 3: Gramicidin S 
1.2: Biosynthesis of Natural Products 
The most important building blocks employed in the biosynthesis of secondary 
metabolites can be derived from intermediates from the acetyl coenzyme A, shikimic 
acid, mevalonic acid and I-deoxyxylulose-5-phosphate pathways as well as amino 
acids. 
Natural products utilise a broad range of enzymes in biosynthesis including 
nonribosomal peptide synthetases, siderophore synthetases, fatty acid synthases, 
polyketide synthases, non-heme iron-dependent and flavin-dependent oxygenases, acyl 
transferases, pyridoxal 5'-phosphate (PLP)-dependent a-oxoamine synthases and 
decarboxylases, hydro lases, and terpene synthases. Two important types of natural 
product biosynthetic systems are described below. 
1.2.1: Polyketide Synthases (PKSs) 
Detailed studies of amino acid sequences and mechanistic similarities in vanous 
polyketides synthase enzymes have led to three types of PKSs being distinguished. 
3 
Chapter I: Genera/Introduction 
Type I enzymes consist of one or more large multifunctional proteins that possess a 
distinct active site for every enzyme-catalysed step. Type II enzymes consist of multi-
enzyme complexes that carry out a set of repeating reactions. Type III PKSs, leading to 
natural products such as quinolines and flavonoids, involve a homodimeric condensing 
enzyme that utilises coenzyme A esters rather than the acyl carrier proteins used by type 
I and type II enzymes. They also employ a single active site to perform a series of 
decarboxylation, condensation, cyclisation and aromatisation reactions. Usual starter 
units for polyketide biosynthesis are propionyl-CoA or acetyl-CoA and the main 
extender units are malonyl-CoA and methylmalonyl-CoA.1 
6-Deoxyerythronolide B synthase (DEBS) is a modular type I PKS involved in 
erythromycin biosynthesis (Scheme 1) which consists of three large multi-enzymes 
(DEBS-I, 2, and 3) each encoded for by a giant gene (eryA-I, II, and III). It has a linear 
organisation of six modules, each of which contains the activities for one cycle of chain 
extension. These modules are broken down into domains. A minimal module contains 
~-ketoacyl synthase (KS), acyltransferase (AT) and acyl carrier protein (ACP) domains. 
These would catalyse a two carbon chain extension reactions. After each condensation 
reaction the oxidation state of the ~-carbon is determined by the presence of ~-ketoacyl 
reductase (KR), dehydratase (DH) and enoylreductase (ER) domains. The sequence is 
finally terminated by a thioesterase (TE) domain, which releases the polyketide from the 
enzyme. In the case of erythromycin, a propionyl-CoA starter unit is condensed with 
successive methylmalonyl-CoA units to give a 14-carbon chain which can then be 
cyclised, giving 6-deoxyerythronolide B 8 (6DeB).2 
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Another important enzyme is phosphopantetheinyl transferase (pPTase) which is 
required to make the ACP domain active (Scheme 2). The conserved serine residue on 
the ACP is not able to reach all the domains present in each module to allow chain 
extension and modification. The phosphopantetheinyl arm allows an extension of 
approximately 20 A in length and can deliver the substrates to all the different parts of 
th . 1 e protem. 
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SH 
Scbeme 2: PPTase activity 
The acyltransferase (AT) domain has an active site serine residue which is acylated by 
an acyl-CoA starter or extender unit. The resulting AT -ester then reacts with the free 
thiol on the adjacent ACP domain to fonn the ACP-thioester as shown in Scheme 3. In 
erythromycin biosynthesis the AT domain in the loading module recognises and loads a 
propionyl-CoA starter unit followed by transacylation onto the ACP domain. The 
remaining AT domains catalyse the transfer of methylmalonyl-CoA onto the 
corresponding ACP domains of the remaining six chain extension modules. 
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Acyl transferase Load Module 
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Scheme 3: Load module and Module 1 acyltransferase activity 
Once the ACP-thioester has been formed, condensation can occur. The keto synthase 
(KS) domain catalyses transfer of the acyl portion of the thioester from the ACP domain 
onto the KS domain. Decarboxylation of methylmalonyl ACP followed by nucleophilic 
attack on the carbonyl carbon of the KS-thioester, results in the release of the KS-thiol 
giving a two carbon chain extension (Scheme 4). 
Load Module 1 Load Module 1 Module 1 
Scheme 4: Activity of the ketosynthase domain 
After each condensation, the oxidation state of the ~-carbon is determined by the 
presence of KR, KR + DH, or KR + DH + ER domains. For example in module one 
only a KR domain is present, but in module four all three domains are present. 
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The ketoreductase (KR) domain uses NADPH as a hydride source to stereoselectively 
reduce the keto-group formed from the condensation reaction to a hydroxyl group. The 
resulting stereochemistry is specific to each module (Scheme 5).4 
Module 4 Module 4 
s 
0 
' "11 
~ HO 
0 
'"11 NADPH 
HO HO 
Scheme 5: Activity of the ketoreductase domain 
The dehydratase (DH) domain uses an active site histidine residue as a base, catalysing 
the elimination of water across the ~-hydroxy thioester, to give a double bond (Scheme 
6). 
Module 4 Module 4 Module 4 
s 
o 
Scheme 6: Activity of the dehydratase domain 
The a,~-unsaturated double bond is reduced by the enoyl reductase (ER) domain using 
another molecule ofNADPH to give a saturated thioester chain (Scheme 7). 
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Scheme 7: Activity of the enoylreductase domain 
The fmal step in the biosynthesis of 6-DeB is the macrocyc1isation of the linear chain to 
release it from the ACP domain in the last module. This step is catalysed by the 
thioesterase (TE) domain. An active serine residue in the TE domain is acylated with 
the 14-carbon chain attached to the ACP domain in module six. The C-12 hydroxyl 
group then attacks the C-l ester assisted by an active site histidine residue that acts as a 
general base, resulting in release of the chain from the PKS and formation of the 
macrocyc1e 8 (Scheme 8). 
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Scheme 8: Thioesterase-catalysed cyclisation and release of the fully assembled polyketide chain 
1.2.2:Non-Ribosomal Peptide Synthetases (NRPS) 
Non-ribosomal peptide synthetases are responsible for the biosynthesis of peptide 
antibiotics, peptide toxins, many siderophores and modified peptides such as penicillins. 
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cephalosporins and other lactams. The biosynthesis of these compounds is carried out 
by multifunctional enzymes with a modular arrangement rather like type I PKSs. They 
are able to incorporate proteinogenic and non-proteinogenic amino acids into peptides, 
as well as amino acids with D-stereochemistry at the a-carbon. I 
The linear sequence of modules usually corresponds to the generated ammo acid 
sequence in the peptide product. A typical module consists of an adenylation (A) 
domain, a peptidyl carrier protein (PCP) domain and a condensation (C) domain. The A 
domain activates a specific amino acid as an aminoacyl adenylate which is transferred 
to the PCP domain forming an aminoacyl thioester. This A domain requires a co-factor 
A TP for activation of the substrates carbonyl group. Nucleophilic attack by the amino 
group of a downstream amino acyl thioester on the PCP bound amino acid is catalysed 
by the C domain and results in amide bond formation. The PCP is responsible for 
"holding" the growing chain and uses its phosphopantetheinyl arm to deliver the chain 
to the various domains. Additional domains, for example an epimerisation (E) domain 
for epimerising L-amino acids to D-amino acids (probably via an enol ate intermediate) 
in the peptide chain, can also occur. A terminal thioesterase domain is responsible for 
terminating chain assembly and release of the peptide from the enzyme. Cyclisation, 
hydrolysis or oligomerisation-cyclisation can be catalysed by this domain. I 
One example of a natural product assembled by an NRPS is the novel siderophore 
coelichelin 9, recently isolated and characterised from Streptomyces coelicolor.
5
.
6 
In 
silico sequence analysis of the cch cluster, which has been shown to encode all of the 
proteins required for the assembly of the coelichelin molecule, predicted that the CchH 
NRPS enzyme contains three modules suggesting that coelichelin is a tripeptide. with 
10 
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modules one, two and three predicted to incorporate L-o-N-formyl-o-N-
hydroxyornithine, L-threonine and L-o-N-hydroxyornithine respectively. However, 
structural characterisation of coelichelin revealed that it is in fact a tetrapeptide.6 This is 
unusual as there is no literature precedent for the formation of a tetrapeptide by a 
trimodular NRPS. This structure probably arises from iterative use of module one as 
well as the C domain of module two or three. 
cchH cchH 
~-----------------> c=============> 
Module 1 Module 2 Module 3 Module 1 Module 2 
H20 / /CchJ 
O'YOH~: ?:~1rrN' HN;;"NH2 HHO N .... OH HO .... N 
AO 9 0)............ 
Module 3 
Scheme 9: Module organisation of the CchH NRPS catalysing coelichelin 9 biosynthesis 
Initially, the required amino acids are selectively recognised by the A domains and 
activated by reaction with A TP followed by attachment of the phosphopantetbeinyl arm 
of the adjacent PCP domains, which again allows delivery of the thioester to other 
domains in the module analogous to the PPTase in PKSs (Scheme 2). 
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The C domains assemble the peptide by catalysing the condensation of the amino acids 
attached to PCP domains in adjacent modules (Scheme 10). 
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Scheme 10: Condensation of PCP bound amino acids catalysed by the C domain 
The epimerisation domain (E) is able to catalyse the racemisation of the L-amino acids 
via an enolate intermediate. The D-epimer is kinetically selected from the mixture by 
the downstream C domain (Scheme 11).7 
Module I Module I Module I Module 2 
Scheme 11: Epimerisation domain 
The experimentally characterised tetrapeptide structure of coelichelin is consistent with 
the iterative use of the A, PCP and E domains of module one and either the C domain of 
module two or three (Scheme 12). The alternative possibility of a second NRPS has 
been ruled out by expressing the cch cluster in an heterologous host ( trepfomyce 
fungicidicus). 6 
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Module I Module 2 Module 3 Module 1 Module 2 Module 3 
Scheme 12: Iterative domain use and domain skipping believed to occur in coelichelin biosynthesis 
In the majority ofNRPS systems a thioesterase (TE) domain catalyses the release of the 
assembled peptide chain from the NRPS, either by cyclisation or hydrolysis. l The 
thioesterase is usually located at the C-terminus of the final module. Transacylation of 
the active thioester to the serine residue of the thioesterase domain, followed by 
deprotonation of an amino or hydroxyl group facilitates cyclisation by attack on the 
carbonyl group of the thioester (as seen in the case of gramicidin S 78) , or deprotonation 
of water leads to cleavage by hydrolysis (Scheme 13). Reductase domains that catalyse 
chain release via NADPH-dependent reduction of the acyl thioester can replace the TE 
domain at the C-terminus of the last module. 1 
13 
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Scheme 13: Chain release by cyclisation or hydrolysis catalysed by the thioesterase domain 
However, another unusual feature in coelichelin biosynthesis is that CchH does not 
contain a thioesterase or a reductase domain at the C-terminus of the final module 
(Scheme 9) to catalyse cleavage of the thioester bond between the fully assembled 
peptide and the last PCP domain. In this case, it is predicted that another protein CchJ 
catalyses the hydrolysis of the peptide to form coelichelin (Scheme 9).6,9 
1.3: Biomimetic Synthesis 
The biomimetic synthesis of a natural product is where one or more steps of a chemical 
route mimic the equivalent steps in the biosynthetic pathway. Biomimetic synthesis also 
allows a postulated biosynthetic route to be probed by looking into the chemical 
feasibility of a key step or steps in vitro. 
Rapoport and Holden carried out a biomimetic synthesis of prodigiosin 12. 10 In the 
final step of their total synthesis there is an acid catalysed condensation of 2-methyl-3-
pentylpyrrole 11 with aldehyde 10, which directly mimics the final proposed 
condensation step in the biosynthesis (Scheme 14).) 1 
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Scheme 14: Biomimetic lO and biosynthetic assembly II of prodigiosin 
Roush and co-workers reported a biomimetic intra and intermolecular Diels-Alder 
reaction to complete the synthesis of chlorothricolide 16, the algycone of 
chlorothricin.12,13 Based on the knowledge of the relative reactivity of the alkene 
components, they chose 13 and 14 as their key synthetic intermediates. The Diels-Alder 
reaction of 13 and 14 took place at 120°C in toluene with high diastereoselectivity. This 
provides strong support for the biosynthetic proposal that spirotetronates are synthesised 
by Diels-Alder reactions (Scheme 15). 
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Scheme 15: Biomimetic synthesis of chlorothricolide 16 
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More recently, both Sorensen and Snider have successfully completed biomimetic 
) th · tural d t 14.15 syntheses of abyssomicin C 19 (Scheme 16 ,ano er sprrotetronate na pro uc. 
It is proposed that this spirotetronate is formed via a Diels-Alder cyclisation in the 
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biosynthetic pathway. Both groups managed to chemically mimic this diastereoselective 
Diels-Alder reaction to give direct access to the natural product. 
Diels-A1der 0 o 
17 HO 
18 19 
Scheme 16: Biomimetic synthesis ofabyssomicin e 19 
Diels-Alder conditions; Snider - chloroform, 70oe, 2 days; Sorensen - toluene, lOOoe, 4 h 
1.4: Aims of the Research Reported in this Thesis 
The research reported in this thesis focused on the biosynthesis and biomimetic 
synthesis of natural products. Initially investigations into the biosynthetic pathway of 
the prodiginines were undertaken. By understanding the biosynthetic pathway it may be 
possible to produce analogues of the prodiginines allowing more potent and less toxic 
drugs to be developed. Secondly, the biosynthetic and biomimetic synthesis of the 
quartromicins was examined. To date no total synthesis has been accomplished and 
little IS known about the biosynthesis of these fascinating compounds. 
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2.1: Introduction to Streptomyces coelicolor 
Streptomyces coelicolor is a Streptomycete, which is a group of GC-rich gram-positive 
actinobacteria that reside in the soil. Streptomycetes are well known for producing a 
large variety of antibiotics. Around two-thirds of the known antibiotics produced by 
micro-organisms are biosynthesised by actinomycetes and approximately 80% of these 
are produced by Streptomyces Spp.16 Some examples of natural products produced by S. 
coelicolor are shown in Figure 4, giving an indication of the wide variety of natural 
products that can be produced by one micro-organism. 
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Figure 4: Examples ofthe number of diverse natural products produced by S. coelicolor 
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2.2: Isolation and Structures of Prodiginines 
Prodiginines are a large family of red pigmented 
antibiotics sharing the same unique structural core as 
prodigiosin 12, which are produced by several 
actinomycetes and other eubacteria. The major pigment 
of Serratia marcescens, originally named prodigiosine, 
now known as prodigiosin was ftrst isolated in 1902. Many methods have been used for 
. . I· 17 18 H . Its ISO atlOn.' owever, ItS structure was only determined in 1960 through total and 
partial synthesis.1o This discovery led to many other prodigiosin related pigments being 
isolated. 
Prodigiosin is a typical secondary metabolite and its intense red colour is due to the 
highly conjugated planar pyrrolylpyrromethene chromophore. 19 The prodigiosin 
pyrrolylpyrromethene skeleton consists of three pyrrole rings of which two are directly 
linked, generating a bipyrrole unit (pyrrole ring A and the methyoxypyrrole ring B) and 
the third, a monopyrrole unit (ring C), joined via a methene bridge 20 (Figure 5). Gerber 
suggested molecules with this tripyrrole aromatic moiety should be known as 
prodiginines.2o 
12 20 
Figure 5: Prodigiosin 12 and the prodigiosin pyrrolylpyrromethene skeleton 20 
There are many structural variations within the prodiginine family. Several of these are 
produced by actinomycetes, including the linear prodiginine (undecylprodiginine) 21 
18 
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originally isolated from Streptomyces sp. Y -42, and several cyclic derivatives; butyl-
meta-cycloheptylprodiginine (Streptorubin B) 22, ethyl-meta-cyclononylprodiginine 
(Streptorubin A) 23, and methylcyclodecylprodigine 24. Some more significant structural 
differences are also seen for example in the anti-tumour antibiotics BE18591 25 and 
roseophilin 26, first isolated in 1998 from Streptomyces sp. BA 18591 and Streptomyces 
griseoviridis respectively,21,22 which are also considered members of the prodiginine 
family.23 The latter of these contains a methoxyfuran in place of the methoxypyrrole ring 
(Figure 6). 
OMe 
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Figure 6: Members of the prodiginine family 
2.3: History of the Prodiginine Pigments 
The story of the prodiginine pigments began a long time ago. Accounts from Europe 
recording "blood" found on food date as far back as 322 B.C to Alexander the Great's 
siege on the city of Tyre. Macedonian troops were disturbed when trickles of "blood" 
were seen on broken bread and they believed it to be a sign of terrible things to come. A 
soothsayer Aristander predicted it as a good omen demonstrating the blood to be shed in 
the besieged town inflicted by Alexander's men, and was rewarded for his prophecy?4 
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Many reports exist of red pigments observed on bread and wafers used for Eucharistic 
liturgy and gradually there became a link with religious and superstitious beliefs for 
Jews and Christians. The most famous example, now referred to as the miracle of 
Bolsena, occurred in 1263. A priest who was struggling with loss of faith noticed 
"blood" as he celebrated mass on a pilgrimage to Rome. He declared the miracle should 
be celebrated as Corpus Christi, and it is still celebrated today. However, many blamed 
maleficent spirits and witchcraft for these events.24,25 
In the 19th century, Sette and Bizio separately investigated these apparent blood-like 
traces which led to significant understanding of their formation and massive advances in 
the understanding of microbiology. Although both Bizio and Sette both made the same 
mistake and thought a fungus was responsible, they were the first to suggest that a living 
organism produced the red pigment. 24 
2.4: Biological Activities of the Prodiginine Family 
Although the prodiginine family have an extremely broad range of antibiotic activities 
being active against Gram-positive bacteria, protozoa, and pathogenic fungi they have 
not been used clinically owing to their toxicity at therapeutic doses. Despite attempts to 
optimise their application profile by studies of the structure activity relationships (SAR), 
it appears that the therapeutic window is too narrow for clinical development in this 
area.26,27 Therefore the interest in these compounds died out after initial investigations 
early last century. However, today there is renewed interest mainly due to the fmding 
that they are potent immunosuppressants. Extensive work has been carried out on their 
pharmacological activity. 
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Prodiginines have been demonstrated to have anti-malarial activity making them an 
attractive target for modem genetic and chemical studies.28-31 Recently prodigiosin has 
been shown to kill the parasites that cause Chagas' disease and is thought to be more 
potent against Trypanosoma than the current treatment of benznidazole.31 Prodiginines 
increased the survival time of malaria infected mice, with cyclic derivatives, for 
example streptorubin A 23, proving most potent.30 
One remarkable property of the prodiginine family is their immunosuppressant activity 
which derives from their ability to inhibit blastogenesis of T -cells and suppress T-cell 
dependent antibody responses without damaging the lymphoid organs.32,33 There are 
only three immunosuppressants currently recognised in medicinal practice. FK506, 
rapamycin and cyclosporin A. Cyclosporin A is used as an immunosuppressant for 
organ transplants and to treat some autoimmune diseases. However, due to its 
deleterious side effects, particularly renal toxicity, new immunosuppressants are 
required.34,35 Prodiginines have demonstrated immunosuppressant activity on T -cells by 
blocking inter-Ieukin-2 (IL-2) dependant proliferation through the down regulation of 
the IL-2Ra receptor32,36 and therefore improving animal survival in mouse graft-versus-
host disease.37 The chemical structures of prodiginines are small enough that minor 
structural alterations are likely to significantly reduce toxicity and increase 
pharmacological activity.34,38 Despite potential side effects observed in vivo, it is likely 
that these compounds will be useful immunosuppressants. In fact, their ability to 
interfere with IL-2 by inhibiting phosphorylation and hence activation of Janus Kinase 3 
(JAK-3) has led to the development ofPNU-156804 (27, Figure 7) a synthetic analogue 
of undecylprodiginine, which is vastly more potent than the natural product. In vivo 
studies have demonstrated that oral administration of PNU-156804 suppresses heart 
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allograft rejection in rats, and a promising synergistic effect was noticed when PNU-
156804 was administered with cyclosporin A.39 
Figure 7: Synthetic analogue PNU-156804, 27 ofundecylprodiginine 
Prodiginines and their synthetic analogues are also considered potential chemotherapy 
agents. In 1888 Dr William B. Coley, a New York surgeon, stumbled across one of the 
most intriguing findings ever made in cancer research. Having combined cultures of 
Streptococcus sp. and Bacillus prodsious (Serratia marcescens) and sterilised them by 
heat, he made a mixed bacterial vaccine (today called Coley's toxin). This therapy, 
which is likely to have contained prodigiosins, was used to treat tumours. Since then, 
prodiginines have been shown to induce apoptosis in many different human cancer cell 
lines with minimal effect on non-malignant cells.40-44 Promising results have been 
obtained against P388 mouse leukaemia cells,27,45 human melanoma, lung and colon 
cancer cell lines and hepatocellular carcinomas for which there is currently no effective 
treatment. 40,4 I In 2007 undecylprodiginine was shown to induce apoptosis in human 
breast carcinoma celllines.46 Furthermore, prodigiosin was demonstrated to effectively 
inhibit tumour metastasis and migration in vitro and in vivo. 47 
The mechanism of action of prodiginines in vivo is not very clear. There is substantial 
evidence for potent DNA damaging properties arising from their ability to co-ordinate 
metal ions, in particular copper (II), which leads to efficient single and double strand 
cleavage.48,49,50 The analogous zinc (II) complex co-ordinates two molecules of 
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prodigiosin around the metal ion.51 Cleavage was not initiated in the presence of iron 
(III), nickel (In and zinc (II) (Scheme 17).51,52 
OMe 
• 
Base 
MeO 
I2 
Scheme 17: The binding of copper (II) and zinc (II) with prodigiosin 12 
It is suggested that these complexes intercalate in the minor groove with a preference 
for AT rich sites. The metal oxidises the electron rich pyrrolylpyrromethene moiety of 
prodigiosin. Redox cycling between Cu(I) and Cu(II) is likely to facilitate prodiginine 
oxidation, converting O2 to H20 2, triggering DNA cleavage.51 ,53 This double stranded 
cleavage is likely to be important therapeutically, as cancerous cells have more copper 
present than non-cancerous ones, making the development of these anti-cancer agents 
advantageous. 54 Structure activity relationship (SAR) and electrochemical investigations 
show that structural modification which interferes with cation binding diminishes 
potency.53,55 Specifically the A-ring, the lone pairs of electrons in conjugation with the 
tricyclic frame work and the B-ring methoxy groups are critical for cytotoxicity (Figure 
5)?7,45,51 Replacement of any of the pyrrole rings with another heteroaromatic ring 
results in a decrease in potency. Surprisingly, roseophilin 26, which has a methoxyfuran 
ring in place of the methoxypyrrole B-ring, exhibits cytotoxcity against K562 human 
erythroid leukaemia and KB human epidermoid carcinoma cell likes. This appears to 
result from a different mechanism of action as roseophilin does not cause DNA 
damage. 55 The proton affinity of the pyrromethene chromophore which is strongly 
influenced by the A-ring, also plays a critical role in its biological activity, and 
inhibition of cell proliferation. 50 
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New synthetic analogues are being developed in the hope of finding compounds less 
toxic than the natural products. 56 Currently the synthetic prodigiosin analogue 
GX15-070 28 (Figure 8) is in phase 1 and 2 oncology clinical trials directed against 
multiple solid tumour and haematological malignancies. GX15-070 is of interest both as 
a combination therapy and as a single agent. It is an antagonist of the BH3-binding 
groove of the Bcl-2 family of proteins. GX15-070 induces apoptosis in several cancer 
cell lines including mUltiple mYeloma57 and mantle cell lymphoma by inhibiting the 
interaction between pro- and anti-apoptotic proteins. 58 
28 
Figure 8: GX015-070, 28 
Another mode of action results from the ability of prodigiosin to reversibly disrupt the 
pH gradient between various cellular compartments (generated by ATPase) by 
functioning as W Icr symporters, resulting in the acidification of the cytoplasm and in 
some cases apoptosis.59,60 This activity is thought to derive from the ability of the 
protonated product to electrostatically interact with cr resulting in the formation of a 
lipophilic ion pair which facilitates proton coupled transmembrane transport of 
halides.5o This mode of action may allow prodigiosins to be developed as anti-tumour 
agents. 
2.5: The Biosynthesis of Prodiginines in S. coelicolor A3(2) 
S. coelicolor A3(2) is a known producer of prodiginine antibiotics that has been studied 
for a number of years. Previous investigations and the recent sequencing of the genome 
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meant that major advances in the understanding of prodiginine biosynthesis have 
d 61-63 Th· II d fun . . occurre . IS a owe ctlOns to be assIgned to the genes involved in prodiginine 
biosynthesis, based on sequence similarities, in 2001.23,64 
The biosynthesis of prodigiosin was originally studied in S. marcescens and several 
actinomycete prodiginines have been examined by the incorporation of labelled 
65-68 E I d· h d precursors. ar y stu Ies s owe that prodigiosin, despite being a pyrrolic 
compound, was not biosynthetically related to porphyrins.69 Studies in Streptomyces 
/ongispororuber showed that undecylprodiginine is biosynthesised from one unit of 
proline, one unit of serine, one unit of glycine and eight units of acetate. These units 
were proposed to make up two putative precursors: 2-undecylpyrrole (UP) 29 and 4-
methoxy-2,-2' -bipyrrole-5-carboxaldehyde (MBC) 10, which are condensed to give 
undecylprodiginine 21. 
The undecylpyrrole moiety 29 is made up of seven acetates condensed in a head to tail 
fashion with the remaining carbon and nitrogen atoms deriving from glycine. Based on 
these studies Gerber et al. concluded that 2-undecylpyrrole 29 is biosynthesised via 
condensation of J3-ketomyristoyl coenzyme A and glycine with loss of carbon dioxide. 70 
Further studies on S. longispororuber and other actinomycetes have shown that the 
monosubstituted A-ring of undecylprodiginine is derived from the pyrrolidine ring of 
proline. The final step in the biosynthetic pathway has been proposed to be a 
condensation of MBC 21 and UP 29. This gives a completely conjugated double bond 
network responsible for the red colour of the pigments. Macrocylic prodiginines (22, 23, 
and 24) are proposed to be formed via a two-electron oxidative cyclisation of 
undecylprodiginine, 21 (Figure 9)?3 
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Figure 9: Proposed condensation and oxidative cyclisation reactions in prodiginine biosynthesis 
Since the initial study of the gene cluster in 2001 , extensive work carried out by Challis 
and co-workers has allowed the function of several of the genes involved in the 
prodiginine gene cluster to be reassigned. Some of these functions were predicted by 
comparison of the genes in the red cluster with those in the Serratia pig cluster that 
directs prodigiosin biosynthesis.64, 11 
The gene cluster responsible for prodiginine biosynthesis in S. coelicolor is known as 
the red cluster. It contains twenty-three genes organised into four transcription units, 
(Figure 10). The left limit of the red cluster is defined by the trkA operon that encodes 
the proteins required for the potassium uptake system. 
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trkA2 redO redW redR redP redN redL redJ redH redF redE 
2kb 
redO redM redK red/ redG 
SC3F7 
SC2E9 SC10A5 
Figure 10: The prodiginine biosynthetic gene cluster in Streptomyces coelicolor A3(2) 
Genes involved in biosynthesis of 2-undecylpyrrole, 5: blue 
4-methoxy-2,2' -bipyrrole-5-carboxaJdehyde, 6: red 
Oxidative cycJisation, 1: 
Condensation, 1: 
PosttransJational modification, 1: green 
Regulatory genes, 2: r ,_ 
White genes have unknown functions or are not required for prodiginine biosynthesis, 7 
Black arrows represent the 4 molecules ofmRNA generated by the transcription of the 
cluster. 
The grey lines show the regions of the cluster as spanned by cosmids. 
To date all but seven (white) of the twenty-three genes have been assigned functions, 
four of these, redY, redF, redE and red!, have been shown not to be required for 
prodiginine biosynthesis in S. coelicolor (Figure 10).71 redD and redZ have been shown 
to encode pathway regulators ( orange). Six genes are assigned to the biosynthesis of 
MBC (red) and five to UP biosynthesis (blue). One of the genes redH has been shown 
to be involved in condensation of the intermediates 10 and 29. The protein encoded by 
redG shows homology to a family of Rieske non-heme, iron-dependent oxygenase 
enzymes and has been shown to be involved in the oxidative cyclisation to form the 
cyclic derivative of undecylprodiginine, streptorubin B. Mechanisms for the 
biosynthesis of these two precursors have been proposed based on genetic and 
biochemical studies. 11,23,72-76 
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2.5.1: Bipyrrole (MBC) Biosynthesis 
RedM and RedW have been shown to catalyse the conversion of L-proline 30 to 
pyrrolyl-2-carboxyl thioester 32.73 Initially RedO is activated by the attachment of a 
phosphopantetheinyl arm, which is catalysed by RedU, followed by the ATP dependent 
acylation of RedO with L-proline catalysed by RedM. Subsequent FAD dependent 
oxidation of 31 catalysed by RedW gives the thioester 32 (Figure 11).73 It is proposed 
that the thioester attached to the PCP RedO 32 is transferred to the KSc domain of 
RedX 35. Subsequent condensation with a malonyl-ACP thioester attached to one of the 
domains of RedN 34 would give the ~-keto-acyl thioester 36, which is cleaved in a 
PLP-dependent reaction with serine catalysed by the C-terminal a-oxoamine synthase 
(OAS) domain. The PLP-assisted deprotonation of serine leads to nucleophilic addition 
to the acyl thioester, followed by decarboxylation, PLP imine hydrolysis, cyclisation 
and dehydration to give the dihydroxybipyrrole 37. Oxidation of 37 which is proposed 
to be catalysed by RedVll to give 38, and subsequent methylation catalysed by RedI77 
yields the bipyrrole 10. 
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Figure 11: Proposed biosynthetic pathway of the MBC 10 
2.5.2: Biosynthesis of 2-undecylpyrrole (UP) 29 
The monopyrrole fragment is biosynthesised from seven acetate units and one glycine 
unit. 65 Recent genetic studies show that 2-undecylpyrrolin-4-one 43 is assembled by 
fatty acid synthase (FAS) and PKS enzymes (Figure 12).74 RedP is thought to generate 
an acetoacetyl thioester on the ACP RedQ. Subsequent reduction and dehydration by 
the ketoreductase, dehydratase and enoylreductase enzymes of the S. coelicolor F AS 
yields butyryl-ACP. Chain extension by RedR and continued reduction and dehydration 
by FAS reductive enzymes would result in the production of dodecanoyl-RedQ 39. The 
dodecanoyl-RedQ thioester 39 is believed to be hydrolysed by an as yet unidentified 
enzyme to give 40, which is loaded onto the first RedL ACP domain to give the 
corresponding thioester 41 where it undergoes one further chain extension with 
maIonyl-RedL 33 catalysed by the KS domain to give 42. This thioester is cleaved from 
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the second ACP domain of RedL by the PLP-dependant OAS domain of RedL to yield 
2-undecylpyrrolin-4-one 43, which is reduced by RedK in a NADH dependent reaction 
to produce 2-undecylpyrrole 290 74,78 
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RedP t 1 
RedR S OH RedL S S 0 FAS :~ ,JlSCoA A domain T\ .. H2O 
<CO; CO2 
0_ 
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COSCoA I-L AT domain 
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39 40 41 :~ 33 
O_ 
j 
RedL 
OAS 
RedL SH S 
OASdomain RedK PLP 
7'\ otT '\ 0 
NAO+ NAOH +........... -c~ H3N CO2 
29 43 42 
Figure 12: Proposed biosynthetic pathway of the UP 29 
2.5.3: The Coupling of UP 29 and MBC 10 
MBC and UP have been proposed as intennediates in the biosynthesis of 
undecylprodiginine and streptorubin B in Streptomyces species23,6S although direct 
1 kin bOl 72,74 evidence for this has been ac g un now. 
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RedM and RedW are proposed to be involved in MBC biosynthesis23 and gene 
replacement mutants were created to inactivate each of these genes.72 Neither 
undecylprodiginine nor streptorubin B could be detected in organic extracts of the 
redM·:aac(3)IVor the redW·:aac(3)IV mutants of S. coelicolor M511 when grown on 
solid R5 medium or in liquid supplemented minimal medium. LC-MSIMS analysis of 
acidified organic extracts of the mycelia of these mutants and comparison with synthetic 
standards of MBC79 and up80,81 showed that the mutants both accumulate UP, but not 
MBC.72 Feeding of synthetic MBC to these mutants restored production of 
undecylprodiginine and streptorubin B, whereas feeding of UP did not, confrrming that 
MBC is an intermediate in their biosynthesis and that RedM and RedW are required for 
assembly of MBC. 72 
Initial analysis of the red cluster led to the proposal that the dodecanyl chain involved in 
UP biosynthesis was transferred after assembly by the RedPQR proteins from RedQ to 
the KSc domain of RedX. Chain elongation and subsequent cyclisation to UP were 
proposed to be catalysed by RedX and RedN. Ketone reduction and subsequent 
elimination of water to give UP was proposed to be catalysed by RedF and RedH.23 
RedL was assigned a role in the MBC pathway. 23 Subsequent experiments have shown 
that RedX and RedN are required for MBC biosynthesis,72since both a redX::aac(3)n' 
mutant and a llredN mutant23 have been shown to accumulate UP and not MBC by LC-
MSIMS analysis of acidified organic extracts of their mycelia. Furthermore, feeding of 
MBC but not UP restored the production of prodiginines in these mutants. Comparison 
of the red cluster of S. coelicolor with the pig cluster of Serratia marcescens also 
revealed no redL homologue in the prodigiosin biosynthetic gene cluster.82 This would 
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suggest that RedL therefore plays a role in UP biosynthesis. Until recently UP had only 
been observed in mutants blocked in the biosynthesis of MBC, implicating it as an 
intermediate or a shunt product in the biosynthetic pathway of undecylprodiginine and 
streptorubin B.72 The observation that redL::oriT-aac(3)IV mutant does not produce 
detectable quantities of undecylprodiginine or streptorubin B, but can be complemented 
with chemically synthesised UP provides clear evidence for its role in UP biosynthesis. 
It also provides direct evidence that UP is an intermediate in the biosynthesis of 
undecylprodiginine and streptorubin B.74 
RedH has been proposed to catalyse the condensation of UP and MBC to yield 
undecylprodiginine ll but this hypothesis had not been experimentally examined. 
Recently experimental evidence for the role of RedH has been obtained. The redH gene 
was replaced on the chromosome of S. coelicolor M511 with a "cassette" containing 
oriT and the acc(3)/V gene conferring apramycin resistance to create the S. coelicolor 
mutant W33. When grown on agar no red pigment was visible indicating that redH is 
required for prodiginine production. LC-MSIMS analysis showed small quantities of 
undecylprodiginine suggesting that MBC and UP can, to an extent, spontaneously 
condense.83 However, control experiments indicated that this is likely to be an artefact 
of the isolation procedure. Further investigations where pPKS 1 (containing redH under 
the control of the ermE promoter) had been integrated into the chromosome of 
Streptomyces venezuelae ATCCI0712 to express the RedH protein in a heterologous 
host were carried out. LC-MSIMS analysis of wild type S. venezuelae showed that 
prodiginines are not produced.83 Feeding ofMBC and UP to wild type S. venezualae did 
not result III visible red-pigment production and only small traces of 
undecylprodiginine, relative to UP, could be seen by LC-MSIMS analysis of acidified 
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extracts of mycelia, probably resulting from the isolation procedure.83 In contrast, 
feeding MBC and UP to the S. venezuelae strain with redH expressed resulted in 
substantial quantities of undecylprodiginine production relative to UP. These data 
provide strong evidence that RedH catalyses the condensation of MBC and UP to form 
undecylprodiginine.83 
2.6: Synthetic Approaches to the Prodiginines 
There are many approaches to the synthesis of prodigiosin and its analogues but very 
few reports exist for the synthesis of the key biosynthetic intermediate bipyrrole 
10.10,27,84-88 
Rapoport and Holden proved the structure of prodigiosin in 1962 after extensive studies 
by the synthesis ofMBC 10 and condensation with 2-methyl-3-amylpyrrole 11.10 Their 
synthesis of 10 is outlined in Scheme 18. Despite all the problems with this synthetic 
route, it was the fust total synthesis and was the first definitive proof of the structure of 
prodigiosin. 
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Scheme 18: Synthesis ofMBC 10 and elaboration to prodigiosin 12 10 
i) Xylene, benzene, 30%; ii) CH2N2, MeOH, 44%; iii) 1) H2S04; 2) heat, 42%; iv) 49, 13%; v) PdlC, p-
cymene, 82%; vi) 1) H2NNH2, 2) TsCI, pyridine, 3) Na2C03, heat, 32%; vii) 11, HCI, MeOH, 55% 
Boger and Patel based their approach to the synthesis of prodigiosin on the application 
of inverse electron demand Diels-Alder reaction of 52 for preparation of the pyrrole ring 
B 55 (Figure 5 and Scheme 19), and subsequent implementation of an effective 
intramolecular palladium(II) promoted 2,2' -diary 1 coupling for the construction of the 
prodigiosin 2,2' -bipyrrole AB ring system. Boger used the conditions developed by 
Rapoport and Holden for the final steps to generate prodigiosin 12 (Scheme 19). This 
route was utilised to synthesise prodigiosene and 2-methyl-3-pentylprodigiosene.27,45 
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Scheme 19: The synthesis of prodigiosin as detailed by Boger and Pate145 
i) 53, 94%; ii) Zn, HOAc, 68%; iii) 1) LiOH, 91% 2) NaI, h, NaHC03, 89%; iv) PdlC, H2, K2C03, 96%; 
v) 1) NaH 2) 58, (COCI)2, DMF, 89%; vi) polymer supported Pd(OAch, CH3C02H, 96%; vii) LiOCH3, 
88%; viii) 1) H2NNH2, 2) TsCI, pyridine, 3) Na2C03, heat, 34% ix) 11, HCI, MeOH, 59% 
Wassennan and co-workers developed two different syntheses to the bipyrrole precursor 
10. The fIrst strategy was based on the cyclisation of vinyl vicinal tricarbonyls 67 to 
generate 3-hydroxypyrrole-2-carboxylates 69 (Scheme 20). The conjugated double bond 
in 67 can be used in a Michael-type addition to fonn substituted a,a' -bipyrroles 69, 
leading to the fonnation of key intennediate 10 which can be transfonned by acid 
catalysis to prodigiosin 12 or other members of the prodiginine family.86 
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Scheme 20: Synthesis of prodigiosin as detailed by Wasserman86 
i) NaH, p-TsCI, 93%; ii) 64, 75%; iii) HCI, 58%; iv) p-Me2N-CJ{.-NO, NaOH, 70%; v)HOAc, 68, 23%; 
vi) 1) NaH, Me2S04, 2) 5% H2S04, TFA, anisole, 3) NaOH, EtOH, heat, 31%; vii) I) H2NNH2, 2) TsCI, 
pyridine, 3) Na2C03, heat, 25%; viii) 11, HBr (cat.), 50% 
The other method developed by Wasserman and co-workers involved pyrrole-singlet 
oxygen reactions leading to a,a' -bipyrroles. Singlet oxygen oxidation of the tert-butyl 
ester of 3-methoxy-2-pyrrolecarboxylic acid 70 activated the pyrrole ring to give 
intermediate imino hydroperoxide 71, which can be used to form substituted pyrrole 
derivatives 73 (Scheme 21). 89-91 
OMe OMe OMe fi-t i) O-C02tBU ii) ~O~" • . 10 N C02 Bu 0 N N H N OOH N H H 0 
H 
70 71 72 73 
Scheme 21: Synthesis of substituted pyrrole derivatives 73 via proton-singlet oxygen reaction as reported 
by Wasserman and co-workers90 
i) 102; ii) 72; 42% over 2 steps 
Bipyrroles such as 73 and 74 can be elaborated by the McFayden-Stevens reduction and 
condensed with a substituted pyrrole as seen in the previous routes by Rapoport 
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(Scheme 18) and Boger (Scheme 19) to produce prodiginine analogues. Ring A 
analogues which had not been produced earlier are easily accessible by this route. This 
pathway also works with substituted pyrroles in place ofpyrrole. (Scheme 22).91,92 
OMe 
OMe i) OMe ii) ~O'"" ~H ~ '/ NH N N N N H H 0 H H 0 
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Scheme 22: McFayden-Stevens reaction to transform 74 to an analogue of the key intermediate in the 
prodigiosin pathway 75 and elaboration to a prodigiosin analogue 7791 
i) 1) H2NNH2, 2) TsCI, pyridine, 3) Na2C03, heat, 40%; ii) 76, HCI, MeOH, 41 % 
Synthesis of cyclic prodiginines, namely metacycloprodigiosin (streptorubin A) 23 and 
streptorubin B 22, is difficult due to the limited success of synthesising the 
corresponding building blocks. However, Wasserman and co-workers completed the 
fITst synthesis of highly strained streptorubin A 23. In this synthesis the pyrrole ring was 
formed by functionalisation of cyclododecanone followed by a Paal-Knorr condensation 
of 79 with ammonium bicarbonate. This method however has a large number of steps 
and is low yielding (Scheme 23).93 
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Scheme 23: Synthesis of metacycloprodigiosin (Streptorubin A), 2393 
i) (N~)2C03, H20, DMF, 115°C; ii) 10, HCI, EtOH, 90% 
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Complementary syntheses of streptorubin B 22 (Scheme 24) and metacycloprodigiosin 
(streptorubin A) 23 (Scheme 25) have also been developed by Fiirstner and co-
workers.94,95 These methods rely on transition metal catalysed C-C bond formation. 
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Scheme 24: Synthesis of streptorubin B 22 core by Fllrstner and co-workers94 
i) [TsNCIlNa+, Se, 75%; ii) 1) NaH, propargyl bromide, 92%, 2) n-BuLi, then ZnCh; 3) butanoyl 
chloride, 82% over two steps; iii) PtCh (5% mol), toluene, 79%; iv) BU3SnH, PdQ cat, HBF 4, 94%; v) 1) 
LiAIH4, 96%, 2) PhOC(S)CI, pyridine, 95%; vii) BU3SnH, AIBN, 64%; viii) 1) KAPA, 2) H20, 55% over 
2 steps 
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Scheme 25: Synthesis ofmetacycloprodiginine 23 developed by FOrstner and co-workers95 
i) 1) t-BuLi; 2) 8-bromooctanal; 67-73% ii) Ph02SCH2COOMe, KH, DMF, 78%; iii) [Pd(Ph3)4]cat. 
dppe cat. THF, 77%; iv) TASF, 55%; v) Dess-Martin, 74%; vi) DBU, 79%; vii) NaOH, MeOH, 78%; 
viii) BnNH2' HOAc, 45%; ix) NaOMe, 91%, x) 1) Pr4NRu04, 63%; 2) NaCl, aq. DMSO, 180°C, 
91%; xi) 1) Ph3P=CHMe, 73%; 2) H2, Crabtree catalyst, 89% 
D' Alessio and co-workers developed a total synthesis of undecylprodiginine. This route 
relies on a Suzuki cross coupling reaction for the formation of the bipyrrole as shown in 
Scheme 26.96,97 
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Scheme 26: Synthesis ofundecylprodigiosin 106 by D' Alessio and co-workers96,97 
i) 102, NaOH, DMSO, 88%, ii) Tf20, 71%, iii) 105, [Pd(PPh3)41 cat. 73% 
Nonylprodigiosin 114 and some other large ring analogues have been synthesised by 
Ffu'stner and co-workers, using Suzuki cross coupling reactions of an easily accessible 
pyrrolyl triflate with aryl boronic acids, the resulting diene was then subject to a ring 
closing metathesis or metathesis dimerisation (Scheme 27). This methodology was 
adapted from the synthesis of undecylprodiginine developed previously by D' Alessio 
and co-workers, and was also used to produce macrocyclic prodigiosin analogues. 88,98 
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Scheme 27: Synthesis ofnonylprodigiosin 114 by Fiirstner and co-workers88 
i) 102, NaOH, DMSO, 94%, ii) Tf20, 93%, iii) 110, [pd(pPh3)41 cat. 57%; iv) 112 cat.; 65%, v) H2, [Rh] 
cat. 90% 
Fiirstner also completed a total synthesis of roseophilin, which is a related natural 
product. In this synthesis the key element is formation of the macrocyclic ring moiety 
which is accomplished with palladium coupling. The heterocyclic rings are formed in 
the presence of the macrocycle before coupling to the methoxyfuran-pyrrole.99 
Roseophilin has also been synthesised by a number of other groups. 100-102 
Several of these synthetic routes are limited owing to the low yielding McFayden-
Stevens reduction. A more recent approach developed by Tripathy and Lavallee 
describe an efficient two step synthesis of bipyrrole 10, which allows easy access to 
prodiginines in good yields (Scheme 28). This methodology treats commercially 
available 4-methoxy-3-pyrolin-2-one 102 with the Vilsmeier-Haack reagent derived 
41 
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from diethylformamide to produce the bromo pyrrole enamine 115. This can then be 
used in a Suzuki cross coupling reaction with N-BOC-pyrrole-2-boronic acid 116, 
leading to the bipyrrole 10.79,103 This synthetic approach, combined with the 
condensation step reported previously by Rapoport and Holden10 allowed access to a 
number of prodiginine analogues. 
OMe OMe 
on Br~N\ OMe i) ii) ~H • Soc N N H 
115 \ 
I H H 0 
(r-S(OHh 102 ~ h 10 
116 
Scheme 28: Methodology developed to bipyrrole developed by Tripathy and Lavallee79,I03 
i) POBr3, diethylformamide, chloroform, 70%; ii) 116, PdcPPh3)4, dioxane, H20, NaC03, 95% 
This methodology has allowed the Challis Group to synthesise bipyrrole 10 analogues 
(Figure 13), which have been used to probe the substrate specificity of the RedH 
enzyme in undecylprodiginine biosynthesis. 83 
OMe 
R-O-l 
H 0 
U .... H 0)-R= I~ ~ I ~ ~ 
H 
S 0 N [)-~ [)-~ o-~ 
~~ ~ OMe ~ 0 h o 
H 
A ring analogues B ring analogue 
Figure 13: Analogues synthesised by Challis group 
2.7: Aims and Objectives - Prodiginines 
The aim of this project was to synthesise the mimic 117 (Figure 14) of a key putative 
intermediate in the biosynthesis of MBC 10 to investigate the biosynthetic pathway of 
the prodiginines produced by S. coelicolor A3(2). The role of redM in MBC 
biosynthesis was then analysed by feeding 117 to a redM deficient mutant unable to 
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produce MBC to see whether prodiginine production was restored. Analogues of 117 
were then synthesised to examine whether novel "natural" products could be produced 
via incorporation of the analogues. 
f!\. s ~ 
'o""'Y ~N~ 
o H 
U\ s ~ 
's/y ~N~ 
o H 
118 119 
~ 0 yys~N~ 
F 0 H 
120 
Figure 14: Mimic of the proposed precursor 117 and structures of analogues 
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3.1: Isolation and Structure Elucidation of Quartromicins 
3.1.1: Determination of Planar Structures 
Quartromicins, first isolated in 1991, are a structurally unique group of spirotetronate 
natural products produced by Amycolatopsis species. I04-I06 A new actinomycete strain 
was isolated from a soil sample collected in Maharastra state in India during a search for 
novel bioactivities. This strain, identified as Amycolatopsis orientalis, No. Q427-8 
(ATCC 53884), was shown to produce novel anti-viral antibiotics, the quartromicins. as 
a complex termed BU3889V. I06 This antibiotic complex was shown to consist of six 
bioactive components: AI, A2, A3, D), D2 and D3 which were isolated after filtration 
. hr h I06 Q .. using a non-ionic porous polymer reSIn and column c omatograp y. uartromIcms 
Al 122a, A2122b, and A3 122c (Figure 15), were isolated as weakly acidic pale-yellow 
amorphous powders. I07 Aglycons quartromicins DI 122d, D2 122e and D3 122f (Figure 
15), were also isolated as only minor metabolites. 
OH OH ~ galacto HO 
8' 
o fragment agalacto fragment 
HO 
o 26 : 8 
11 '9 R1 
HO I 
o 
o 
2ff 0 OH HO\-O~ ~ 
OH 
122a: Quartromicin A1 R1=R2=CHO 
122b: Quartromicin A2 R1 = CHO. R2= CH20H 
122c: Quartromicin A3 R1= R2 = CH20H 
"galacto" fragment agalacto fragment 
agalacto fragment "galacto" fragment 
122d: Quartromicin D1 R1 = R2 =CHO 
122e: Quartromicin D2 R1 = CHO. R2=CH20H 
122f: Quartromicin ~ R1 = R2 = CH20H 
Figure 15: Quartromicins AJ-A3 and DJ-D3 (122a-f) 
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The structures of these bioactive compounds were investigated. Using negative ion 
FAB-mass spectrometry quartromicin Al and A3 were found to have the molecular 
formula C78H88030, mJz 1525 (M-2 + Nar 1541 (M-2 + Kr and C78H920 30, mJz 1545 
(M 2+K)- . I 104 I B 
- respectlve y. H and C NMR spectra suggested the presence of a sugar 
which was determined to be D-galactose after isolation from acid hydrolysis of the 
natural products. The BC NMR spectra of quartromicin Al and A3 each exhibit thirty-
nine well defined carbon signals hence showing they both possess symmetrical dimeric 
structures. 2D NMR data led to partial structures accounting for thirty-three of thirty-
nine carbon signals. The remaining six signals were accounted for in two sets of 
carbonyl and olefin groupS.I04 Simultaneously, structure elucidation was carried out on 
quartromicin DI, D2 and D3, and it was shown by l3C NMR spectroscopy that they 
contained thirty-three carbon atoms in comparison to the thirty nine carbon atoms 
present in quartromicin A], A2 and A3. It was determined that quartromicin Al afforded 
quartromicin DI and methyl D-galactoside upon mild acid methanolysis. In a similar 
way quartromicin A2 yielded quartromicin D2, and quartromicin A3 yielded quartromicin 
D3. The difference between quartromicins Al and DI of 324 mass units corresponds to 
two equivalents of galactose, suggesting that Al is a dimer of two thirty-nine carbon 
monomers. Hence Al is a galactoside derivative of D1• This led to the proposed 
structure 122c for quartromicin A3, a unique thirty-two-membered carbocyclic ring 
possessing four spirotetronic acid moieties connected by enone or dienone linkers in a 
head to tail fashion (although no stereochemistry had been assigned at this stage). A 
synthetic model of a spirotetronate was produced which possessed intense IR signals at 
1630 cm-I and 1450 cm-I as well as similar NMR signals to the natural product (Figure 
16). This allowed the structures of 122a and 122b to be deduced, and hence 122d, 122e 
and 122f (Figure 15).107 
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Figure 16: Synthetic model of a spirotetronate 
Quartromicins are the largest members of a family of antibiotics whose macrocyc1ic 
framework consists of only C-C linkages. These compounds are intriguing because they 
have alternating endo- and exo-spirotetronic acid units, with opposite "comers" being 
identical. 122a and 122c are C-2 symmetric and contain two distinct spirotetronate 
units. Two of the units have a-galactopyranosyl residues appended, which are known as 
the galacto fragments (Figure 15). 122d and 122f are also C-2 symmetric but the 
"galacto" fragments are des-D-galactosyl analogues. The remaining members of the 
quartromicin group, 122b and 122e, differ from the C-2 symmetric members, in that the 
agalacto fragments have different oxidation states at the C-8 and C-8' carbons. It has 
been confirmed that all members of the family have the same carbon skeleton by 
reducing quartromicins AI, A2, Dl and D2 with sodium borohydride to A3 and 0 3.
108 
There have been several other macrocyclic antibiotics reported containing tetronic acid 
units (Figure 17), including tetrocarcin A 123, 109,llOpyrroindomycins A and B 124a and 
11 112113" 26 114 ki' . .. 127 115 116 124b, I pyrrolosporin A 125,' chlorothricln 1, JarnmIcm " 
tetronothiodin 128117 and MM46115 129. 118 These differ from quartromicin 122 in 
having only one tetronic acid functional group in the molecule and being asymmetric. 
Quartromicins 122 and kijanimicin 127115 are both known to chelate metal ions (Na+. 
K+ and Cal stronglyl04 as has been reported for other 2-acyl tetronic acids, for example 
tetronasin. 119 
46 
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Figure 17: Other members of the spirotetronic acid family 
3.1.2: Stereochemical Assignment of Quartromicin AJ and D3 
1 H NMR data for quartromicins A3 and D3 revealed that the two spirotetronic fragments 
had strikingly different properties. 104,I07 The methyl groups attached to C-22 and C-4 in 
the galacto and agalacto fragments were in very different environments, indicated by 
the large difference in chemical shifts (0=0.83 and 0=1.23 respectively). However. the 
most diagnostic feature was the different appearances of the ABX pattern of signals for 
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the methylene groups at C-29 and C-II. In the galacto fragment both H-29a and H-29b 
exhibit coupling to H-27 (J = II Hz and 5.8 Hz respectively) whereas in the agalacto 
fragment the coupling is only seen between H-Ila and H-9 (J = 8.6 Hz); no coupling is 
seen between H-Ilb and H-9 (Figure 18).108 
o 
130 
galacato fragment 
H-29a IiH 2.04; J29a-27 = 11 Hz 
H-29b IiH 1.94; J29b-27 = 5.8Hz 
C-22 Me IiH 0.83 
H11a 
131 
agalado fragment 
H-11a IiH 2.37; J 11 a-9 = 8.6 Hz 
H-11b1iH 1.54; J11 b-9= no coupling 
C-22 Me IiH 1.23 
Figure 18: NMR data showing the difference in chemical environment of the galacto and agalacto 
fragments in quartromicin J08 
This data was similar to that reported for the exo- and endo- spirotetronates prepared in 
connection with the synthesis of chlorothricolide and kijanolide, the aglycones of the 
natural products chlorothricin 126 and kijanimicin 127 respectively. 108 
3.1.3: Synthesis and NMR Studies of the Possible Four Diastereoisomers of the 
Quartromicin Spirotetronate Subunits 
Roush and co-workers have attempted to verify the stereochemical assignments 
discussed above by developing a synthesis for all four possible diastereoisomers of the 
core spirotetronate structure and ultimately hope to develop a total synthesis of the 
•• 108 quartromlclns. 
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133 
OMOM 
OTBDPS 
OTBDPS 
135 
Figure 19: The four stereodivergent spirotetronate moieties that could correspond to the spirotetronates in 
quartromicin 
In order to synthesise the four stereodivergent spirotetronate moieties (Figure 19), 132 
and 133, which possess the stereochemistry assigned for the galacto and agalacto 
fragments of quartromicin, and 134 and 135, synthesised for comparative studies, two 
issues had to be addressed. Firstly, up until this point, no stereochemistry had been 
assigned to the quartromicin structures. By comparing the NMR data of quartromicin D3 
122f and the synthetic spirotetronates corresponding to those in chlorothricin 126120 and 
kijanimicin 127,121 it was suggested that the stereochemistry of the galacto fragment in 
the quartromicins was endo- (i.e. stereochemically analogous to the spirotetronate 
pyrrolosporin A 125),112 and that in the agalacto fragment it was exo- (i.e. 
stereochemically analogous to the spirotetronate of chlorothricin).122 This assignment 
could also be compared with other natural products containing spirotetronate units, for 
example PA-46101 AI23 (exo-spirotetronate) and A88696 C and FI24 (endo-
spirotetronates ). 
The second issue was the installation of a methyl group onto one of the quaternary 
centres of 132, 133, 134 and 135. It was thought that this extra methyl group would 
49 
OTBS 
OTBDPS 
132 
OTBDPS 
134 
Chapter 3: Introduction to Spirotetronate and 
Exomethylene Tetronate Antibiotics 
OTBDPS 
133 
OTBS 
O~ 
10 .) OMOM 
OTBDPS 
135 
Figure 19: The four stereodivergent spirotetronate moieties that could correspond to the spirotetronates in 
quartromicin 
In order to synthesise the four stereodivergent spirotetronate moieties (Figure 19). 132 
and 133, which possess the stereochemistry assigned for the galacto and agalacto 
fragments of quartromicin, and 134 and 135, synthesised for comparative studies, two 
issues had to be addressed. Firstly, up until this point, no stereochemistry had been 
assigned to the quartromicin structures. By comparing the NMR data of quartromicin D3 
122f and the synthetic spirotetronates corresponding to those in chlorothricin 126120 and 
kijanimicin 127,121 it was suggested that the stereochemistry of the galacto fragment in 
the quartromicins was endo- (i.e. stereochemically analogous to the spirotetronate 
pyrrolosporin A 125),112 and that in the agalacto fragment it was exo- (i.e. 
stereochemically analogous to the spirotetronate of chlorothricin).I21 This assignment 
could also be compared with other natural products containing spirotetronate units. for 
example PA-46101 A123 (exo-spirotetronate) and A88696 C and F124 (endo-
spirotetronates ). 
The second issue was the installation of a methyl group onto one of the quaternary 
centres of 132, 133, 134 and 135. It was thought that this extra methyl group would 
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hinder the bimolecular Diels-Alder approach used for the synthesis of chlorothricolide 
and kijanolide spirotetronates. Roush and co-workers decided to pursue the synthesis of 
exolendo- spirotetronates via an intramolecular Diels-Alder (lMDA) reaction of 137 
generated from 136 (Scheme 29). It was anticipated that this reaction would lead to a 
mixture of exolendo-cycloadducts hence leading to two of the four spirotetronates 
needed for the stereochemical assignment of the quartromicins. l22 
This first generation strategy was used to produce 137 and hence 138 and 139 (Scheme 
29). However, in practice, the IMDA reaction of 137 produced a mixture of three 
products 138, 139 and 140, in yields of 23%, 3% and 13%, respectively (Scheme 29). 
While 138 and 139 derive from 137 via endo- and exo- transition states respectively, it 
is clear that 140 must arise by a pathway involving diene isomerisation prior to IMDA 
1· . 122 cyc IsatlOn. 
The Diels-Alder adducts were elaborated to spirotetronates 133, ent-132 and ent-135 
(Scheme 29). Spirotetronate 133 corresponding to the agalacto fragment of the 
quartromicins, was first prepared from exo-Diels-Alder adduct 138 and hence was 
called the exo-spirotetronate. Ent-132 was referred to as the endo-spirotetronate and ent-
135 as the iso-endo-spirotetronate (Scheme 29).122 
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Scheme 29: First generation strategy which produced spirotetronates 133, ent-132 and ent_13S122 
i) 1) mCPBA, CH2Ch, -78°C; 2) PhH, P(OEt)3, 210°C, 20 h; ii) 1) TBAF, THF; 2) HPLC separation; 3) 
TBDPSCI, imidazole, DMF 
The intramolecular Diels-Alder reaction of 137 proved less selective than anticipated at 
the outset, owing to a competing olefm isomerisation that led to cycloadduct 140 
(Scheme 29). This route was clearly too inefficient, both in terms of chemical yield and 
stereo selectivity, for use in a hypothetical total synthesis of the quartromicins. 
Nevertheless, three of the four required spirotetronates had been synthesised and 
elaborated to contain part of the unsaturated side chains present in quartromicins 
(Scheme 30).122 
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Scheme 30: Elaboration of spirotetronate intermediate 138 to the exo-spirotetronate 133. A similar 
procedure was used to produce ent-132 and ent-13S122 
i) I)HS(CH2)2SH, BF3.Et20; 2) AC20, pyridine; 3) TMSCHN2 THFlMeOH; ii) I) HgCh, CaC03; 
2) piperidine, CaCh; 3) PhSeCI, -78°C; 4) H20 2; 5) TMSCHN2; iii) I) LiHMDS, THF -78 to O°C; 
2) MOMCI, HMPA; iv) I) DIBAL, THF, -100 to -78°C, 2) TBS-OTf 
Roush and co-workers developed a second generation route to synthesise the fourth 
spirotetronate 134 and to improve the yield of 132 in order to allow the introduction of 
the unsaturated side chain (Scheme 31). This route allowed the stereochemistry of the 
two methyl centres in the spirotetronate subunits to be controlled in early intennediates. 
The enolate Ireland Claisen rearrangement of 145 allowed the correct stereochemistry to 
be produced (Scheme 31). However, subsequent enolate hydroxylation proceeded with 
poor selectivity. An ozonolysis-intramolecular aldol sequence from 148a provided 149, 
which could be elaborated to produce the desired fourth spirotetronate diastereomer the 
"iso-exo" isomer 134 (Scheme 31 ).125 
52 
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i) 
• 
141 
149 
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~,N 
11\\ 0 
00 
147 
ii) 
148a R1= C02Me, R2=OH 
148b R1=OH, R2=C02Me 
OTBS O ~Z("'O~OMOM 
Me 
~ Me 
OTBDPS 
134 
Scheme 31: Second generation strategy which allowed the synthesis of the" iso-exo" isomer 134125 
i) 1) LDA, THF, TBS-CI, HMPA; 2) TMSCHN2, 96%; ii) 147, LiNEt2' THF, -78°C, 61% 
Although the original goal of total stereo-control was unsuccessful this route allowed 
the synthesis of all four spirotetronates and hence was superior to the previous route. 
Cyclopentene 148b was further modified into 150 (an intermediate in the synthesis of 
ent-135) by the sequence in Scheme 32. By choosing (R)-151 and 152 as starting 
materials, 153 and 154 were prepared as intermediates in the synthesis of 133 and 132 
respectively (Scheme 32). 
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Scheme 32: Second generation strategy to the spirotetronates 133, ent-135 and 132 125 
I H NMR studies of the model spirotetronate diastereomers revealed that all four 
spirotetronates adopt conformations where the two methyl groups are in equatorial 
positions. This was verified by the coupling constants for H-9 and H-ll, which in all 
cases were in the range of J 8.3-10.8 Hz and J 6.3-6.8 Hz, respectively (Figure 20). This 
data supported the idea that the methyl group is shielded by the tetronate unit in the 
equatorial position. It also verifies that none of these spirotetronates match the NMR 
data for the fourth agalacto fragment 131 of quartromicins 122 (Figure 18) in which the 
secondary methyl group is in an axial position.108 Roush presumed that conformational 
constraints caused the agalacto fragment to occur in the natural product and adopt a 
different conformation to 133. This could of course mean that all four spirotetronates 
have the same stereochemistry in quartromicins such that it exists with two galacto 
fragments in dimethyl equatorial conformations and the aga/acto fragments in "chair 
54 
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inverted" conformations. However, extensive molecular modelling studies showed this 
to be unlikely. 108 
TBSO 
132 
H11a: OH=1.99; J11a_9=10.8 Hz 
H11 b: oH=1. 73; J11b-9=6.3 Hz 
C-4-Me: oH=1.07 
135 
H11a: oH=1.95; J 11a_9=8.3 Hz 
H11b: oH=2.08; J11 b-9=6.8 Hz 
C-4-Me: oH=1.19 
OTBS 
o 
134 
H11a: oH=2.00; J 11a_9=10.3 Hz 
H11b: oH=1.84; J 11b-9=6.6 Hz 
C-4-Me: oH=1.27 
OMOM 
o 
OTBDPS 
11bH ~ H11a ,,' 
""Me 
133 OTBS 
H11 a: oH=2.04; J 11a-9=10.4 Hz 
H11 b: oH=1.83; J 11b-9=6.6 Hz 
C-4-Me: oH=1.05 
Figure 20: NMR analysis of the synthetic spirotetronates108 
3.2: Studies Towards the Total Synthesis of Quartromicins 
Elucidation of the stereochemical features of the quartromicins has set the stage for their 
total synthesis. Studies towards this goal are described in the following subsections. 
3.2.1: Diastereoselective Synthesis of Spirotetronates 132 and 133 via Diels-Alder 
Reactions of Acyclic (Z,E)-I,3-diene, by Roush and Co-workers 
A third generation synthesis of 132 and 133 was carried out by Roush and co-
workers. 126 In principle, the most straightforward approach to the synthesis of 
spirotetronates 132 and 133 involves Diels-Alder reactions of an acrylic (Z)-substituted 
1,3-diene such as 155a and an appropriate a-acetoxy acrylate dienophile (Scheme 33). 
If this reaction could be induced to produce the endo- and exo- Diels-Alder adducts with 
good selectivity, then 132 and 133 would be easily accessible, and the isomeric diene 
155b could serve as a viable Diels-Alder reaction substrate to the isomeric pair 134 and 
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135 (Scheme 34). Attempts to perfonn Diels-Alder reactions of 155a with acrvlate 
dienophiles using Lewis acid catalysts were unsuccessful; therefore the reaction with a-
acetoxy acrylate was not explored. However, treatment of 155a with four equivalents of 
a-acetoxy acrolein 156, and one equivalent of MeAlCh in toluene provided the Diels-
Alder adduct 158. This compound was deprotected to fonn 159, which was further 
elaborated to the desired spirotetronate 132 (Scheme 33).126 
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Scheme 33: Conversion of diene 1553 into spirotetronates 132 and 133126 
Lewis acid-catalysed Diels-Alder reactions of 155a with other dienophiles were also 
investigated in order to obtain routes to fonnal exo-cycloadduct 160. It was detennined 
that a-bromoacrolein 157 was a good dienophile for the production of 160, which in 
turn could be deprotected to fonn 161 and further elaborated to produce the desired 
spirotetronate 133 (Scheme 33).126 
In order to demonstrate the generality of the Lewis acid catalysed Diels-Alder reaction, 
Roush et ale synthesised the isomeric diene 155b and were able to produce cycloadducts 
163 and 162 with >97:3 diastereoselectivity and in 84-88% yield (Scheme 34).108 
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OAe 
~CHO 
156 
OTBS 
OTBDPS 
163 
>98:2 endo 
Scheme 34: Conversion of diene 155b into cycloadducts 162 and 163108 
Elaboration of the racemic hydroxyesters 159 and 161 to the quartromicin endo- and 
exo- spirotetronates 132 and 133 has been accomplished. However, the use of these in a 
total synthesis of quartromicin D3 requires them to be prepared as single enantiomers to 
avoid production of racemates / diastereomers in the late stage coupling sequences. 
Therefore, further reactions of 155a with chiral dienophiles were investigated.108 Thus 
all four spirotetronates have been successfully synthesised by Roush and co-workers. 
3.2.2: Assembly of Bis-spirotetronate Quartromicin Fragments by Roush and Co-
workers 
In 2006 Roush and co-workers published the synthesis of both the vertical 164 and 
horizontal 165 bis-spirotetronate precursors to quartromicin D3 (Figure 21 ).127 
TBD~~O~ 
'. ~ 
~ OTBS 
MeO r 0 
o 0 
TBDPSO 
164 
vertical, endo-exo 
bis-spirotetronate 
o 
OTBS 
165 
horizontal, exo-endo 
bis-spirotetronate 
Figure 21 : Vertical endo-exo bis-spirotetronate 164 and horizontal exo-endo bis-spirotetronate 165 
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Roush and co-workers have also recently synthesised endo-169 and exo-166 (Scheme 
35). These were then further m d'fi d t th . . o 1 Ie 0 e correspondmg 2-bromo sprrotetronates 
exo-173 and endo-175 and the unsaturated aldehydes exo-174 and endo-176 (Scheme 
35) which were required for coupling experiments to access the vertical and horizontal 
fragments of quartromicin. 127 
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Scheme 35: Synthesis of exo-173 exo-174, endo-175 and endo-176127 
i) 1) LiHMDS, THFIHMPA, -78°C, NBS; 2) CH2N2, 58-86%; ii) 1) LiHMDS, THFIHMPA, -78°C, 69-
78%; 2) CH2N2; iii) 1) PPTS, MeOH; 2) S03.Pyridine, 71%; iv) 1) PPTS, MeOH; 2) S03.Pyridine; 3) 
172, 110°C, 43% 
Both the vertical 164 and horizontal 165 fragments of quartromicins A3 and D3 could 
then be accessed via the 1,2-addition of organocerium intennediates derived from 173 
and 175 onto the required enals 176 and 174, respectively, followed by oxidation of the 
resulting alcohols to ketones (Scheme 36). 164 and 165 are proposed to be used in a 
total synthesis of quartromicins 122.127 
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iii) 
165 
iii) 
164 f OMe ~o PO~"IO 
178 
Scheme 36: Synthesis of vertical endo-exo bis-spirotetronate 164 and horizontal exo-endo bis-
spirotetronate 165 
i) 1) THF, 4A sieves, -78°C, n-BuLi. 2) Activated CeCh THF solution. 3) endo-176, 58%; ii) 1) THF, 4A 
sieves, -78°C, n-BuLi. 2) Activated CeCh THF solution. 3) ao-174, 65% iii) Mn02, ether O°C to 23°C, 
58-78% 
3.2.3: Synthetic Approaches of Bedel and Co-workers to Quartromicins 
Recently Bedel and co-workers have also published a synthetic route to access the 
agalacto-spirotetronate subunit of quartromicins (Scheme 37). The key steps in an 
approach are the Ireland-Claisen rearrangement followed by an ene-yne metathesis ring 
closure to give 185 from 184. The galacto subunit can also be prepared in this manner 
using a modified alcohol. 128 
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Scheme 37: Synthesis of the agalacto subunit 188 developed by Bedel and co-workers128 
i) DCC, DMAP, CH2Ch, O°C; ii) LiHMDSITMSC1, -78°C; iii) AcOH, THF, -78°C, 69% over three steps; 
iv) 1) KHMDS, Toluene, TMSCI, -7SoC to rt; 2) H20 then CH2N2; v) 1) K2C03, MeOH; 2) Grubbs II, 
toluene, SO°C, 73% over 2 steps; vi) AD mix ~, MeS02NH2, t-BuOH, H20; vii) 1) NaI04, rt; 2) NaB~, 
O°C, THFIH20, 4S% over 2 steps; viii) 1) PhSH, AICh, CH2Ch; 2) AC20, SC(OTf)3, MeCN; 3) LiHMDS, 
MOMCI, THF, 94% 
3.3: Biological Properties of Quartromicins and Related 
Spirotetronates 
Quartromicins have a range of biological properties including activity against several 
important viral targets, such as herpes simplex virus type 1 (HSV _1),107 influenza A 
virus 107 and Human Immunodeficiency Virus (HIV).105 Cytopathic effect (CPE) 
reduction was used to evaluate the antiviral activity of quartromicins against HSV-1 
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infection in Vero cells and influenza virus A infection in Madin-Darby canine kidney 
(MDCK) cells in vitro. Quartromicins AI, A2 and A3 exhibited potent antiviral activity 
against HSV -1 infection (lDso: 11 JlglmL) , but little or no antiviral activity against 
influenza virus infection. Quartromicin D}, D2 and D3 showed activity against influenza 
virus (lDso: 6.8~34 JlglmL) but less anti-HSV-I activity, without cytotoxicity against 
respective host cells. 107 
It has also been shown that quartromicins Al and DI significantly inhibit (HIV)-induced 
cytopathic effect and virus specific antigen expression at concentrations of 25-100 
Jlg/mL in MT -4 cells, which were infected with HIV -Ills. 105 The reverse transcriptase 
activity of disrupted HTL V -IIIB particles, recombinant HIV -1 enzyme and purified 
avian myeloblastosis virus (AMV) enzymes were also inhibited. The combined antiviral 
effect of quartromicin Al and 3-azido-2' ,3' -dideoxythymidine (AZT) (the first drug 
licensed for treatment of certain HIV -related disorders) on the replication of HIV in 
MT -4 cells showed that quartromicin synergistically enhanced the inhibitory effect of 
AZT. As a result of immune defects, almost all patients with AIDS also suffer from 
opportunistic infections such as Pneumocystis carinii pneumonia, HSV and 
malignancies like Kaposi's sarcomas. Micro-organisms such as HSV enhance the 
transcription of HIV. Similarly cytokines such as TNF -(1 and -f3 stimulate transcription 
of HIV. It seems that various stimuli that activate cells lead to the production of virus 
resulting from loss of CD4+ cells and appearance of immunodeficiency. Thus 
quartromicins also have an inhibitory effect against HSV -1 and influenza virus A 
infection. This means that quartromicin Al might not only be useful for suppressing the 
causative agent of AIDS but also opportunistic infections, which may be important for 
the pathogenesis of AIDS. 105 
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A study by Berry and co-workers investigated the use of quartromicins AI, A::_ A3, 0 1• 
D2 and D3 as phospholipase A2 inhibitors. It was determined that quartrornicin O2 
inhibits phospholipase A2 (PLA ) " 106 108 . 
2 actIvIty. ' PLA2 IS a human enzyme that catalyses 
the hydrolysis of membrane phospholipids in the biosynthesis of eicosanoids, an 
important step in the inflammatory response associated with arthritis, psoriasis, asthma, 
and atherosclerosis. It is thought that the other quartromicins may also be active 
phospholipase A2 inhibitors. 
3.4: Biosynthetic Studies of Tetronate-Containing Natural Products 
While there have been no studies on the biosynthesis of quartromicins 122, the 
biosynthesis of several related acyltetronic acid-containing natural products has been 
investigated. 
3.4.1: Investigation of the Biosynthetic Origin of Tetronic Acids by Feeding Studies 
Many tetronic acid-containing natural products are known and as a result there have 
been several independent biosynthetic investigations of such metabolites over the last 
twenty years. Although the biosynthesis of the a-acyltetronic acid moieties in caloric 
acid and protoanemonin has been reported to involve C4 compounds from the Krebs 
cycle (succinnate and a-ketoglutarate, respectively), most a-acyltetronic acid moieties 
I d . d . 129-131 appear to be biosynthesised from three-carbon glycero - enve uruts. 
Feeding studies using 13C labelled precursors have been carried out on tetronic acids 
and it has been determined that acaterin 189, isolated from Pseudomonas sp. A92, and 
the agglomerin A 190, isolated from Enterobacter agglomerans PB-6042, both 
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mcorporate a three carbon 't d . d fr . . ... . 
urn enve om glycerol mto the tetromc aCId mOIetIes. In 
both cases it is thought that the direct precursor of the three carbon unit is 1 3-
biphosphoglycerate (Figure 22).1 32-135 
o 0 
5 
190 189 
[ ",. " [U-" Cia"",,,. .......... "[U-"Cig~cem' 1 
Figure 22: Biosynthetic origins of acaterin 189 and agglomerin A 190 
Although these two natural products do not possess the same spirotetronic acid moiety 
as quartromicin 122 or chlorothricin 126, it is has been shown that spirotetronic acids 
such as chlorothricin 126 also incorporate a glycerol derived unit. Early biosynthetic 
studies established the origin of most of the carbon framework of chlorothricin 126 
(Figure 23). The modified 6-methylsalicylic acid unit is derived from four acetate units 
via a polyketide pathway; the additional O-methyl group is derived from methionine; 
the two 2,6-dideoxyhexose moieties are derived directly from glucose; and the aglycon 
(chlorothricolide) is biosynthesised primarily via a polyketide pathway from ten acetate 
and two propionate units that account for all but three of the carbon atoms of 
chlorothricolide (C-22, C-23 and C-24), which are not labelled by acetate or propionate 
(Figure 23).136,137 Large numbers of compounds were tested in order to identify the 
missing precursor of these three carbon atoms. 114 While [V_14C]pyruvic acid and [1-
14C]lactic acid were not found to be specifically or efficiently incorporated, it was 
determined that [2-14C]glycerol was an efficient precursor of chlorothricin. To test if 
glycerol was specifically incorporated into C-22, C-23 and C-24 of chlorothricolide as 
an intact three-carbon unit, [U-13C3]glycerol was synthesised and fed to S. antibioticus 
Ttl 99.114 NMR analysis showed that glycerol was incorporated intact into these three 
carbons (Figure 23). In order to detennine the orientation of the 3-carbon moiety, 
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glycerol was stereospecifically labelled at C-l (the pro-R hydroxymethyl group which 
undergoes phosphorylation during metabolism) giving rise to C-3 of triose phosphates 
3-phosphoglyceric acid and phosphoenolpyruvate. Incorporation experiments with this 
labelled precursor determined that the C-I of glycerol gives rise to C-22 of 
chlorothricolide.114 Floss and co-workers proposed phosphoenolpyruvate as a 
mechanistically attractive precursor to C-22, C-23 and C-24, consistent with the above 
results (Scheme 38). 
COOH 
HO~O~ 0 
OH I o~o 
OH 
o 
OH 
126 191 
.;e = [U-13C]acetate ,.......... = [U-13C]propionate 
",......... = [U-13C]glycerol ~ = [U_13C]butyrate 
Figure 23: Biosynthetic origins of chlorothricin 126 and versipeiostatin 191 
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Scheme 38: Mechanism for formation of the spirotetronic acid moiety in chlorothricin proposed by Floss 
and co-workers. p=P032-
Versipelostatin 191 has been shown to be biosynthesised via condensation of a linear 
polyketide chain and a C3 branching unit. Feeding experiments established that C-28, C-
29 and C-30 are derived from an intact glycerol molecule rather than pyruvic acid or 
succinic acid (Figure 23).138 It seems likely that chlorothricin 126 and versipelostatin 
191 share a common biosynthetic pathway. 
3.4.2: Cloning, Sequence and Analysis of Gene Clusters that Direct Spirotetronate 
Biosynthesis 
The gene clusters that direct chlorothricin 126 and kijanimicin 127 biosynthesis were 
published in 2006 and 2007, respectively (Figure 24 and Figure 25):39,140 Gene 
sequencing, preparation of mutant strains and BLAST searching has allowed the 
assignment of putative functions to the genes in both clusters and the genes that 
putatively direct assembly of the spirotetronate moiety to be identified. DNA 
sequencing and genetic studies of chlorothricin 126 biosynthesis led to the proposal that 
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ChlD!, ChlD2 and ChID3, which are homologues of KijC, KijD, the N-terminal domain 
of KijE, respectively, ar' 1 d' e Invo ve ill the biosynthesis of the glycerol-derived three 
carbon unit.139,140 
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Figure 24: Cblorothricin 126 gene clusterJ39 
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This led Liu and co-workers to predict that the five proteins encoded by ldjABCDE are 
involved in activation of the glycerol-derived three carbon unit, its attachment to the 
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polyketide chain, and subsequent intramolecular Diels-Alder cyc1isation required to 
generate the spirotetronate ring system 192 as shown in Figure 26. 140 
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Figure 26: Proposed pathway for generation of spirotetronate 192 in kijanimicin 127140 
3.5: Diels-Alderase Enzymes 
Despite the belief that many natural products are biosynthesised by Diels-Alder 
reactions (including those containing spirotetronates), there are only three known Diels-
Alderase enzymes of which only one has been structurally characterised. Solanapyrone 
synthase,141,142 lovastatin nonaketide synthase l43 and macrophomate synthase (MPS)I44 
catalyse not only Diels-Alder reactions but also oxidation, polyketide chain fonnation 
and decarboxylation, respectively. These enzymes convert their corresponding 
substrates into reactive Diels-Alder precursors, forcing them into reactive 
conformations to undergo cycloaddition and releasing them from the active site. 
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The phytopathogenic fungus Macrophoma commelinae transforms 2-pyrone derivatives 
193 into the corresponding benzoate 195; this reaction is catalysed by the MPS enzyme 
(Scheme 39).144,145 
0 e M92:/0~0 eye ~ '~ 9 I CO2 -CO2 : ,0 o<\~ 
, --Mg;+ 
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02C h-
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Scheme 39: Proposed reaction catalysed by MPS 144 
The active site of MPS is at the C-terminal end of the ~-barrel, which is covered by the 
long loop from the three-fold-related chain. At one side of this catalytic cavity, Mg(II) is 
located in an octahedral coordination. Based on the crystal structure (Figure 27) a 
binding model was produced (Figure 28). In this binding model, the 2-pyrone molecule 
is likely to be fixed in place through two hydrogen bonds between the carbonyl oxygen 
of the 2-pyrone and Arg 101, and the C5-acyl oxygen of the pyrone and Tyr 169. Tyr 
169 is in turn placed in the proper orientation through II-II stacking with Phe 149. The 
flexible loop (residues 139-170) with hydrophobic side-chains (Phe 149, Pro 151 and 
Trp 152) from the three-fold related protomer shields this transition state from the 
solvent. 
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Figure 27: Overall structure ofMPS 
a) Protomer structure of MPS showing an a-helix swapped (Wa)s barrel fold. The p-barrel core (blue) is 
surrounded by 11 a-helices. The long a-helix (magenta) belongs to a neighbouring protomer related by 
the two fold axis and joins the p-barrel to form the (Wa)s barrel. The divalent magnesium ion (red) is 
located at the C-terminal region of the p-barrel. A long loop (magenta) opposite to the swapped helix 
interacts with an adjacent protomer by the three fold axis - shown in b); b) Three protomers related by the 
three fold axis, each loop joins the active site to the next protomer. c) The functional unit of MPS 144 
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Phe 1~9 
Tyr 169 ' 
Figure 28: The residues in the active site pocket of MPS and proposed model for the early transition state 
of the Diels-Alder reaction catalysed by tills enzyme l44 
However, more recently Jorgensen and co-workers have suggested that this enzyme 
may not catalyse a Diels-Alder reaction, but a Michael-aldol reaction. They carried out 
mixed quantum and molecular mechanics (QMJMM) combined with Monte Carlo 
simulations and free energy calculations to investigate the relative stabilities of the 
transition states for both reaction mechanisms. The results of these studies indicated that 
the Diels-Alder transition states are less stable than the Michael-aldol transitions states 
and therefore that MPS may not be a Diels-Alderase enzyme. 146 However, no 
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experimental evidence has yet been published to confirm whether the enzyme catalyses 
a Diels-Alder or Michael aldol reaction. 
3.5.2: Lovastatin Nonaketide Synthase 
o pfi=SEnz 
Scheme 40: Lovastatin Diels-Alder cyc1isation 
Fungal metabolite lovastatin 196 (Figure 29) and derivatives are cholesterol lowering 
drugs. Studies of the biosynthesis of lovastatin in Aspergillus terreus suggest it is 
formed by a polyketide synthase incorporating an enzyme catalysed Diels-Alder 
cyclisation of a hexaketide triene to a decal in system (Scheme 40). The enzymes 
encoded by lovB and love are involved in the Diels-Alder cyclisation. Expression of 
lovB and love in a heterologous host Aspergillus nidulans resulted in the formation of 
dihydromonacolin 197 (Figure 29).143 
o 
196 197 
Figure 29: Lovastatin 196, and dihydromonacolin 197 
However, expression of lovB without love resulted in pyrone formation and no Diels-
Alder cyclisation reaction. To ascertain whether lovastatin nonaketides (LNKS, encoded 
by lovB) could catalyse Diels-Alder reactions, the 335kD enzyme was purified from A. 
nidulans and added to 198 (Figure 30). It was determined that, in the absence of LNKS, 
cyclisation occurred spontaneously to give a mixture of exo and endo products (1: 1 ratio 
200:201, 202 and 199 were not observed). The endo product 202 is produced in the 
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presence ofLNKS (the stereochemistry of which corresponds to the lovastatin precursor 
197) as well as 200 and 201 (in a ratio of 15:15:1 200:201:202, again 199 was not 
observed).143 When LNKS was inactivated production of 202 was no longer seen. It is 
assumed that a key function of LNKS is to bind to the substrate in a conformation 
resembling the endo stereochemistry that leads to 202 in which the branching methyl 
group is pseudo-axial (unfavourable). Hence the product is formed when the enzyme is 
present. 143 Although the enzyme encoded by love has not yet been purified, preliminary 
experiments suggest that it binds to LNKS along with the usual co-factors and 
substrates. 
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COR 
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Diels-Alder 
cydisation 
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COR H ~OR 
""cfr ""CO"" H H 
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Figure 30: Intramolecular Diels-Alder cyclisation reactions of 198. Product 202 is only observed in the 
presence of LNKS 143 
3.5.3: Solanpyrone synthase 
Feeding experiments have demonstrated that the phytotoxins salanopyrones produced 
by Altermaria solani are biosynthesised by a [4+2] cycloaddition which proceeds with 
high exo-specificity. Oikawa and co-workers have partially purified the enzyme 
salanopyrone synthase, and shown that this converts synthetic substrate 203 into 204 
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and 205 in the presence of molecular oxygen, on a semi-preparative scale without loss 
of enantioselectivity or diastereoselectivity (Scheme 41 ).141,142 
HO i) 
203 204 205 
51% (>98% ee) 
Scheme 41: Enzymatic Diels-Alder reaction of a synthetic prosolanopyrone 
i) Partially purified the enzyme salanopyrone synthase 
3.6: Proposed Biosynthetic Pathway to Quartromicins 
Although little has been determined about the biosynthetic pathway of the 
quartromicins, a plausible biosynthetic pathway to the carbon skeleton of 122a-f has 
been proposed by Challis and co-workers, which could proceed via the intermediates 
206 and 207 (Figure 31). The pathway is initially proposed to involve a type I modular 
polyketide synthase-mediated assembly of two enzyme bound ~-ketothioesters. The 
type I PKS is likely to contain five modules (Figure 32). Both of the two enzyme bound 
~-ketothioesters could be produced by the same PKS, although the assembly of 206 
would require "skipping" of module four. 
206 207 
Figure 31: Proposed intennediates 206 and 207 in the quartromicin biosynthetic pathway 
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Figure 32: Proposed module organisation of the PKS catalysing the assembly of linear polyketide chains 
in putative intermediates 206 and 207 
Module "skipping" occurs in several other PKSs, for example the pikromycin PKS.147-
149 Pikromycin is a 14-membered macrolide produced by Streptomyces venezuelae. This 
bacterium also produces several other macrolides, including the 12-membered 
macrolide methymycin.150 Methymycin is produced by the same PKS as pikromycin, 
except the fmal module is "skipped" hence a shorter chain is fonned.147-149 It is 
proposed that the rate of transfer of the polyketide chain from module five to the 
thioesterase of module six is similar to the rate of loading of the fmal extension unit 
onto the ACP domain of module six. Thus the fmal condensation can be skipped and the 
TE catalysed cyclisation can occur to form the smaller 12-membered ring. In 
quartromicin biosynthesis, the same situation could apply if the loading of the 
malonyl-eo A extender unit onto the ACP domain of module four occurs at a similar 
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rate to the transfer of the ~-ketothioester from module three to module five. Module four 
would then be skipped and the shorter chain of precursor 206 would be produced. 
A FkbH-like stand alone protein would then load 1,3-biphosphoglycerate on to a KijD-
like stand alone ACP and catalyse phosphate hydrolysis to give the glyceryl-ACP. An 
enzyme similar to the N-tenninal domain of KijE would convert the glyceryl-ACP into 
glycerol-CoA, and a KijB-like enzyme would condense the ~-ketothioester chains 
attached to module five of the PKS with glyceryl-CoA. An enzyme similar to the C-
terminal domain of KijE would catalyse lactonisation and release of the polyketide 
chain from the ACP of module five and a KijA-like protein catalyses dehydration of the 
resulting 2-acyl-4-hydroxy-methyl tetronic acid, which would then undergo Diels-Alder 
cycloadditions. 
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Scheme 42: Proposed biosynthetic pathway to quartromicin intermediates 206 and 207 
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Analogous enzymes to those proposed to assemble the putative exomethylene tetronic 
acid intermediates in kijanimicin / chlororthricin biosynthesis have been found encoded 
within the tetronomycin 208 biosynthetic gene cluster (Figure 33).151 A recent 
publication shows that enzymes from the tetronomycin biosynthetic gene cluster divert 
glyceryl units from glycolysis into the tetronate ring formation. 152 
208 
Figure 33: Tetronomycin 208 
Other exomethylene tetronic acids such as tetrodecamycin 209153 and FR-900109154 
210 are known and are probably biosynthesised by similar PKS systems (Figure 34). 
~l{o W,li 
HO OH 
209 210 
Figure 34: Structures oftetrodecamycin 209 and FR-900109 210 
An endo-Diels-Alder reaction between the two acyl tetronic acids 206 and 207 would 
yield the corresponding heterodimer. This dimer could then undergo homodimerisation 
via exo-Diels-Alder cyclisations to yield the carbon skeleton of the quartromicins 
(Scheme 43). Subsequent oxidations and galactosylations would yield the 
quartromicins. Similar biosynthetic pathways, all involving elimination of water from a 
tetronic or tetramic acid followed by IMDA cyclisation, have been proposed for the 
other members of the spirotetronic acid family of natural products. 
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Scheme 43: Diels-Alder cyc1isation of proposed intermediates 206 and 207 to produce carbon skeleton of 
quartromicin 122 
3.7: Aims and Objectives 
The aim of this project was to develop a concise and versatile synthetic route to 2-
enoyltetronic acids. Such tetronic acids include the proposed precursors 206 and 207 of 
the quartromicin antibiotics (Figure 35). 
o 0 
206 207 
Figure 35: Proposed precursors in quartromicin biosynthesis 206 and 207 
Once a synthetic route had been developed to these two precursors it was proposed to 
investigate the biomimetic synthesis of the carbon skeleton of the quartromicin 
algycone from the precursors. 
77 
Chapter 4: Synthesis and Feeding of Analogues of 
a Key Intermediate in Prodiginine Biosynthesis 
Chapter 4: Synthesis and Feeding of Analogues of a Key 
Intermediate in Prodiginine Biosynthesis 
4.1: Aims of the Work Described in this Chapter 
Chemically-synthesised analogues of proposed biosynthetic intennediates can be used 
in conjunction with mutants containing knockouts in individual biosynthetic genes to 
investigate natural product biosynthetic pathways. In an effort to investigate the 
biosynthetic pathway of the prodiginines produced by S. coelicolor A3(2), a synthetic 
route was developed to produce a mimic 117 of a proposed key intennediate 32 in the 
biosynthesis of the bipyrrole 10, which is in turn a key intennediate in prodiginine 
biosynthesis. Further analogues of intennediate 32 were also synthesised and the ability 
of mimic 117 and its analogues to direct production of natural prodiginines and 
analogues modified in the A-ring by feeding to bipyrrole-deficient mutants of S. 
coelicolor was explored. 
4.2: Preparation of a Mimic 117 of a Proposed Key Intermediate 32 in 
the Biosynthesis of Bipyrrole 10 
In order to establish the sequence of biochemical events in the biosynthesis of several 
natural products, N-acetylcysteamine (NAC) thioester analogues of putative carrier 
protein bound intermediates have been used.73,155-161 Therefore, it was thought that the 
NAC thioester of pyrrole-2-carboxylic acid 117 would be a suitable mimic for the key 
intennediate 32 in the biosynthesis of the bipyrrole 10 (Figure 36). 
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Figure 36: A mimic 117 of a proposed key intermediate 32 in the biosynthesis of bipyrrole 10 
The preparation of pyrrole-2-carboxyl-N-acetylcysteamine thioester 117 from pyrrole-2-
carboxylic acid 211 and N-acetylcysteamine was attempted initially using the coupling 
reagents DMAP and EDCI. The reaction was investigated using a variety of solvents, 
including anhydrous DCM, DCE and toluene, at different temperatures. However, these 
attempts were unsuccessful and multiple products were fonned in each of these 
reactions. This is likely to be because of the low electrophilicity of the carbonyl carbon 
of the activated ester derivatives of pyrrole-2-carboxylic acid, resulting from the 
donation of electron density from the electron rich pyrrole ring into the carbonyl II. 
orbital. Owing to the failure of these reactions, alternative procedures were sought. 
Conversion of pyrrole-2-carboxylic acid 211 to the acid chloride 212 followed by 
coupling with N-acetylcysteamine was thus examined. 
A procedure to synthesise compound 117 has been previously reported by Thomas et 
01.73 who converted pyrrole-2-carboxylic acid 211 to the corresponding acid chloride 
212 using excess oxalyl chloride, then coupled the acid chloride and N-acetylcysteamine 
by heating to reflux overnight in DCE, yielding the product 117. This method was 
attempted but none of the desired 117 was obtained. It appeared that the acid chloride 
had not formed in the reaction; several other possible methods are available for 
preparing the acid chloride, 212. One method reported by Bourguignon and co-workers 
involves heating pyrrole-2-carboxylic acid with thionyl chloride at 80°C in benzene. 162 
However when this was attempted, a brown solid was produced which could not be 
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dissolved in any solvent or combination of solvents, probably due to polymerisation of 
the starting material. Other methods utilised a catalytic amount of DMF and oxalyl 
chloride to aid the conversion of the carboxylic acid to the acid chloride probably via 
C'. t· f th V·I . I 163-166 U . . . . d J.orma IOn 0 e 1 smeler sa t. smg this modIficatIOn of Thomas an co-
workers procedure resulted in the desired acid chloride product, as determined by IR 
spectroscopy which showed a significant change in the frequency of absorption of the 
carbonyl group (pyrrole-2-carboxylic acid 1651 cm-1 and pyrrole-2-carbonyl chloride 
1718 cm-I) (Scheme 44). 
QyOH 
H 0 
211 
i) QyCI 
H 0 
212 
ii) U\ s ~ "~/y ~N~ 
H 0 H 
118 
Scheme 44: Preparation of pyrrole-2-carboxyl-N-acetylcysteamine thioester 117 
i) Oxalyl chloride, DMF, reflux, lh. ii) N-acetylcysteamine, DMAP, reflux, 14h, DeE, 75% over 2 steps 
Coupling of acid chloride 212 with N-acetylcysteamine was initially attempted by 
heating to reflux the acid chloride and N-acetylcysteamine in DCE, without success. It 
was thought that the N-acetylcysteamine may have dimerised via disulfide formation 
after exposure to the air. However, a IH NMR spectrum of the N-acetylcysteamine 
showed the signal for the SH proton at 1.4 ppm. The N-acetylcysteamine was then 
dissolved in deuterated methanol. The solvent was removed in vacuo and a further 1 H 
NMR spectrum was recorded showing that the signal corresponding to the SH proton at 
1.4 ppm was no longer present due to the acidic thiol hydrogen exchanging with 
deuterium. This confirmed that no N-acetylcysteamine dimer was present, because if a 
dimer of the starting material was present no SH proton would have been seen in the 
original I H NMR spectrum, i.e. both spectra would have been identical. 
Having determined that oxidative dimerisation of N-acetylcysteamine was not causing 
the problem, the reaction was attempted again with the addition of DMAP as a 
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nucleophilic catalyst. The reaction was successful and the desired synthetic analogue 
117 was produced in a good yield (75%). It was determined that the reaction proceeded 
better utilising DCE as solvent, as opposed to DCM, as this allowed the reaction to be 
carried out at a higher temperature, thus increasing the rate of reaction. The harsh 
conditions required for the synthesis of acid chloride 212 and its conversion to thioester 
117 reinforce the hypothesis that the carboxyl group in pyrrole-2-carboxylic acid and its 
derivatives are unreactive towards nucleophiles. 
Purification of compound 117 was undertaken by passing the pyrrole-2-carboxyl-N-
acetylcysteamine thioester through a plug of silica impregnated with copper sulphate. 
The excess N-acetylcysteamine was removed by the formation of a copper complex. 
The silica impregnated with copper sulphate changed from blue to yellow as the 
complex formed and remained at the top of the column. 167 
4.3: Feeding of Pyrrole-2-carboxyl-N-acetylcysteamine thioester 117 to 
redM::aac(3)IVMutant of S. coelicolor M511 
A mutant of Streptomyces coelicolor M511 (redM· :aac(3)JV) has been prepared by 
Stanley (a former PhD student in the Challis group) by replacing redM on the 
chromosome of S. coelicolor M511 with a "cassette" containing oriT and the acc(3)JV 
apramycin resistance gene.72,168 Neither undecylprodiginine 21 nor streptorubin B 23 
could be detected in organic extracts of the redM· : aac(3)JV mutant. However, 2-
undecylpyrrole 29 was seen by LC-MS analysis and LC-MSIMS comparison with a 
synthetic standard of 29 (Scheme 45 and Figure 37). No accumulation of the bipyrrole 
10 was seen by LC-MSIMS comparisons to a chemically synthesised authentic standard 
(Scheme 45 and Figure 37).72 
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Scheme 45: Proposed roles ofRedM, RedW and RedO in assembly ofbipyrrole intermediates in the 
biosynthesis of prodiginines 
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Figure 37: LC-MSIMS analysis of redU' :acc(3)IV mutant of S. coelicolor showing A) accumulation of 
UP in this mutant B) EIC showing mlz 222 corresponding to the mass of UP C) Fragmentation pattern of 
2-undecylpyrrole 
Direct transfer of the pyrrole-2-carboxyl group between the RedO PCP and the RedX 
enzyme is proposed to occur in the assembly ofMBC 10 (Scheme 46).72,76 Thus feeding 
of the synthetic mimic 117 ofpyrrole-2-carboxyl-RedO should restore production of the 
prodiginines in the redM::aac(3)IV mutant of S. coelicolor. 
RedO 
QyT 
H 0 Direct Transfer 
32 35 
Scheme 46: Proposed pathway for the transfer of the pyrrole-2-carboxylic group from RedO to RedX 
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Accordingly feeding ofpyrrole-2-carboxyl-N-acetylcysteamine thioester 117, to a liquid 
culture of the redM· :aac(3)JV mutant was shown to restore prodiginine production as 
judged by HPLC and MS analysis at concentrations of 0.1 mglmL (Figure 38). The 
concentration of the NAC thioester added to the cultures was found to be vital; 
increasing the concentration to 0.5 mglmL resulted in no restoration of antibiotic 
production. This could be because the NAC thioester could act as an inhibitor of later 
steps in the biosynthetic pathway at higher concentrations. 
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Figure 38: UV chromatogram of the wild type Streptomyces coelicolor (black) and redM·:acc(3) IV 
mutant (blue) mycelia after prodiginine production had been restored 
Ion extraction from the LC-MS chromatogram revealed that the large peak with 
retention time of 5.5 minutes corresponded to streptorubin B 22 (mlz 392.3) and the 
small peak at a retention time of 7.0 minutes corresponded to undecylprodiginine 21 
(mlz 394.3). Interestingly, the purity of the NAC thioester was not an important factor 
in the success of this experiment. Both crude and purified samples of the NAC thioester 
were fed and both restored production of prodiginines in the S. coelicolor 
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redUo:aac(3)IV mutant. These studies are consistent with the hypothesis that direct 
transfer of the pyrrole-2-carboxyl group from the RedO PCP to the Red-X enzyme 
occurS.72,76 
Further feeding studies of analogue 117 with bipyrrole-deficient redUo:aac(3)IV and 
redW·:aac(3)IVmutants (Scheme 45) were carried out by Stanley.168 When 117 was fed 
to the redW·:aac(3)IV mutant, prodiginine production was also restored, providing 
further confrrmation of the above results and those reported by Walsh and co-
workers.73,76 
4.4: Generation of Analogues of the Substrate Mimic 117, and 
Investigation of their Incorporation into Prodiginine Analogues by 
Mutasynthesis 
The results obtained in the feeding studies using NAC thioester 117 indicated that 
feeding analogues of 117 to the redUo :acc(3) IV mutant could generate novel analogues 
of undecylprodiginine and streptorubin B, which might have superior biological 
activity. Thus furan 118, thiophene 119, fluorobenzene 120 and pyridine 121 analogues 
of 117 were synthesised from commercially available materials using the procedure 
outlined in Scheme 47, and fed to the redM::acc(3)IVmutant. 
Unfortunately, feeding of these analogues did not lead to the production of novel 
prodiginines by mutasynthesis. This may be because the NAC thioesters do not 
penetrate S. coelicolor cells, or because the substrate analogues are not substrates of 
RedX. If the latter is the case, then perhaps another analogue more similar in structure 
to NAC thioester 117, for example 215, would successfully lead to prodiginine 
analogues (Figure 39). However, it is possible that one or more of the enzymes involved 
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in prodiginine biosynthesis are very specific for their substrates, thus precluding the 
production of prodiginine analogues by mutasynthesis. 
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Scheme 47: Preparation ofpyrrole-2-carboxylic acid-NAC thioester 117 analogues 
i) Oxalyl chloride, DMF, reflux, lh. ii) N-acetylcysteamine, DMAP, reflux, l4h, DCE, 11875%, 119 
58%, 120 73%, 121 69% 
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Figu re 39: Another potential analogue of 117 that could be used in feeding studies 215 
4.5: Conclusion 
The synthesis of pyrrole-2-carboxyl-N-acetylcysteamine thioester 117 using modified 
literature conditions was achieved. Feeding of this analogue of the proposed pyrrole-2-
carboxyl-RedO intermediate in prodiginine biosynthesis to a redM':acc(3)IV mutant of 
S. coelicolor restored prodiginine production, consistent with the hypothesis that direct 
transfer of the pyrrole-2-carboxyl group from the RedO-PCP to the Red-X enzyme 
occurs. 
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Furan 118, thiophene 119, fluorobenzene 120 and pyridine 121 analogues of 117 were 
also synthesised and fed to the redM::acc(3)JV mutant. This did not lead to the 
production of novel prodiginines by mutasynthesis. However, in work carried out by the 
Challis group, bipyrrole 10 analogues have been synthesised (Figure 13) and used to 
probe the substrate specificity of the RedH enzyme in undecylprodiginine biosynthesis. 
These analogues were incorporated to produce novel prodiginines by mutasynthesis.83 
This would suggest that either NAC thioesters 118, 119, 120 and 121 did not penetrate 
S. coelicolor cells, or that one or more of the enzymes involved in prodiginine 
biosynthesis subsequent to RedM are very specific for their substrates. 
In the future, in order to demonstrate whether or not analogues of 117 could be 
incorporated, a deuterated analogue could be synthesised and fed to determine whether 
or not it is incorporated into the corresponding prodiginine analogue. If this was 
successful some more similar analogues could also be generated such as substituted 
pyrroles to determine whether or not the pathway is specific for pyrrole substrates. 
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Chapter 5: First Generation Synthetic Approaches to Putative 
Key Intermediates in Quartromicin Biosynthesis 
In order to probe the biosynthetic pathway to quartromicins the two precursors 206 and 
207 (Figure 40) would need to be synthesised in labelled form to ultimately be used in 
feeding studies aimed at investigating their incorporation into the natural product. Thus, 
any synthetic route to these would need to incorporate stable isotope labels at a late 
stage. 
206 207 
Figure 40: Proposed precursors in quartromicin biosynthesis 206 and 207 
5.1: Initial Retrosyntbetic Analysis 
A review of the literature revealed that targets 206 and 207 have not previously been 
synthesised. Therefore a first generation synthetic approach was based on the 
retrosynthetic analysis of target 206 which is shown in Scheme 48. 
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Scheme 48: Three possible retrosyntheses of 206 
Retrosynthetic analysis of 206 identified two main initial disconnections a and b. 
Disconnection a leads back to two different possible precursors; the known ~-
ketothioester-'Y-phosphonate 224169 and the Meldrum's acid derivative 225, as well as a 
common precursof, dienal 219. Disconnection b leads back to the tetronic acid 
derivative 218 and dienal 219. It was envisaged that similar chemistry to that used for 
the synthesis of 224 could be used for the preparation of the Meldrum's acid derived 
phosphonate 225 and the tetronic acid derived phosphonate 218, both of which 
represent attractive precursors fOf the synthesis of 207. 
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5.2: Exploration of Route 1: Thioester Phosphonate Chemistry 
The methodology for the synthesis of ~-ketothioester-'Y-phosphonates 224 was 
developed by Ley and co-workers. 169 This led to the proposed eight step synthesis 
outlined in Scheme 49.169-171 Initially Meldrum's acid 226 would be acylated with 227 
or 228 to give 229 or 230 respectively. The Meldrum's acid derivatives would then be 
ring opened with tert-butane thiol and reaction with sodium diethyl phosphite would 
yield known ~-ketothioester-'Y-phosphonates 224 or 233. Homer-Wadsworth-Emmons 
reaction of 224 with aldehyde 219 or 233 with aldehyde 234 would afford the thioesters 
222 or 235, which could be coupled with hydroxy ester 236 to give 237 or 238. Ring 
closure of 237 and 238 would yield tetronic acid derivatives 239 and 240 respectively. 
These would be deprotected and the mesylation followed by elimination would give the 
target compounds 206 and 207. 
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Scheme 49: Proposed synthetic route to 206 and 207 
OTr 
OH 
i) 227 or 228, pyridine, DCM, O°C; ii) HStBu, toluene, reflux; iii) NaP(O)(OEth, NaH, THF, O°C to 
rt; iv) NaH, THF, 219 or 234, O°C to rt ; v) 236, CF3C02Ag, THF, rt; vi) TBAF, rt; vii) TF A, rt; viii) 
1) MsCI, pyridine; 2) NaOH 
This route required access to dienal 219 and trienal 234 to synthesise 206 and 207 
respectively. Initially 219 was synthesised using the literature chemistry outlined in 
Schemes 50 and 51.172 However, several steps required significant optimisation. 
Conditions for the production of ylide 245 were screened. A one-pot reaction with 
triphenylphosphine and 243 in toluene followed by treatment with n-BuLi proved very 
low yielding due to aggregation of the ylide salt 244. 173 Crushing the intermediate 
before the addition of n-BuLi did not increase the yield significantly. A variety of 
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solvents and temperatures were investigated, and it was determined that by using ethyl 
acetate under conditions described by Werkhoven et al. 174 the ylide salt 244 could be 
obtained as a white crystalline solid which precipitated from the reaction mixture in 
excellent yield (88%) (Scheme 50). However, this method did not prove very 
reproducible. With fresh supplies of triphenylphosphine the white crystalline solid 
(ylide salt 244), was no longer produced. Instead an extremely viscous oil, which 
prevented the reaction mixture stirring freely, was obtained resulting in ylide salt 244 
being produced with lower yield and purity. Using DCM as solvent and with an excess 
of triphenylphosphine, the product could be obtained, although not in pure form. The 
remnant triphenylphosphine could be removed by flash column chromatography after 
the Wittig reaction. Compound 244 needed to be deprotonated to form ylide 245; a 
variety of conditions were examined. Deprotonation with NaH, n-BuLi or aqueous 
NaOH173-175 were all successful, with washing using aqueous NaOH being the most 
efficient giving 245 in excellent yield (90%) (Scheme 50). 
e ffi 
Br Br PPh3 ii) PPh3 /yo~ i) /yo~ ~o~ • • 
0 0 0 
243 244 245 
Scheme 50: Preparation ofylide 245 
i) PPh3, EtOAc, reflux, 24 hrs, 88%; ii) 2 equivalents of NaOH(aq) , DeM, rt, 90% 
Once ylide 245 had been formed a Wittig reaction with tiglic aldehyde 246 was carried 
out. This reaction proceeded smoothly in good yield (80%), affording ethyl ester 247 
which was then reduced with DIBAL-H to produce primary alcohol 248 in excellent 
yield (85%) (Scheme 51). Subsequent oxidation conditions were investigated to produce 
176 • 177 d"d 'd f 172 aldehyde 219, including Swem, Dess-Martln and manganese 10XI e OXI a IOns, 
of which manganese dioxide proved to be the most efficient giving 219 in excellent 
yield (96%) (Scheme 51). 
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Scheme 51: Synthesis of dienal aldehyde 219 
248 
i) 246, toluene, reflux, 80%; ii) OIBAL-H Et20 O°C 85%- iii) MnO OCM rt 960 / , , " 2, ,,1"0. 
Another key building block required for this synthetic route was ester 236. The 
chemistry used for the synthesis of 236 from commercially available 249, is outlined in 
Scheme 52.178 Removal of the acetonide group in 249 gave dihydroxy ester 250 and 
subsequent selective protection of the primary alcohol with a trityl group gave u-
hydroxy ester 236 in excellent yield (79% over 2 steps). 
o-t- i) OH ii) OH Meo~O ----.. MeO~OH --__ .. MeO~OTr 
o 0 0 
249 250 236 
Scheme 52: Synthesis of ester 236 
i) MeOH, IN HCl, rt, 86%; ii) Ph3CCI, OMAP, OCM, rt, 93% 
The final building block to be synthesised was ~-ketothioester-'Y-phosphonate 224 
(Scheme 54). Acylation of Meldrum's acid 226 with bromoacetyl bromide 227 was 
carried out following the procedure developed by Haynes, affording 229 in good yield 
(65%) (Scheme 53).169,179 Unfortunately, compound 229 was extremely air and moisture 
sensitive. Upon contact with air it forms an insoluble black substance - probably a 
polymeric material. However, its direct use without further purification allowed ring 
opening by tert-butanethiol to be carried out producing 231. Initially toluene was used 
as a solvent, but competing side reactions meant low yields were obtained. The use of 
1,2-dichloroethane as a solvent circumvented this problem giving much improved 
yields, 57% over the two steps (Scheme 53). 
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ii) o 0 1.,.-Br~s~ 
231 
Scheme 53: Synthesis of231 from Meldrum's acid 
i) 227, pyridine, DCM, O°C to rt; ii) HStBu, DCE, reflux, 57% over 2 steps 
Compound 231 was relatively stable at low temperatures under argon, but rapidly 
decomposed at room temperature, again forming a black insoluble solid. Reaction of 
231 with sodium diethylphosphite proceeded smoothly giving the ~-ketothioester-'Y-
phosphonate 224 in excellent yield (85%) as an orange oil, which was stable at low 
temperatures (Scheme 54). 
o 0 1.,.-Br~s~ 
231 
i) 0 0 0 1.,.----~ EtO/~JJS~ 
DEt 
224 
Scheme 54: Conversion of 231 to the p-ketothioester-y-phosphonate 224 
i) NaH, THF, NaP(O)(EtO)2, -lOoC to rt, 85% 
Initially, in model reactions, phosphonate 224 was coupled with a variety of 
commercially available aldehydes in Homer-Emmons reactions to give a range of E-
alkenes in good to excellent yields (Scheme 55 and Table 1). Homer-Emmons reaction 
of phosphonate 224 and aldehyde 219 was successful and gave 222 in good yield 
(64%), although some minor geometrical isomerisation was observed (Scheme 55 and 
Table 1). 
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Scheme 55: General procedure for synthesis ofthioesters 222, 251. 252 and 253 
i)NaH, RCHO, THF, O°C to rt 
ReHO Product Yield 
o 0 J( 
< > 1° ~s 83% 
251 
0 0 
sJ( ~O ~ 70% 
252 
0 0 erO ~ sk 98% 
253 
0 0 
sk ~o ~ ~ ~ 64% 
222a 
Table 1: Synthesis ofthioesters 222, 251, 252 and 253 
Length of 
reaction 
16 hours 
---
48 hours 
--
16 hours 
--
48 hours 
Taylor and co-workers have developed one-pot tandem alcohol oxidation-Homer-
Wadsworth-Emmons reactions, using manganese dioxide as the oxidising agent. 180 Both 
lithium hydroxide and guanidine bases were found to be very efficient in the process 
giving rise to high yields. The literature also stated that pre-existing double bond 
geometry remained unchanged and that E-alkene products were predominant under the 
standard conditions used. 180,181 In an effort to make the synthesis of 206 and 207 more 
efficient this methodology was employed and although the alcohol 248 was oxidised to 
the aldehyde 219 during the reaction, none of the desired E-alkene 222 was produced 
(Scheme 56). This was not completely unexpected as the dianion of 224 is required for 
the Homer-Wadsworth-Emmons reaction to occur. NaOH and guanidine are not strong 
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enough bases to form the dianion of 224 which is why NaH was used in the original 
reaction conditions. 
~OH 
248 222 
Scheme 56: Attempted preparation of222 one pot reaction l80,181 
i) Mn02, 248, LiOH, molecular sieves, THF 
The ~-ketoester 222 was condensed with hydroxyl ester 236 by silver salt promoted 
condensation to give 237 (Scheme 57). This reaction proved problematic and low yields 
ranging from 11-23% of product 237 were obtained. 
OH 
MeO J-. "OTr 
i) If ~ 
o 0 1/ ~s~ 
o 
236 
.. 
o 0 
~O 
MeoA 
237 0 OTr 222 
Scheme 57: Silver mediated coupling reactions to synthesise 237 
i) 236, CF3C02Ag, THF, shielded from the light, 23% 
It was discovered that silver trifluoroacetate was readily hydrolyses in air, meaning 
trifluoroacetic acid (TF A) was present in the reaction mixture. The acidity of the 
reaction mixture caused removal of the trityl group. To overcome this problem, 
triethylamine was added to basify the reaction before the substrate was added. 182 
Although this prevented deprotection, the yield of the reaction did not improve 
significantly (27%). To see whether or not the polyene chain was causing any 
difficulties during the reaction, silver salt promoted condensation of the hydroxy ester 
236 and thioester 252 was also attempted. Compound 254 was obtained (Scheme 58), 
but the yields could not be improved, suggesting the presence of the polyene does not 
affect the outcome of the reaction. 
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o 
i) 
252 
OH 
Meo~OTr 
o 
236 
254 
o 
""=::: 0 
MeO~oTr 
o 
Scheme 58: Silver mediated coupling reactions to synthesise 254 
i) 236, silver trifluoroacetate, THF, shielded from the light, rt, 16 h, 16% 
Dieckmann cyclisation of 237 and 254 was investigated under a variety of conditions 
using different bases but with little success (Scheme 59). The use of sodium methoxide 
resulted in trans-esterification. Sodium hydride appeared to afford the desired tetronic 
acid 239 together with some undesired by-products; however, the desired product could 
not be purified. Tetra-n-butylammonium fluoride (TBAF) was reported as the base of 
choice for such cyclisations,170,171,178,183 but despite numerous attempts under a variety 
of conditions none of the desired material could be synthesised. It is possible that the 
use of anhydrous TBAF generated in situ may be required for this chemistry to work. 
This would allow the impact of water in commercially-available samples of this reagent 
d th 1·· . 184 to be assesse upon e cyc IsatlOn reaction. 
o 0 
~o MeO~OTr 
o 
220 
o 
""=::: 0 
254 
MeO~OTr 
o 
7 
239 
255 
Scheme 59: Attempted synthesis of 239 and 255 
TrO 
TrO 
Two major problems were encountered in this synthetic route; the first being the low 
yields of the silver trifluoroacetate coupling reaction and the second being the 
Dieckmann cyclisation to afford tetronic acids derivatives. For this reason alternative 
synthetic routes were examined while these conditions were being investigated further. 
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Once it was established that the route described in Chapter 6 was successful, no further 
investigations were carried out on this synthetic route. 
5.3: Exploration of Route 2: Meldrum's Acid and Tetronic Acid-
derived Phospho nates 
As an alternative strategy, it was thought that a more direct route to the desired 
precursors 206 and 207 could involve acylation of Meldrum's acid 226 or tetronic acid 
256 with bromo acetyl bromide 227, followed by conversion of the resulting products to 
the corresponding phosphonium salts or phosphonates. The resulting compounds could 
be coupled in Wittig or Homer-Emmons reactions with aldehyde 219 (Scheme 60). 
98 
Ai) 
226 
BrJ;( 
o~o~ 
229 
o 
~ ~ ~ 0 
MeOyLOTf 
237 0 
Av) : 
t 
Chapter 5: 1st Generation Approach to Putative 
Key Intermediates in Quanromicin Biosynthesis 
Aii) EK)-~~ 
Eta ~~~) 
o o~ 
----------------- .. 
225 
Alii) 
Aiv) 
223 
Scheme 60: Proposed route 2 to desired compounds 206 and 207 
Ai) 227, pyridine, DCM O°C; Ali) NaH, THF, NaP(O)(OEth, O°C to It; Aiii) 219, NaH, THF; Aiv) 236, 
heat; Av) TBAF; Bi) 227, pyridine, DCM O°C; Bii) NaH, THF, NaP(O)(OEth, O°C to It; Biii)l) 219, 
NaH, THF, 2) n-BuLi then MOMCI 
Initially this route was investigated by Haynes, but was unsuccessful; neither 225 nor 
218 could be synthesised.179 However, the Arbuzov-like reaction used for the 
preparation of phosphonate 224 following the procedure of Ley and co-workersl70 
(Scheme 55) used two equivalents of sodium hydride. It was thought that two 
equivalents of sodium hydride might be required to react diethyl phosphate with 2-
bromoacetyl tetronic acid 257 and Meldrum's acid derivative 229 because they contain 
highly acidic protons that are likely to be removed by sodium diethyl phosphate. If the 
99 
Chapter 5: 1st Generation Approach to Putative 
Key Intermediates in Quartromicin Biosynthesis 
sodium salt of the tetronic acid derivative 257 is formed fITst the desired reaction should 
take place. 
Synthesis of the Meldrum's acid derivative 229 had already been carried out 
successfully (Scheme 53). Therefore the same reaction conditions were used to 
synthesise the tetronic acid derivative 257. This reaction proceeded smoothly to give 
257 in good yield (66%) (Scheme 61). 
0 0 0 
150 i) B'~O 0 0 Br~ 0 256 257 
Br 
227 
Scheme 61: Synthesis of 257 
i) 227, pyridine, DCM O°C to rt, 66% 
Unfortunately the tetronic acid derivative 257 was just as unstable as the Meldrum's 
acid derivative 229, making it difficult to work with. The Arbuzov reaction was 
attempted at a variety of temperatures with both the Meldrum's acid derivative and the 
tetronic acid derivative, none of the desired products 225 or 218 could be isolated 
(Scheme 62). Instead a mixture of inseparable compounds was produced. This may have 
been because tetronic acid and Meldrum's acid derivatives are susceptible to 
nucleophilic attack at C-l, which would give rise to competing side reactions. 
0 0 ~~ B'~ ~ • ,P 7 EtO GEt 0 
0 0 
257 218 
o 0 ~!{ B'~o ~ . EtO/~ 0 7 
o 0)( OEt )( o 0 
229 225 
Scheme 62: Attempted synthesis of218 and 225 
i) 257 or 229, NaH, THF, NaP(O)(OEth -10°C to rt 
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Having found a method for the preparation of ylide 245 (Scheme 50) it was thought that 
reaction of 257 with triphenylphosphine may lead to the production of the tetronic acid 
ylide (Scheme 63). Although initial attempts under these conditions looked promising. 
by mass spectrometry none of 258 could be detected in the reaction mixture. 
5.4: Conclusion 
o 0 
Br~o 
o 
257 
7 
258 
Scheme 63: Attempted synthesis of 258 
i) PPh3, DCM, rt 
Neither of the above two synthetic routes investigated proved to be very successful. 
Route one looked promising at first, but owing to the low yields of the silver 
trifluoroacetate reaction and the failure of the Dieckmann cyclisation, this method was 
not suitable for developing an efficient and concise route to 206 and 207. If route two 
had been successful a very concise synthesis would have been developed. However, 
because suitable conditions for the synthesis of 225, 218 and 258 were not found, this 
route could not be developed further. 
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Chapter 6: Second Generation Approach to Key Putative 
Intermediates in Quartromicin Biosynthesis and 
Investigations of Biomimetic Diels-Alder Reactions 
Because the previously described attempts to synthesis 206 and 207 did not meet with 
much success, a new route was investigated. Retrosynthetic analysis of desired 
compound 206 identifies aldehyde 234 as a starting material, which can be synthesised 
using precedented synthetic procedures and known methyl protected exomethylene 
tetronate 261 (Scheme 64). 
~CHO 
246 
+ 
(PhhP~O 
259 
+ 
(PhhP~ /.'0... 
'"V'" ~O 
260 
~~ 
206 
JJ 
0 0 
<== ~jrJ;vCHO ~o ~ ~o @ H2C'X 
MeO K MeO e 
234 261 262 263 
Scheme 64: Retrosynthetic analysis of 206 
This alternative approach to the synthesis of acyl tetronic acids developed by Yoshii and 
co-workers in 1987 utilises the lithiated derivative of the methyl protected 
exomethylene tetronate 261 (Scheme 65).185 Several total and partial syntheses of 
tetronate natural products have utilised these lithium derivatives, for example 
. . . d D 1415186-188 W'th thi th d I . . d tetrodecamycm and abyssomlcms Can. ' , 1 S me 0 0 ogy m mm 
the following synthetic route was proposed (Scheme 65). First, the lithiated derivative 
of the methyl protected exomethylene tetronate 261 could be generated using lithium 
diisopropylamide (LDA) as the base, followed by the addition of an appropriate 
aldehyde, RCHO, to generate the secondary alcohols 265 and 266. Oxidation of the 
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alcohols 265 and 266 to ketones 267 and 268 followed by deprotection would give the 
desired compounds 206 and 207. 
0 g 
MeO 
261 
i) 
----- ... 
206n=0 
207 n = 1 
0 up< 
MeO 
264 
__ i~) ___ 
iv) 
.. -----
265 n = 0 
266 n = 1 
: iii) 
, 
t 
267 n = 0 
268n=1 
Scheme 65: Proposed route to 206 and 207 based on methodology developed by Yoshii and co-
workers 185 
i) LDA, -78°C; ii) RCHO, -78°C; iii) Mn02, DCM, rt; iv) LiCI, DMSO, 50°C 
Both Yoshii and Paintner describe methods for the synthesis of the methyl protected 
exomethylene tetronate 261 (Scheme 66).185,186 The first method involves 
(dimethylamino)methylenation at C(5) by reaction of the commercially available 4-
methoxy-2(5H)-furanone 269 with dimethylformamide dimethylacetal (DMF-DMA) to 
give 270. Subsequent reduction of 270 with sodium cyanoborohydride to give 271, 
followed by quaternisation of the resulting 5-( dimethylamino )methyl tetronate with 
methyl iodide and treatment with aqueous NaHC03 to yield 261 (Scheme 66}185 The 
latter method involves the preparation of 4-methoxy-5-phenylseleno-2(5H)-furanone 
273 from 4-methoxy-2(5H)-furanone 269 followed by alkylation with methyl iodide to 
give 274 and subsequent oxidative removal of the phenylseleno-group using mCPBA to 
yield 261 (Scheme 66).186 
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0 0 
aiii) R R ~ MeO MeO Me2N Me3N 
271 272@ 0 g 
MeO 
0 0 ~ 261 Q bii) R MeO SePh MeO SePh 
273 274 
Scheme 66: Two literature routes for the synthesis of the exomethylene tetronate 261 
ai) Me2NCH(OMe)2; aii) NaCNBH3; aiii) Mel; aiv) NaHC03 bi) n-BuLi, PhSeCl; bii) t-BuLi, Mel; biii) 
mCPBA 
6.1: Synthesis of Exomethylene Tetronate 261 via the Phenylselenide 
273 
As the route to 261 described by Painter is more concise this route was initially 
investigated. Commercially available 4-methoxy-2(5H)-furanone 269 was deprotonated 
with n-BuLi at C(5) to form the corresponding anion 262 which was reacted with 
phenylselenyl chloride. This reaction proved successful on a small scale (5 mmol) 
giving the desired product 273 in moderate yield (43%) (Scheme 67). 
~o 
MeO 
i)a[ ~~ 1 
MeO e 
ii) ~ MeO SePh 
269 262 273 
Scheme 67: Synthesis of273 
i) n-BuLi, -78°C; ii) PhSeCl, -78°C to rt, 16 h, 43% 
The reaction was attempted on larger scales, however significant amounts of the 
disubstituted selenyl-compound 275 (Figure 41) were formed during the reaction and 
the two compounds were difficult to separate by flash column chromatography. 
Attempts were made to prevent this by-product from forming. Originally the anion was 
formed by the addition of n-BuLi to a solution of 4-methoxy-2(5H)-furanone 269 at 
104 
Chapter 6: 2nd Generation Approach to Key 
Putative Intermediates in Quartromicin Biosynthesis 
-78°C, then a solution of phenylselenyl chloride was added dropwise. This approach 
resulted in a large quantity of the undesired disubstituted compound 275; it was 
proposed that formation of 275 occurs via deprotonation of 273 by 262 and reaction 
with a second molecule of phenylselenyl chloride. It was thought that the formation of 
275 would be avoided if anion 262 was added to a solution of the phenylselenyl 
chloride thus reducing the concentration of 262 in the solution. These conditions were 
attempted on a small scale (5 mmol) resulting in yields of approximately 52% of 273. 
Unfortunately, when these reaction conditions were scaled up (10 mmol) a second by-
product was isolated that had the same retention time as the desired product 273 making 
it extremely difficult to separate the two compounds. The structure of this by-product 
was determined by 1 H NMR spectroscopy and mass spectrometry to be the chlorinated 
species 276 (Figure 41). 
MoOB-sePh 
275 
Figure 41: By-products isolated 275 and 276 
In an attempt to increase the yield of 273 a different approach was taken in which the 
methyl protected tetronate 269 was reacted with n-BuLi followed by 
diphenyldiselenide. Similar methodology has been reported by Pelter and co-workers 
where 269 was reacted with n-BuLi followed by diphenyldisulfide 277 resulting in a 
high yield of the monosubstituted phenyl sulfide 278 (Scheme 68).189 
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i) b MeO SPh 
278 
Scheme 68: Synthesis of278 189 
i) n-BuLi, -78°C; ii) PhSSPh, -78°C to -60°C, 90% 
However, when this reaction was attempted with diphenyldiselenide usmg the 
conditions reported by Pelter only starting material was isolated (Scheme 69).189 
Extensive investigations into these conditions would be required to establish why no 
reaction occurred, thus this was not pursued further. 
0 0 0 ¢o i) Q ii) oQ ~/ 7 MeO MeO e MeO SePh 
269 262 273 
Scheme 69: Alternative approach to the synthesis of273 
i) n-BuLi, -78°C; ii) PhSeSePh, -78°C to rt, 24 h 
As an alternative it was thought that it would be possible to alkylate 269 with methyl 
iodide first to give 279 (Scheme 70), then react 279 with n-BuLi and phenylselenyl 
chloride to afford 274 i.e. reverse steps one and two in the proposed synthesis (Scheme 
66). However, the low yields of 279 obtained meant that this methodology was not 
investigated further. 
~o 
MeO 
269 
o 
i) Q 
• ~ 0 
e MeO 
262 
ii) 
Scheme 70: Synthesis of279 
10 
MeoK 
279 
i) n-BuLi, -78°C; ii) Mel, -78°C to rt, 24 h, 29% 
Due to the inability to increase the yield of 273, attention was turned to the remaining 
two steps in the synthesis of 261. Alkylation of 273 with methyl iodide proceeded 
smoothly to give 274 in excellent yield (78%). This reaction was carried out using (-
BuLi rather than n-BuLi due to reports that generating the anion with n-BuLi resulted in 
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the cleavage of the selenyl-carbon bond to considerable extent resulting in the fonnation 
of 279.
186 
Subsequent oxidation of 274 with mCPBA gave the desired product 261 in 
excellent yield (74%) (Scheme 71). 
o Q 
MeO SePh 
i) 
o 
MeO~t"" ii) o to MeO'J-----\ 
273 274 261 
Scheme 71: Synthesis of the exomethylene tetronate 261 
i) 1) t-BuLi, Mel, -78°C to rt, 16 h, 78%; ii) mCPBA, DCM, O°C, 74% 
6.2: Synthesis of Exomethylene Methyl Tetronate 261 via Enamine 270 
As the phenylselenide based method one was low yielding in the first step and required 
painstaking separation of the products a second alternative approach was considered for 
the synthesis of 261. This would in tum allow the most efficient synthesis of 206 and 
207 to be designed. 
Related research carried out by the Challis group resulted in the synthesis of en amine 
270 in excellent yield via a literature synthesis (94%).189 The literature route involves 
reduction of 270 to 271 with sodium cyanoborohydride (Scheme 72). However, sodium 
triacetoxyborohydride in acetic acid was used for this transfonnation instead.I90-192 This 
resulted in an in situ protonation of the amino group in the initially fonned intennediate 
followed by elimination of dimethyl amine affording 261 directly in excellent yield 
(88%) (Scheme 73). This methodology improves on both literature methods for the 
synthesis of 261 as it involves fewer steps and results in high yields of the desired 
product. 
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Scheme 72: Alternative literature synthesis of the exomethylene tetronate 261 and the new consise route 
developed by this study 
i) Me2NCH(OMe)2 94%; ii) NaCNBH3; iii) Mel; iv) NaHC03 Bii) NaBH(OAc)3, AcOH, DCE, 88% 
o 
H Ac 
-d 
~\ 0 
MeO ~'\::: 
Me2NO 
270 
e OAC 
e 
- B(OAc)4 
10 
MeoJ--\. 
261 
+ 
OH f9 
Meo~ 
Me2N~ 
H Ac 
-d 
j : 
H'-OAC Cl.9 Meo~ 
Me2HN) 
(f) 
Scheme 73: Possible mechanism for direct conversion of270 to 261 by NaBH(OAc)iAcOH 
6.3: Synthesis of Trienal 234 and Tetraenal 285 
Having synthesised tetronate 261 attention turned to the synthesis of aldehydes 234 and 
285, which were synthesised from 219 (Scheme 74; the synthesis of dienal 219 is 
described in chapter 5). Chain extension of 219 was achieved using a Wittig reaction 
with phosphorane 280 to give ester 281 (67%), which was reduced using DIBAL-H to 
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give the primary alcohol 282 in excellent yield (79%). Alcohol 282 could either be 
oxidised with manganese dioxide giving desired aldehyde 234 in excellent yield (96%) 
(step Biv, Scheme 74), or chain extended further in a one-pot oxidation-Wittig reaction 
(step Aiv Scheme 74) to give ethyl ester 283 in good yield (60%), using methodology 
developed by Taylor and co_workers: 80,193-195 DIBAL-H reduction and subsequent 
oxidation with manganese dioxide yielded the desired aldehyde 285. Although these 
final two steps were successful, albeit in low yield (250/0 over two steps), they proved to 
be problematic. DIBAL-H reduction under the conditions established for reduction of 
281 to 282 was not possible, only degradation products were observed. When the 
reaction was carried out at lower temperature (-78°C) it was possible to isolate the 
desired alcohol, although small quantities of geometrical isomers were also observed. 
Oxidation of the crude alcohol 284 gave aldehyde 285, along with geometrical isomers 
and degradation products (~ 6% determined by 1 H NMR spectroscopy on the crude 
product) (Scheme 74). With good synthetic routes to both aldehydes 234 and 285 and 
the exomethylene tetronate 261 in hand, coupling conditions were investigated next. 
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• ~CHO 
219 
o 
ii) PPh3 ~O--./ 
o 
280 
o 
~O~ 
281 
iii) 
~O~ ~OH 
283 282 
Biv) 
~OH 
284 
Avi) 
234 
285 
Scheme 74: Synthesis of desired aldehydes 234 and 285 
i) 1) 245, toluene, reflux, 72 h; 2) DffiAL-H, Et20, O°C, 3 h; 3) Mn02, DCM, rt, 66% over 3 steps; ii) 
280, toluene, reflux, 72 h, 67%; iii) DIBAL-H, Et20, O°C, 3 h, 79%; Biv) Mn02, DCM, 96%; Aiv) 245, 
Mn02, DCE, reflux, 72 h, 60%; Av) DIBAL-H, Et20, -78°C, 3 h; Avi) Mn02' DCM, rt, 25% over 2 steps 
6.4: Addition of Lithiated Exomethylene Tetronate 261 to Aldehydes 
Attempts were made to add lithiated 261 to octanal in a model reaction. This reaction 
proceeded smoothly giving the desired product 286 in good yield (57%) (Scheme 75). 
10 
Meo'J---\. 
i) OH 0 
261 286 
Scheme 75: Model reaction; synthesis of 286 
i) LDA, then octanal, THF, -78°C to -60°C, 57% 
Formation of the lithiated derivative of the methyl protected exomethylene tetronate 261 
with LOA followed by the addition of the synthesised aldehyde 234 gave 265 in 
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moderate yield (35%) (Scheme 76). Both commercially available and freshly prepared 
LDA solutions were investigated as bases. The freshly prepared LOA gave 265 in 
approximately 10% higher yield than the commercial LOA. Oxidation of the product 
265 to 267 was attempted under Swem conditions but none of the desired product could 
be isolated and it appeared that the starting material had degraded under these 
conditions. However, oxidation with Oess-Martin periodinane afforded 267 but in low 
yield (15%). A rearrangement product 287 resulting from a competing reaction was also 
isolated (Schemes 76 and 77) as well as many degradation products. The assignment of 
structure to the rearrangement product 287 was based on HRMS, and 1- and 2-0 NMR 
analysis. HMBC correlation observed for 287 are shown in Figure 42. Similar results 
were obtained when manganese dioxide was used instead ofOess-Martin periodinane. 
0 
0 '-'::: '-'::: 
i) ii) g .. '-'::: ""'-:: ~CHO 267 
0 0 MeO 
261 234 265 
287 
Scheme 76: Synthesis of265 and subsequent oxidation to give 267 and 287 
i) LDA, then 234, THF, -78°C to -60°C, 35%; ii) Dess-Martin periodinane, DCM, rt, 267 15%,287 10% 
111 
· Chapter 6: 2nd Generation Approach to Key 
PutatIVe Intermediates in Quartromicin Biosynthesis 
t~ 
HoMn:(?) 0 
H+ transfer 
265 
HO ~) I \ Mn ~n::::O HO/ ''0 c/( 0 
H 0 
f'I"~ 
"-':.: "-':.: 
j 
o 
+ Mn(OHh 
Scheme 77: Possible mechanism for formation of rearrangement product 287 by reaction of265 with 
manganese dioxide 
Figure 42: HMBC correlations observed for compound 287 
Attempts were also made to carry out the coupling reaction with tetraene aldehyde 285 
(Scheme 78), but although the desired product 266 could be observed by mass 
spectrometry of the crude product, the IH NMR spectrum revealed that many 
degradation products and isomers had also been formed during the reaction. 
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i) 
~CHO 
285 
Scheme 78: Synthesis of266 
266 
i) LDA, then 285, THF, -7SoC to -60°C, 11 % impure 
6.5: Alternative Strategies for Coupling Tetronate 261 with Triene and 
Tetraene Fragments 
The failure to adapt the literature procedures for alkylation of 261 for our purposes 
prompted the exploration of other strategies for coupling of261 with triene and tetraene 
fragments. 
A literature survey revealed a report of a coupling reaction between methyl tetronate 
288 and methyl acrylate 289 (Scheme 79).196 
288 
i) 
o 
~OMe 
289 
~o 0 I 0 MeO ~ 
290 
Scheme 79: Coupling reaction between 288 and methyl acrylate 289 1% 
i) LDA, then 289, THF, -7SoC to rt, N~CI(sat.) quench, 50% 
It was reasoned that if the previously synthesised ethyl esters 281 and 283 could be 
coupled with 261 rather than the aldehydes, then fewer steps would be required in the 
overall synthesis of the two precursors 206 and 207, resulting in a more concise 
synthesis. This methodology would also circumvent the problematic low yields and the 
by-product formation of the oxidation step. Initially, as a model reaction, coupling of 
the methyl-protected exomethylene tetronate 261 to methyl acrylate 289 was attempted 
using the procedure reported by Buck et al. 1% This involves lithiation of261 using LDA 
at -78°C followed by the addition of three equivalents of methyl acrylate to the reaction, 
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before allowing the mixture to warm to room temperature. The reaction was quenched 
with saturated ammonium chloride. Unfortunately none of the expected product 291 
was isolated and instead a mixture of two other products 292 and 293 was obtained 
(Scheme 80). This was probably due to the in-situ rearrangement of the desired product. 
261 
i) 
o 
V--oMe 
289 
~o 0 I 0 MeO 
291 
----.~g~:+ 
o 
292 
Scheme 80: Attempted synthesis of291 
i) LDA, -78°C, then 289, THF, -78°C to rt, NlltCl(sat.) quench 
293 
Previous research by Farina et al. showed that the presence of ammonia in a solution of 
tetronic acid derivatives converted them to the corresponding tetramic acid 
derivatives. 197 It is therefore likely that quenching the reaction with ammonium chloride 
led to some ammonia being present in the reaction work-up allowing this conversion to 
occur, giving 293 in low yield (11%) (Scheme 81). 
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o HO 6) 
~NH3 ~ 0 MeO 
JlNH Meo~ 
jH' 
Scheme 81: Possible mechanism for formation of 293 
On the other hand compound 292 appeared to have been formed via a novel 
rearrangement during the coupling reaction. The methoxy amon generated 10 the 
reaction could attack the carbonyl carbon of the tetronic acid, resulting in ring opening 
and the formation of ester 294. Ring closure after attack of the enolate on the other 
carbonyl group gives a highly functionalized novel compound 292 (Scheme 82). 
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Scheme 82: Proposed mechanism for formation of292 
Different conditions were screened to avoid the rearrangements occurring during the 
above reaction. Quenching the reaction with saturated citric acid rather than with 
ammonium chloride meant that the conversion to the tetramic acid derivative was 
avoided (Scheme 83). It was thought that by using phenyl acrylate 295 these 
rearrangements could be prevented, because the phenoxy anion generated would be 
more bulky and more stable than the methoxy anion, and thus less nucleophilic. The 
reaction was successful using phenyl acrylate 295, and keeping the temperature at 
-78°C, giving 291 in low yields (~ 5%), but the product was extremely volatile thus 
isolation proved difficult (Scheme 83). 
10 
Meo'J--\. 
i) ~ 
261 291 
Scheme 83: Synthesis of291 using phenyl acrylate 295 and citric acid to quench the reaction 
i) 1) LDA, -78°C; then 295, THF, -78°C, 16 h, citric aci~sat.» 5% 
Further attempts employing either methyl acrylate 289 or phenyl acrylate 295 afforded 
the target compound 291 in improved yields. Removing the solvent in vacuo without 
heating helped to minimize loss of the volatile product 291. Under these new conditions 
it was possible to isolate the desired product 291 in 180/0 yield (Scheme 84). 
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i) 
o 
~oMe 
289 
• ~ 
291 
Scheme 84: Synthesis of 291 using methyl acrylate 289 and citric acid to quench the reaction 
i) LDA, then 289, THF, -78°C, 16 h, citric aci~sat.), 18% 
The synthesised 291 could allow the development of a new synthetic route to the 
putative key intermediates in quartromicin biosynthesis. This method would utilise 
Heck coupling with a vinyl bromide allowing the polyene chain to be installed at a later 
stage in the synthesis (Scheme 85). This was not explored due to time constraints. 
~ 
i)~Br 
296 
------ --- --- - ----~ 
291 
Scheme 85: Proposed Heck reaction 
i) Pd(OAc)2 
267 
The success of the model reaction to form 291 led to attempts to couple the diene ethyl 
ester 247 and triene ethyl ester 281 with the methyl protected exomethylene tetronate 
261 (Scheme 86 and 87 respectively). In both cases two products were isolated; the 
desired compounds 297 and 267 in low yields (11% and 14% respectively) and their 
ethyl protected analogues, 298 and 299. It was thought that both 298 and 299 were 
formed by transesterification via nucleophilic addition of the ethoxy anion generated in 
the reaction to the carbon bearing the methoxy group followed by elimination of the 
methoxy group. 
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o 0 ~o 
, 'Meo'J----\. 
297 
o 0 ~o~ 
247 ~o 
, , EtO'J----\. 
298 
Scheme 86: Synthesis of297 
i) LDA, then 247, THF, -78°C, 24 h, citric aci~sat.)quench, 11% of 297 and 9% of298 
o 
~o 
Meo'J----.\. 
i) 
o 
~o~ 267 
261 281 
Scheme 87: Synthesis of 267 
i) LDA, then 213, THF, -78°C to -60°C, citric aci~sat.)quench, 267 14%, and 299 14% 
In order to circumvent the problem of transesterification the methyl ester equivalent of 
281 was synthesised (Scheme 88). Chain extension of 219 with Wittig chemistry using 
phosphorane 300 proceeded smoothly to give the desired compound 301 in excellent 
yield (83 %). 
~o 
219 
o 
i) PPh3 
UYOMe 
o 
300 ~OMe 
301 
Scheme 88: Synthesis of301 
i) 300, toluene, reflux, 72 hrs, 83% 
Ester 301 could then be coupled with the methyl protected exomethylene tetronate 261 
to give the product 267 in low yield as shown in Scheme 89. 
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i) 
o 
~OMe 
301 
o 0 
267 
Scheme 89: Synthesis of267 avoiding transesterification 
i) TMP, then 301, THF, -78°C, 24 h, citric aci~sat.) quench, 17% 
Another possibility to prevent transesterification is to use the ethyl-protected 
exomethylene tetronate 304, which was synthesised as shown in Scheme 90 using the 
methodology developed previously (Scheme 72). Reaction of tetronic acid and ethanol 
in toluene under Dean-Stark conditions gave the ethyl protected tetronate 302 in 
excellent yield (86%).198 (Dimethylamino)methylenation at C(5) followed by reduction 
and elimination gave the ethyl protected exomethylene tetronate 304 in excellent yield 
(79% over the two steps) (Scheme 90). 
0 0 0 0 ¢o i) P ii) iii) 'R • g HO EtO EtO ~ EtO 
Me2N 
256 302 303 304 
Scheme 90: Synthesis of ethyl-protected tetronate 304 
i) EtOH, Toluene, reflux, 86%; ii) Me2NCH(OMe)2 89%; iii) NaBH(OAc)3, AcOH, DCE, 89% 
Coupling of the tetraene ethyl ester 283 and the ethyl protected exomethylene tetronic 
acid 304 gave compound 305 in low yield (27%) (Scheme 91). A similar reaction was 
carried out with the triene ethyl ester 281 to give the ethyl protected product 299 in low 
yield (25%), an improvement on the coupling reaction between the methyl ester 301 and 
tetronate 261 
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304 281 299 
Scheme 91: Synthesis of305 and 299 
i) TMP, then 283 or 281, -78°C, 24 h, citric aci~sat.) quench, 27%, and 25% respectively 
In order to optimise the reaction, four different bases LDA, Lithium-2,2,6,6-
tetramethylpiperidide (Li-TMP), lithium-dicyclohexylamide and lithium-
hexamethyldisilazide (Li-HMDS) and a variety of reagent concentrations were 
investigated. Using 1.25 equivalents of Li-TMP to one equivalent of 261 was found to 
give the cleanest reaction and highest yields (~30%). 
Deprotection of compounds 267 and 305 was carried out using LiCI (Scheme 92). 
Deprotection of 267 was carried out in DMSO at 50°C giving 206 as the sole product 
(100% conversion as determined by IH NMR). The end point of the reaction was 
established by following the reaction by IH NMR spectroscopy. Purification of 206 was 
carried out by HPLC on two milligrams of the crude product. 
i) 
267 206 
i) 
.. 
305 207 
Scheme 92: Deprotection of267 and 305 to give 206 and 207, respectively 
i) LiCl, DMSO( ~), 50°C, 16 h, 100% conversion to 206, 95% conversion to 207 
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However, when using the same conditions to deprotect the ethyl protected tetraene 
derivative 305 the reaction proceeded at a much slower rate (after 24 hours only 5% 
deprotection had occurred). This is possibly because the boiling point of the methyl 
chloride by-product of the reaction is a lot lower than that of the ethyl chloride by 
product (-24°C compared to 12.5°C) so at the lower temperature the ethyl chloride is 
lost from the reaction at a lower rate but more likely to be because of the increased 
steric bulk of the ethyl group in comparison to the methyl group. The temperature was 
increased to 65°C and, again following the reaction by 1 H NMR spectroscopy, the end 
point was established after seventy-two hours. Although only 95% of the starting 
material had been converted to product after this time no further deprotection was 
observed over a subsequent three hours by 1 H NMR spectroscopy, and geometrical 
isomers of the tetraene product 207 also began to appear. The product was only partially 
purified by HPLC. Thus the synthesis of the methyl ester analogue 306 of the ethyl ester 
283 was explored. 
The methyl phosphorane required for the synthesis of the tetraene methyl ester 306 was 
not available commercially. A survey of the literature showed that methods exist for the 
synthesis of this phosphorane174,199 but first it was decided to attempt to convert the 
ethyl ester 283 to methyl ester 306 by a transesterification reaction using sodium 
methoxide in methanol. This reaction proceeded smoothly to give the desired methyl 
ester 306 in good yield (74%) (Scheme 93). 
o 
~o~ i) 
283 
Scheme 93: Synthesis of 306 
i) NaOMe, MeOH, rt, 3 h, 74% 
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Coupling of the methyl-protected exomethylene tetronate 261 and methyl ester 306 
proceeded smoothly to give 268 in low yield (23%) (Scheme 94). The deprotection of 
ester 268 with LiCI / DMSO gave a clean IH NMR spectrum for the crude product 207 
(with minor geometrical isomers of the tetraene observed), which was purified by 
HPLC. 
0 
i) 
~ 
ii) 4 • ~ ~ ~ ~ ~ 291 MeO 
261 268 207 
Scheme 94: Coupling and deprotection reaction to afford 207 
i) LTMP, then ester 306, -78°C, 24 h, citric aci~sat.)quench, 23%, ii) LiCI, DMSO(~), 50°C, 16 h, 100% 
Compounds 206 and 207 will be utilised in labelled form for feeding experiments in the 
bacteria that produce quartromicins to help investigate the biosynthetic pathway. It 
would be possible to prepare these two compounds easily via the procedure described 
using labelled DMF-DMA. This reagent could be prepared from N,N-dimethylform-13C-
amide (which is commercially available), NaOMe, and Me2S04 in methanol.2oo 
The exomethylene group is a good place to incorporate an isotope label as there are only 
two steps to make the methyl protected exomethylene tetronic acid 261 from [l3C] 
DMF-DMA (both of which are high yielding). Two further steps from 261, the coupling 
reaction and deprotection, would yield the desired compounds 206 and 207 in labelled 
form (Scheme 95). 
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~/ [13C] DMF-DMA 0 ~ q MeO MeO 
Me2N MeO 
269 270 
261 
207 267 
Scheme 95: Synthesis of l3e labelled putative key intermediates in quartromicin biosynthesis 
6.6: Investigation of Biomimetic Diels-Alder Reactions of Putative Key 
Intermediates 267 and 305 
Quartromicins 122a-f fall into the spirotetronate family of natural products that are 
proposed to be biosynthesised via Diels-Alder reactions (Scheme 96). The most 
intriguing aspect of the quartromicins is the alternating exo- and endo- stereochemistry 
that arises from the Diels-Alder reactions, with the opposite comers being 
stereo chemically identical. As no total synthesis has been accomplished and the 
biosynthetic pathway has yet to be established, the quartromicins are attractive targets 
for biomimetic synthesis investigations. 
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[4+2] 
Endo 
[4+2] 
Exo 
Scheme 96: Proposed biosynthetic Diels-Alder cyclisations between 206 and 207 to generate the 
quartromicin carbon skeleton 
It was therefore proposed to investigate the biomimetic synthesis of the quartromicins 
by heating the two synthesised precursors 267 and 305 to determine if the cyclo-pseudo-
tetrameric carbon skeleton of the quartromicin aglycone 307 could be formed (Scheme 
97). 
Heat 
267 
or Lewis acid 
305 
307 
o 
o o 
o 
Me 
Scheme 97: Proposed biomimetic experiment Diels-Alder reaction of267 and 305 to give the 
quartromicin carbon skeleton 307 
Initially the Diels-Alder reaction was carried out at 100°C in toluene (10 mg in 3 mL); 
conditions used by Sorenson and co-workers in the biomimetic studies of 
abyssomicins. 15 However, after forty-eight hours no change was observed by LC-MS 
and the starting material remained. The reaction was then attempted in a sealed tube, 
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initially at 100°C for three days, as this would increase the pressure in the reaction 
vessel. It was hoped that the increased pressure would speed up any reaction that would 
take place. 100 fll aliquots were analysed by LC-MS: After forty-eight hours, ions with 
mJz corresponding to a homodimer of the triene 308a-d (m/z 549) and a heterodimer of 
the tetraene and the triene 3094a-j (m/z 603) were observed (Figure 43). 
Inlens. biomim day 2_51_01_B249.d: EIC 549 +AII MS 
xl0B A 
0.5 ~A x~iJ~ biomim day 2_51_01_B249 .d: EIC 603 +AII MS 
1.0 B 
0.5 M x~iJ~ biomim day 2_51_01_B249.d: EIC 657 +AII MS 
C 
0.5 
0.0 
2 4 6 B 10 12 14 Time [min] 
Inlens. +MS. 4.42-4 .53min 
xl0B A 311'11 
0.5 54~ .23 
x~iJo, +MS. 4.75-4.96min 
A 31r1 4 
2 54~ .23 
xl 00, +MS. 5.36-5.4Bmin 
1 A 54r4 
311 .12 
xl 00, +MS. 6 .34-6.55min 
2 B 60129 
xl 00, 
339.1B 
+MS. 7.00-7.23min 
B 6°f9 1 
0 
200 400 600 BOO 1000 1200 m/z 
Figure 43: Extracted ion chromatogram (EIC) from LC-MS analysis 
Showing masses corresponding to A: a homodimer of the triene (mlz 549), B: a heterodimer of the 
tetraene and the triene (mlz 603) and C: a homodimer of the tetraene 
After another twenty-four hours no further change was observed, so the temperature 
was increased to 125°C. 100 flL aliquots were analysed after seven, eleven, fourteen and 
eighteen days and peaks were observed that corresponded to homodimers of the tetraene 
310a-f (m/z 657), as well homodimers of the triene 308a-d and the heterodimers 309a-j 
previously observed suggesting these compounds had again been formed (Figure 44). 
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Intens.7; -:lb;;:'mim sealed 261007_62_01 _ 6472 .d: EIC 549 +AII MS Smoothed (e 7 x10 : 
1 ~ A I 
1 . Jl X 1 0~ ~ hinmiArn sealed 261007_62_01_6472.d: EIC 603 +AII MS. Smoothed (e 7 
1 -: B 
: ,A.A 
X10~ hinmim sealed 261 007_62_01_6472.d: EIC 657 +AII MS. Smoothed (e 7 , 
1 C 
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Figure 44: EICs from LC-MS analysis 
Showing masses corresponding to A: a homodimer 308a-d of the triene (m/z 549) and B: a heterodimer 
309a-j of the tetraene and triene (m/z 603) and C: a homodimer 310a-f of the tetraene (m/z 657) 
The extracted ion chromatograms showed that several peaks corresponded to the same 
mass for example three peaks were seen with mJz 549 (Figure 43). This was not 
unexpected as there are a number of ways in which Diels-Alder reactions can occur 
within each molecule to produce the homo or heterodimers; some of these are 
represented in Figures 45, 46 and 47. The enantiomers of each dimer can also be 
produced but for clarity only one is shown. 
308a lO8b lOSe 308d 
Figure 45: Some possible homodimers 308a-d of the triene 267 
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Figure 46: Some possible heterodimers 309a-j formed by reaction oftriene 267 and tetraene 305 
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Figure 47: Some possible homodimers 3108-( of the tetraene 305 
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Comparison of the EIC for day two and day eighteen of the biomimetic experiment in 
Figure 48 shows that over a period of time the three mass ion peaks corresponding to 
rnJz 549 became one signal with a different retention time. It is possible that the Diels-
Alder reaction is reversible and therefore a more thermodynamically stable compound is 
produced over a period of time. However it is also possible that some degradation of the 
dimer is occurring. As can be seen in Figure 48, the intensity of the peak after eighteen 
days is approximately 10 fold lower than after two days which could also indicate 
degradation of the dimer. 
Intens. 
x108 
0.5 
A 
~ O.Q,~--~~---....."..------,---....,..I 
B 
Intens.
7 
bil:>mim sealed 261007 _62_01_8472.d: EIC 549 +AII MS, Smoothed ( 7. 
x10 : 
1 i I 
0, , J1 
Figure 48: Eel showing A: Day 2 three mass ion peaks corresponding to m/z549 and B: Day 18 one 
mass ion peak corresponding to m/z549 
It is also apparent that the tetraene monomer 305 is either less reactive then the triene 
monomer 267, perhaps because the ethyl group in the tetraene derivative 305 was 
sterically blocking the exomethylene preventing it from reacting readily at this position; 
compounds with rnJz corresponding to the dimer of the tetraene required a longer period 
of heating before they formed, i.e. dimers are not observed after forty-eight hours but 
are observed after eighteen days. 
After three days of heating in a sealed tube a 20 ~L aliquot from the reaction was 
separated by LC-MS and fractions were collected every thirty seconds for analysis by 
ESI-TOF-MS. The data from these analyses (Table 2) suggest that a species with a ESI-
TOF-MS molecular formula corresponding to the cyclo-pseudo-tetrameric carbon 
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skeleton of the quartromicin aglycone had been generated during the reaction (mlz 1227 
[M+ Na]l. It was not surprising that only the sodiated mass ion signal was seen, 
because quartromicin and the precursors have oxygen atoms in a 1,3-diketone 
configuration and are thus strong metal chelators. It has been reported that the 
quartromicins bind strongly to sodium, potassium, calcium and magnesium. 104 Other 
mass ion signals correspond to the molecular fonnula of the homodimer of the tetraene 
and triene species as well as the homotrimer of the triene (Table 2). 
Sample m/z observed m/z calculated Error [ppm] Molecular 
Formula 
Homodimer triene 549.2478 [M+Ht 549.2483 [M+Ht 0.83 C23H~70S 
Homotrimer triene 823.3654 [M+Ht 823.3688 [M+Ht 4.15 C4sH5501~ 
Heterodimer 625.2772 [M+Nat 625.2777 [M+Nat 2.98 C36H42OsNa 
Heterotetra01er 1227.5602 [M+Nat 1227.5652 [M+Naf 4.00 C72Hs4016Na 
Table 2: HRMS for observed O1asses corresponding to hOO1odimers of the triene, tetraene, hOO1otrimer of 
the triene, and heterotetramer, the error and molecular fornnula generated 
The LC-MS data was re-examined to locate the heterotetramer speCIes; however, 
although there were some small signals corresponding to protonated molecular ion (mJz 
1205) and the sodiated molecular ion (mJz 1227), the intensity of these signals was very 
low. This could be for a number of reasons: The quartromicin aglycone may be 
produced in such small quantities in comparison to other species it is not visible because 
of the noise. The species may be doubly-charged and therefore a signal would be seen at 
mJz 603, but because of the strong signal at mJz 603 due to the heterodimer, the 
heterotetramer signal could be masked. Also the mJz 1227 signal may not in fact 
correspond to the heterotetramer at all, but merely a mass spectrometry artefact, i.e. 
from two heterodimers that have chelated a sodium ion. 
In an attempt to increase the rate and specificity of the Diels-Alder reaction it was 
carried out in a microwave reactor. Several different reaction times and solvents were 
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tested to see if this increased or decreased the rate of the Diels-Alder reactions (Table 
3). Four solvents were tested: toluene, nonane, isopropanol and a toluene/water mixture. 
Solvents can greatly affect the rate of Diels-Alder reactions. Hydrocarbons, which are 
non-polar, are generally used because they dissolve the reactants easily; hence toluene 
and nonane are good choices. However, in a microwave reactor these solvents do not 
couple with the microwave energy, hence the temperature of the reaction increases more 
slowly. Isopropanol on the other hand is polar, so is not such a good choice for a Diels-
Alder reaction, but it couples well with microwave energy. Water surprisingly 
accelerates Diels-Alder reactions and it is thought that the non-soluble reactants are 
pushed together in oily drops formed in the water and are therefore forced into close 
proximity to allow the reaction to occur. 
Solvent TimeC m/z TimeC m/z TimeC m/z TimeC m/z 
Toluene8 0.5 549,603 1.5 549,603 3.5 549,603, 7.5 549,603, 
657 657 
Nonaneb 0.5 549,589, 1.5 549,589, 3.5 549,589, 7.5 nlad 
629 629 629 
Iso- 0.5 old 1.5 n1de 3.5 n1ad 7.5 nlad 
propanolb 
Toluene/ 0.5 549,589, 1.5 549,589, 3.5 549,589, 7.5 nlad 
water mixb 629 629 629 
Table 3: Dimers observed by LCMS from reactions in various solvents and reaction times in a 
microwave 
BUses ethyl protected tetraene 305 and methyl protected triene 267.b Uses methyl protected tetraene 268 
and methyl protected triene 267. ctime in hours. d not attempted; enone detected 
The reaction using toluene as the solvent showed that using the microwave considerably 
increased the rate of reaction; the mass corresponding to the tetraene homodimer 310a-f 
was observed after three and a half hours. However, when the reaction was carried out 
in nonane or the toluene water mixture, the masses corresponding to the homodimer of 
the tetraene were seen after thirty minutes. This could be because these solvents 
improve the rate of reaction, but more likely because the methyl protecting group on the 
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tetraene 268 used in this reaction does not sterically block the exomethylene group as 
much as the ethyl protecting group on 305 used in the reaction with toluene, allowing it 
to react more readily. As can be seen from Table 3, none of the desired masses were 
observed when isopropanol was used as solvent. 
Preliminary biomimetic transformations of these precursors to the cyclo-pseudo-
tetrameric carbon skeleton of the quartromicin aglycone suggest that Diels-Alder 
reactions occur to give both hetero and homodimers of the two intermediates. HRMS 
evidence suggesting the presence of a heterotetramer has also been obtained. 
6.7: Conclusions and Future Work 
Overall, the initial aIms of this project were achieved. A conCIse and reasonably 
efficient synthesis of both putative quartromicin precursors 206 and 207 was completed. 
However, the acylation of the lithiated methyl-protected exomethylene tetronate 261 
required further optimisation to improve yields. Preliminary biomimetic studies were 
carried out to ascertain whether the cyclo-pseudo-tetrameric carbon skeleton of the 
quartromicin aglycone could be produced and test the hypothesis that spirotetronates 
such as the quartromicins are biosynthesised by Diels-Alder reactions. HRMS and LC-
MS data provide evidence that homo and heterodimers of the putative precursors have 
been formed and suggest that a compound with a molecular formula corresponding to 
the quartromicin aglycone has been produced. 
In the future, both compounds 206 and 207 should be prepared in labelled form, for use 
in feeding studies to help elucidate the biosynthetic pathway to the quartromicins. 
Optimisation of quartromicin production by the producing Amycolatopsis strains will be 
131 
Chapter 6: 2nd Generation Approach to Key 
Putative Intermediates in Quartromicin Biosynthesis 
required prior to undertaking these experiments. Malek Kourdi-Zerikly, a PhD student 
in the Challis Group, has identified the putative quartromicin biosynthetic gene cluster 
in two Amycolatopsis species. Thus compounds 206 and 207 will be useful as standards 
for in vivo and in vitro experiments designed to probe the mechanism of quartromicin 
biosynthesis. 
The biomimetic synthesis experiments will also be further investigated, by developing 
better conditions to generate the carbon skeleton of the quartromicin aglycone, which 
would allow the reactions to be carried out on a larger scale. This in tum would allow 
the structures of the homo and heterodimers produced to be fully characterised. Using 
the deprotected precursors 206 and 207 may also change the electronics sufficiently to 
allow greater specificity to occur during the biomimetic reactions. Another possible 
approach would be to isolate and characterise the heterodimers, and use the heterodimer 
with the appropriate stereochemistry in further biomimetic experiments aimed at 
producing the quartromicin carbon skeleton. 
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7.1: General Experimental 
Dry toluene was obtained by evaporation of the toluene/water azeotrope in vacuo 
followed by distillation from calcium hydride under argon, and stored over 4 A 
molecular sieves. Dry dichloromethane, methanol and acetonitrile were produced in the 
same way. Dry tetrahydrofuran was pre-dried over sodium wire and dried in a still over 
potassium for three days before use. Dry triethylamine and diisopropylamine were 
obtained by distillation from sodium hydroxide pellets under argon and stored over 
sodium hydroxide pellets. All other reagents and solvents were used as supplied. 
Petroleum ether refers to the fraction of light petroleum boiling between 40°C and 
60°C. Solvents were evaporated using a Buehl Rotavapor R-200 equipped with a Buchi 
Vacuubrand pump. 
Flash column chromatography was conducted on Fluka Silica Gel (40-63 ).lm, 60 A), or 
basic aluminum oxide (activated basic Brockman 1 standard grade 150 mesh) or florisil 
(l00-200 mesh). TLC was performed on aluminium backed plates pre-coated with 
Merck silica gel 60 F254, visualised by UV radiation. Preparative TLC was performed on 
glass plates pre-coated with Merck silica gel 60 F 254, visualised by UV radiation. 
Phosphomolybdic acid, potassium permanganate, and vanillin were also used for 
visualisation of TLC plates. 
IR spectra were recorded on solid compounds using a Perkin-Elmer Avatar 320 Fourier 
Transformation spectrometer. Only selected absorptions are reported, in units of 
wavenumbers (em-I), using the following abbreviations: w, weak; m, medium; s, strong; 
br, broad. 
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IH NMR spectra were recorded at 300, 400 or 700 MHz using Bruker DPX300, 
DPX400 or A V700 spectrometers respectively. Chemical shifts (&H) are quoted in ppm 
with reference to the residual solvent peale The data in parentheses follow the order (i) 
number of equivalent protons, (ii) multiplicity: s, singlet; d, doublet; 1, triplet; q, quartet; 
m, multiplet, (iii) coupling constant (J): in Hz to the nearest 0.5 Hz, (iv) assignment. 
COSY was used in selected cases to aid assignment. 
l3C NMR spectra were recorded on Bruker DPX300, DPX400 and A V700 
spectrometers at 75, 100 or 175 MHz. HMBC and HMQC spectra were recorded to aid 
assignments. Chemical shifts (&e) are quoted in ppm with reference to the residual 
solvent peak. The assignment is given in parentheses. 
CHN analysis was performed by Warwick Analytical Services usmg an Exeter 
Analytical CE 440. 
Low resolution EI and CI mass spectra were recorded using a Micromass Autospec 
spectrometer. Low resolution ESI mass spectra were recorded using a Bruker Esquire 
2000 spectrometer. Only molecular ions and major fragments are reported with 
intensities quoted as percentages of the base peak. High resolution mass spectra were 
recorded on a Micromass Autospec spectrometer equipped with EI or CI source, or on a 
Broker microTOF spectrometer equipped with an ESI source. 
Melting points were determined (uncorrected) on a Stuart Scientific SMP10 machine to 
the nearest degree. 
LC-MS was carried out on an Agilent 1100 HPLC instrument with the outflow 
connected via a splitter (10% to mass spectrometer, 90% to waste) to a Broker Daltonics 
esquire HCT plus mass spectrometer equipped with an ESI source. 
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Bacteria were grown on solid medium in an incubator GenLAB 2216e or in liquid 
medium in a New Brunswich Scientific shaker, model Innova 4330, at 30°C. 
Microwave reactions were carried out in a CEM Discover microwave. 
7.2: Experimental- Results and Discussion Chapter 4 
General procedure for preparation of acid chlorides 
To a solution of oxalyl chloride (0.30 mL, 3.75 mmol) in dry DCM (50 mL) was added 
a catalytic amount of DMF. After the evolution of gas had finished, pyrrole-2-
carboxylic acid, picolinic acid, or 2-fluorobenzoic acid (1.35 mmol) was added, and the 
mixture was heated to reflux for one hour under nitrogen. The solvent was removed in 
vacuo. The product was analysed by IR spectroscopy and IH NMR spectroscopy, and 
used in the preparation of the N-acetyl-cysteamine thioesters without further 
purification. 
I-pyrrole-2-carbonyl chloride 21273 
3 4 
2~CI 
H 0 
1 
Yielded 0.14 g (1.05 mmol, 77%). Ou (400 MHz, CDCI3), 6.30 (lH, dd, J6.0, 6.0, H-3), 
7.10-7.15 (2H, m, H-2 and H-4), 9.20 (lH, br s, Nfl), hydrogen coupling confirmed by 
COSY. vltlllJl'cm-1 3353 (N-H), 2900 (C-H), 1718 (C=O), 1658, 1531 (C=C-N), 754 (C-
CI). 
135 
Picolinoyl chloride 214 
4 3m! 2~~~CI 
1 0 
Chapter 7: Experimental 
Yielded 0.l3 g (0.94 mmol, 69%) Ou (400 MHz, CDC h), 7.51 (lH, ddd, J 1.0, 4.5.8.0, 
H-3), 7.86 (lH, ddd, J 1.5,8.0,8.0, H-4), 7.91 (lH, d, J8.0, H-5), 8.64 (lH, d, J 4.5, H-
2), vttUDl'cm-1 2900 (C-H), 1735 (C=O), 1655, 1613, 1590 (C=C and C=N aromatic). 793 
(C-Cl). 
2-fluorobeozoyl chloride 213 
4 3m 5 2~CI 
F 0 
Yielded 0.16 g (1.00 mmol, 74%) 00(400 MHz, CDCh), 7.l8 (lH, ddd, J 11.0,8.0,1.0, 
H-2), 7.23 (lH, ddd, J 7.5, 7.5, 1.0, H-4), 7.58 (lH, m, H-3), 7.84 (lH, ddd, J 7.5, 7.5, 
1.0, H-5), vttUDl'cm-1 2900 (C-H), 1782 (C=O), 1670, 1605, 1576 (C=C aromatic), 879 
(C-F), 733 (C-CI). 
General method for preparation of NAC thioester analogues 
To a solution of acid chloride (pyrrole-2-carbonyl chloride 212, furan-2-carbonyl 
chloride, thiophene-2-carbonyl chloride, 1-fluorobenzene-2-carbonyl chloride 213 or 
pyridine-2-carbonyl chloride 214) (1.05 mmol) in DCE (40 mL) was added DMAP 
(0.30 g, 2.50 mmol), followed by N-acety1cysteamine (0.20 mL, 0.24 g, 2.50 mmol). 
The resulting mixture was heated to reflux overnight. The solvent was removed in 
vacuo and the crude residue was analysed by IH NMR spectroscopy. The product was 
purified using a short column of silica impregnated with CUS04 to give the desired 
product 117, 118, 119, 120 or 121. 
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Pyrrole-2-carboxyl-N-acetylcysteamie thioester 11773 
3 4 
2n..S S ~ "~/ Y '-./"-N-----" 
H 0 H 
1 
The product (0.13 g, 0.63 mmol, 60%) was a yellow-white crystalline solid. Ou (400 
MHz, CDCh), 2.04 (3H, s, Me), 3.10 (2H, t, J 6.0, SCli2CH2), 3.52 (2H, dt, J 6.0, 6.0, 
SCH2Cli2), 5.95 (1H, br s, Nfl), 6.29 (1H, dd, J 3.5, 3.5, H-3), 7.03 (2H, m, H-2 and H-
4), 9.28 (1H, br s, NH(CO)), hydrogen couplings were confirmed by a COSY 
experiment. Oc (100 MHz, CDCh), 23.3 (Me), 27.8 (SCH2CH2), 40.1 (SCH2CH2), 
111.0 (C-3), 115.7 (C-4), 124.1 (C-2), 129.8 (C-5), 170.7 (NHC(O)CH3), 181.7 
(C(O)SCH2). mlz (EI) 235 ([M + Nat, 35%), 185 (30), 149 (6), 123 (100). vnuu/cm-1 
3353 (N-H), 2931 (C-H), 1691 (C=O), 1536 (C=C aromatic). mp: 108-110°C. HRMS 
Calculated for [C9H12N20 2SNat: 235.0513, observed: 235.0512. 
S-2-acetamidoethyl furan-2-carbothioate 118 
3 4 
2 n..s s ~o 
'0/ y '-./"-N 
1 0 H 
The product (0.18 g, 0.79 mmol, 75%) was a white crystalline solid. Ou (400 MHz, 
CDC h), 1.98 (3H, s, Clh), 3.21 (2H, t, J 6.0, SCli2CH2), 3.53 (2H, dt, J 6.0, 6.0, 
Cli2NH), 5.90 (IH, br s, NH), 6.56 (1H, dd J 3.5, 1.5, H-3), 7.22 (lH, dd, J 3.5, 1.0, 
H-4), 7.60 (1R, dd, J 1.5, 1.0, H-2), hydrogen couplings were confmned by a COSY 
experiment; Oc (100 MHz, CDCh), 23.3 (CH3), 27.8 (SCH2CH2), 39.9 (CH2CH2NH) 
112.4 (C-3), 116.2 (C-4), 146.6 (C-2), the signal C=O was not observed in the spectrum, 
signal assignment confirmed by HMQC. vnuv/cm-1 3317 (N-H), 2933 (C-H), 1641 
(C=O), 1550 (C=C aromatic), mp: 91-92°C eHN Calculated: C, 50.69; H, 5.20; N, 
137 
Chapter 7: Experimental 
6.57; S, 15.04 found: C, 50.20; H, 5.19; N, 6.40; S,14.57. mlz (EI) 214 ~] (2%), 154 
(44), 126 (19), 118 (35), 95 (100), 86 (23), 76 (19). 
S-2-acetamidoethyl thiophene-2-carbothioate 119 
3 4 
211\5 S 0 
"S/ Y ~N---4' 
1 0 H \ 
The product (0.14 g, 0.61 mmol, 58%) was a white crystalline solid. 00 (400 MHz, 
CDCb), 1.94 (3H, s, C!h), 3.18 (2H, t, J 6.5, SCli2CH2), 3.53 (2H, td, J 6.5, 6.5, 
SCH2Cli2), 6.40 (1H, br s, NlJ), 7.08 (1H, dd, J 5.5, 4.0, H-3), 7.60 (1H, dd, J 5.5, 1.0, 
H-4), 7.76 (1H, dd, J 4.0, 1.0, H-2), hydrogen couplings were confirmed by a COSY 
experiment; Oc (100 MHz, CDCb), 23.1 (CH3), 28.8 (SCH2CH2), 39.8 (SCH&J-h), 
128.1 (C-3), 131.6 (C-4), 133.2 (C-2), 141.6 (C-5), 170.6 (NHC=O), 184.1 (Q=O)S) 
Carbon assignments were confirmed by HMQC. vnuu/cm-1 3301 (N-H), 2929 (C-H), 
1643 (C=O), 1541, 1509 (C=C aromatic) mlz (EJ) 229 [~] (1%),170 (39),144 (1), 
128 (6), 118 (21), 111 (100), 86.0 (123), 83 (11), 76 (7), CHN Calculated: C, 50.69; H, 
5.20; N, 6.57; S, 15.04; found: C, 50.20; H, 5.19; N, 6.40; S, 14.57. 
S-2-acetamidoethyl 2-(I-fluorobenzo )thioate 120 
The product (0.18 g, 0.77 mmol, 73%) was a white crystalline solid. 00 (400 MHz, 
CDCb), 1.98 (3H, s, Clh), 3.23 (2H, t, J 6.5, SClt2CH2), 3.55 (2H, dt, J 6.5, 6.5 
SCH2Clb), 5.88 (lH, br s, NH), 7.17 (lH, ddd, J 11.0, 8.5, 1.0, H-2), 7.23 (1H, ddd, J 
7.5, 7.5, 1.5, H-4), 7.51-7.58 (IH, m, H-3), 7.86 (1H, ddd, J 7.5, 7.5, 1.5, H-5), 
hydrogen couplings were confirmed by a COSY experiment.; Oc (100 MHz, CDCh), 
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23.1 (QI3), 28.9 (SCl-hCH2), 39.3 (SCH2CH2), 116.9 (d, J22, C-2), 124.3 (d, J 3.0, C-
4), 125.2 (d, J 11.0, C-6), 129.7 (d, J 11.0, C-5), 134.6 (d, J 9.0, C-3), 160.3 (d, J 255. 
C-1), 170.5 (NHCOMe), 190.0 (C(O)SCH2CH2), assignments were confmned by an 
HMQC experiment. vnuv/cm-1 3299 (N-H), 2900 (C-H), 1639 (C=O), 1607. 1545 
(aromatic C=C), 1101 (C-F). mlz (EI) 242 [Ml (7%), 182 (21), 123 (100), 118 (37), 95 
(44), 86 (14), 75 (21). eHN Calculated: C, 54.76; H, 5.01; N, 5.81; S, 13.29; F, 7.87, 
found: C, 54.22; H, 5.00; N, 5.70; S, 13.41; F, 7.65. mp 74-7YC. 
S-2-acetamidoethyl pyridine-2-carbothioate 121 
The product (0.16 g, 0.72 mmol, 69%) was a yellow oil that was not fully purified. On 
(400 MHz, CDCh), 1.95 (3H, s, C!h), 3.16 (2H, t, J 6.5, SClbCH2), 3.48 (2H, dt, J 6.5, 
6.5 SCH2Clb), 6.30 (lH, br s, NlJ), 7.50 (1H, ddd, J 7.5, 5.0, 1.5, H-3), 7.83 (1H, ddd, 
J 7.5, 7.5, 1.5, H-4), 7.91 (lH, d, J 7.5, H-5), 8.65 (1H, d, J 5.0, H-2), hydrogen 
couplings were confirmed by a COSY experiment.; mlz (EI) 224 [Ml (1%), 165 (69), 
137 (31), 118 (51), 106 (66), 86 (87), 78 (100). 
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Solid Media 
R5 
Chemical Amount / litre 
Sucrose 103.0 g 
K2S04 0.25 g 
MgCh.6H20 10.12 g 
Glucose 20.0 g 
Difco Casaminoacids 0.10 g 
Difco Yeast Extract 5.00 g 
TES Buffer 5.73 g 
Distilled H2O To 1000 ml 
Table 4: R5 Medium 16 
100 mL of the above solution (Table 4) was poured into 250 mL Erlenmeyer flasks each 
containing 2.2 g Difco Bacto Agar. The flasks were closed and autoclaved. The medium 
was re-melted at the time of use in a microwave and to each flask was added a sterile 
solution of each of the following, (as shown in Table 5) 
Chemical Amount / 100 mL of R5 medium 
KH2P04 (0.50/0) 1.0mL 
CaCh.2H20 (5M) O.4mL 
L-proline (20%) 1.5mL 
NaOH (IN) 0.7mL 
Trace Element Solution: 0.2 mL 
ZnS04.7H20 (0.1 gIL) 
FeS04.7H20 (0.1 gIL) 
MnCh.4H20 (0.1 gIL) 
CaCh.6H20 (0.1 gIL) 
NaCI (0.1 gIL) 
Table 5: Sterile solutions added to R5 media before use 
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SMM 
Chemical Amount I liter 
Agar 20 g 
Mannitol 20 g 
Soya flour 20 g 
Table 6: SFM Medium 16 
The mannitol and soy flour were dissolved in 1 litre of tap water. 100 mL portions of 
this solution were poured into 250 mL Erlenmeyer flasks, each containing 2.0 g of agar. 
The flasks were closed and autoclaved. 
SMMS 
SMMS medium consisted of Difco Casaminoacids 2.0 gil, TES buffer 5.73 gil and 
distilled water to balance, the pH was adjusted to 7.2 with NaOH. 200 mL portions of 
this solution were poured into 250 mL Erlenmeyer flasks, each containing 3.0 g of 
Difco Bacto agar. The flasks were closed and autoclaved. At the time of use the media 
was re-melted and the following sterile solutions were added: 
Sterile Solution (Initial Concentration) Amount I litre 
NaH2P04 (50 mM) + K2HP04(50 mM) 20mL 
MgS04(lM) 10mL 
Glucose (50% w/v) 36mL 
Trace Element Solution As for R5 medium 0.2 mL 
(Table 5) 
Table 7: SMMS Medium16 
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Liquid Media 
SMM 
Sterile solution (initial Concentration) Amount / 100 ml 
MgS04.7H20 (24 giL) 2.5 mL 
TES Buffer (0.25 M, pH 6.2) 10mL 
NaH2P04 (6 gIL) + K2HP04 (6.8 giL) 1.0mL 
Trace Element Solution (as for R5 medium Table 5) 0.1 mL 
Casaminoacids (20% w/v) 1.0mL 
Water 8l.9 mL 
Glucose (sterile filtered and added separately) (20% w/v) 5.0mL 
Table 8: Supplemented Minimal Medium 16 
Growth of the redM::aac(3)IVmutant of Streptomyces coelicolor M511 
10 f.11 of a spore stock of the mutant (supplied by Stanley) were used to inoculate 100 
mL of SMM liquid medium and the resulting culture was incubated for 2 days at 30°C 
and 200 rpm. The culture was then divided into ten 10 mL aliquots. To each 10 mL 
culture, a different concentration of a NAC thioester was added. The compounds and 
amounts added are shown in Table 9. 
Compound 1: Mass 2: Mass 3: Mass 
added /mg added 1m2 added Img 
Pyrrole-2-carboxyl-N- 1 5 10 
acetylcysteamie thioester, 118 
S-2-acetamidoethyl furan-2- 1 5 10 
carbothioate, 119 
S-2-acetamidoethyl pyridine-2- 1 5 10 
carbothioate, 122 
S-2-acetamidoethyl thiophene-2- 1 5 10 
carbothioate, 120 
S-2-acetamidoethyl-2-(l- 1 5 10 
tluorobenzo )thioate, 121 
Table 9: Mass ofNAC thioester added 
After 4 days the mycelia were pelleted by centrifugation, washed with water and 
extracted into 1.0 mL of 50:50 acetonitrile/methanol (acidified using 10 J.11 of 20% 
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HC1). The extract was centrifuged at 4000 g for 10 minutes, decanted, and passed 
through a 0.4 micron filter. 50 Jll of the filtrate was analysed by HPLC. 
LC-MS analysis of prodiginines in culture extracts 
The method used for analysis of undecylprodiginine and streptorubin B in the culture 
extracts is detailed below (Table 10). 
Time (mins) H20 (pH3 Acetonitrile, 0/0 Flow rate (mLI 
adjusted with min) 
HCI),% 
0 50 50 1.0 
1 50 50 1.0 
4 25 75 1.3 
21 20 80 1.4 
23 50 50 1.0 
Table 1 0: HPLC method for prodiginine analysis 
Column: 4.6x 150 mm Agilent Xorbax C8 column 
Temperature: room temperature 
Detection wavelength: 533 nm 
Total run time: 30 minutes 
Retention time of undecylprodiginine: 5.5 minutes 
Retention time of streptorubin B: 7 minutes 
7.3: Experimental - Results and Discussion Chapter 5 
(1-ethoxy-l-oxopropan-2-yl)triphenylphosphonium bromide 244174 
Ethyl acetate (60 mL) was dried with MgS04 and filtered into a round bottom flask to 
which triphenyl phospine (PPh3) (10.48 g, 40.0 mmol) was added. After complete 
dissolution 2-bromopropionate ethyl ester 243 (5.20 mL, 7.24 g, 40.0 mmol) was added 
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and the mixture was heated to reflux for 16 hours. After this time, the product 
precipitated from the solution as a white solid which was removed by filtration. The 
precipitate was washed with ethyl acetate giving the desired product (15.61 g, 35.23 
mmol, 88%) as a white crystalline solid. 08 (400 MHz, CDCb), 0.98 (3H, t, J 7.0, 
C(O)OCH2Clt3), 1.67 (3H, dd, J 18.5, 7.5, Clt3CH(pPh3)(CO)), 3.96 (2H. m, 
C(O)OClbCH3), 6.85 (1H, dq, J 16.0, 7.5, CH3CH(PPh3)(CO)), 7.66 (6H, m, aromatic), 
7.76 (3H, m, aromatic), 7.97 (6H, m, aromatic), hydrogen couplings were confirmed by 
a COSY experiment; Oc (lOO MHz, CDCb), 13.0 (9~hCH(CO)(PPh3)), 13.7 
(C(O)OCH3CH2), 37.0 (d, J 50.5, CH3CH(CO)(PPh3)), 62.9 (C(O)OCH3CH2), 118.3 (d, 
J 86.5, aromatic), 130.2 (d, J 13.0, aromatic), 134.4 (d, J 10.0, aromatic), 134.9 (d, J 
3.0, aromatic), 168.1 (Q 0), carbon signal assignments were confumed by HMBC and 
HMQC experiments. CHN Calculated: C, 62.31; H, 5.46; Br, 18.02; Found: C, 62.31; 
H, 5.41; Br, 18.00; vrruv/cm-1 1732 (C=O), 2981 (C-H), 1584, 1580, 1474 (C=C 
aromatic). m/z (ES/) 363.09 [M+Ht, 335.06, 261.88, 182.78. HRMS Calculated for 
[C23H240 2Pt: 364.1605, observed: 364.1611. mp: 128-130°C 
Method 2 
Triphenyl phosphine (22 g, 85 mmol) was dissolved in DCM. 2-bromopropionate ethyl 
ester 243 (5.4 ml, 42 mmol) was added. The reaction was stirred at room temperature 
for 72 hours. The solvent was removed in vacuo to give crude 244, which was used 
without further purification. 
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(l-ethoxycarbonylethylidine )triphenylphosphorane 245 174 
The ylide salt 244 (15.61 g, 35.2 mmol) was dissolved in DCM (100 mL) and washed 
with a solution ofNaOH (2.82 g, 70.5 mmol dissolved in 70 mL of water). The organic 
phase changed from colourless to yellow. The organic layer was separated, dried with 
MgS04 and concentrated in vacuo to give the product (11.49 g, 31.70 mmol, 90%) as a 
yellow crystalline solid. Ou (400 MHz, CDCh), 0.45 (3H, t, J 7.0, C(0)OCH2C[h), 1.60 
(3H, d, J 14.0, PCHC[h), 3.71 (2H, q, J 7.0, C(0)OClbCH3), 7.44 (6H, m, aromatic), 
7.53 (3H, m, aromatic), 7.60 (6H, m, aromatic), hydrogen couplings were confinned by 
a COSY experiment; Oc (100 MHz, CDCh), 13.1 (C(O)OCH2CH3), 14.0 
90.4, aromatic), 128.2 (d, J 12.0, aromatic), 131.6 (aromatic), 133.6 (d, J 10.0, 
aromatic), 170.6 (Q 0), carbon signal assignments were confmned by HMQC 
experiments. CHN Calculated: C, 76.23; H, 6.40; Found: C, 75.79; H, 6.35; vnuv/cm-J 
1625 (CO), 2978 (CH), 1588, 1570, 1483 (aromatic). mlz (ESJ) 363.07 [M+Ht, 
335.03, 261.87, 182.82. HRMS Calculated for [C23H2302Pt: 363.1508, observed: 
363.1530. mp: 158-162°C literature value 159_160°C?OI,202 
Ethyl-(2E,4E)-2,4-dimethylhexa-2,4-dienoate 247 172 
~C02Et 
To a solution oftiglic aldehyde 246 (9.95 g, 118.0 mmol) in dry toluene (120 ml) under 
argon was added ylide 245 (47.40 g, 131.0 mmol). The mixture was heated to reflux for 
48 hours then allowed to cool to room temperature and concentrated under reduced 
pressure. Et20 was added, and the resulting precipitated triphenylphosphine oxide was 
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removed by filtration. This was repeated until no precipitate was fonned. The yellow 
filtrate was concentrated in vacuo and the residue purified by flash column 
chromatography (19:1 petroleum ether / diethyl ether), to give the product (15.87 g, 
94.40 mmol, 80%) as a colourless oil. Ou (400 MHz, CDCh), 1.28 (3H, t, J 7.0, 
C(O)OCH2Clh), 1.73 (3H, d, J 7.0, ClhCH=C), 1.82 (3H, s, =C(CltJ)CH=), 1.98 (3H, 
s, =C(Clh)CO), 4.17 (2H, q, J 7.0, C(O)OC[bCH3), 5.69 (1H, q, J 7.0, CH3CH C), 
7.10 (1H, s, =C(CH3)CH), hydrogen couplings were confmned by a COSY 
experiment; Oc (100 MHz, CDCh), 14.4 (CH3CH=C) and (=C(CH3)CO), 14.6 
(C(O)OCH2CH3), 17.7 (=C(gf3)CH=), 60.5 (C(0)OCH2CH3), 124.9 (=C(CH3)CO), 
130.8 (CH3CH=C), 133.l (C(CH3)CH=), 142.9 (=C(CH3)CH=), 169.3 
(C(O)OCH2CH3), carbon signal assignments were confmned by HMBC and HMQC 
experiments. vmo/cm-1 2981 (C-H), 1702 (C=O), 1625 (C=C). mlz (ESI) 168.89 
[M+Ht, 140.88, 122.94, 95.15. HRMS Calculated for [C IOHI60 2Nat: 191.1043, 
observed: 191.1044. 
(2E,4E)- 2,4-dimethylhexa-2,4-dien-l-ol 248172 
~OH 
To a stirred solution of ester 247 (18.0 g, 107.0 mmol) in dry Et20 (250 mL) under 
argon at O°C, was added DIBAL-H (225 mL of a 1M solution in hexanes, 225.0 mmol) 
dropwise. After 1 hour, the reaction mixture was quenched by the cautious addition of 
MeOH (10 mL). The reaction mixture was diluted with ether (200 ml) and a saturated 
solution of sodium potassium tartrate tetrahydrate (300 mL) was added. The mixture 
was stirred vigorously for several hours until the organic and aqueous layers had 
completely separated. The organic layer was separated, washed with brine (200 mL), 
dried over MgS04, filtered and concentrated under reduced pressure. The crude residue 
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was purified by flash column chromatography (20:1 petroleum ether / diethyl ether) to 
give the product (11.47 g, 90.95 mmol, 85%) as a colourless oil. On (400 MHz, CDCb). 
1.65 (3H, d, J 7.0, CltJCH=C), 1.72 (3H, s, =C(CltJ)CO), 1.77 (3H, s, =C(CltJ)CH=), 
2.31 (1H, s, Oli), 3.99 (2H, s, Cli20H), 5.38 (lH, q, J 7.0, CH3CH-C), 5.85 (lH, s. 
=C(CH3)CH ), hydrogen couplings were confmned by a COSY experiment; Oc (100 
MHz, CDCb), 13.9 (0I3CH=C), 15.5 (=C(CH3)CH=), 16.7 (=C(gI3)CO). 69.7 
(0I20H) , 124.8 (CH3CH=C), 129.8 (=C(CH3)CH=), 133.3, (=C(CH3)CH=), 134.1 
(=C(CH3)CO), carbon signal assignments were confinned by HMBC and HMQC 
experiments. vnuv/cm-J 3334 (O-H), 2913, 2857, (C-H), 1651 (C=C). mlz (ESI) [M-
H20t 109.10, HRMS Calculated for [C8H140 INat:149.0937 observed: 149.0943. 
(2E,4E)-2,4-dimethylhexa-2,4-dienaI219 172 
~CHO 
To a stirred solution of alcohol 248 (2.29 g, 18.1 mmol) in dry DCM (200 mL) was 
added Mn02 (23.60 g, 270.0 mmol) at ambient temperature. After 72 hours the mixture 
was filtered through celite and concentrated in vacuo to give the product as a yellow oil, 
which was used without further purification (2.15 g, 17.36 mmol, 96%). 00 (400 MHz, 
CDCh), 1.78 (3H, d, J 7.0, CltJCH=C), 1.91 (3H, s, =C(CltJ)CO), 1.94 (3H, s, 
=C(CltJ)CH=), 5.95 (lH, q, J7.0, CH3CH C), 6.69 (lH, s, =C(CH3)CH=), 9.30 (lH, s, 
CHO), hydrogen couplings were confirmed by a COSY experiment; Oc (100 MHz, 
CDCh), 11.6 (=C(Q-h)CH=), 14.3 (0I3CH=C), 15.5 (=C(0I3)CO), 134.1 
(CH3CH C(CH3», 135.0 (CH3CH=C(CH3)-CH C(CH3)-C(=0)H), 135.6 (CH3CH=C), 
155.0 (=C(CH3)CH=), 196.1 (0 0), carbon signal assignments were confinned by 
HMBC and HMQC experiments. vltUlJl'cm-J 2920 (C-H), 1670 (C=O), 1620 (C=C). mlz 
147 
Chapter -:': Experimental 
(ESJ) 124.97 [M-H20t, 107.06, 79.36. HRMS Calculated for [C8H120 INat: 
147.0780, observed: 147.0787. 
Methyl 2,3-dihydroxypropanoate 250178 
OH 
MeO~OH 
o 
To a solution of 2,2-dimethyl-l,3-dioxalone-4-carboxylate 249 (3.00 mL, 3.54 g, 20.0 
mmol) in methanol (60 mL) was added HCI (1M, 27.0 mL, 27.0 mmol). The mixture 
was stirred at room temperature for 4.5 hours. The methanol was evaporated in vacuo, 
and the reaction mixture neutralised with saturated sodium bicarbonate. The product 
was extracted with 10% isopropanol in ethyl acetate successively (5 x 40 mL). The 
organic layer was dried with MgS04 and concentrated in vacuo to give the product 
(1.03 g, 8.60 mmol, 86%) as a colourless oil which was used without further 
purification. Ou (400 MHz, D20), 3.75 (3H, s, OClh), 3.76 (2H, dd, J 4.0, 1.5 
HOClhCH(OH)), 4.31 (IH, t, J 4.0, HOCH2CH(OH)), O-H signal not visible in D20, 
hydrogen couplings were confirmed by a COSY experiment; Oc (100 MHz, 0 20), 52.7 
(OCH3), 63.2 (Q-h), 71.6 (CH), 174.3 (C-O). vnuv/cm-l 3375 (O-H), 2956 (C-H), 1732 
(C=O). mlz (ESJ) 142.88 [M+Ht. HRMS Calculated for [C~804t: 143.0315, 
observed: 143.0318. 
MethyI2-hydroxy-3-(trityloxy)propanoate 236178 
OH 
MeO~OTr 
o 
To a solution of ester 250 (1.39 g, 11.6 mmol), in dry DCM (60 mL) under argon at 
ambient temperature, was added triphenylchloromethane (4.20 g, 15.1 mmol), 
triethylamine (2.30 mL, 16.5 mmol), and N,N-dimethylaminopyridine (DMAP) (0.99 g, 
148 
Chapter 7: Experimental 
0.81 mmol), and the mixture was stirred for 24 hours. The reaction mixture was poured 
onto ice-water (50 mL) and extracted into DCM (50 mL). The organic layer was washed 
with brine, dried (MgS04), and concentrated. The residue was purified by flash column 
chromatography (DCM) to give the product (3.91 g, 10.78 mmol, 93%) as a colourless 
solid. Ou (400 MHz, CDCh), 3.07 (lH, d, J 8.0, 0!1), 3.29 (IH, dd, J 9.5, 3.0, 
TrOC1t2CH(OR)CO), 3.40 (IH, dd, J 9.5, 3.0, TrOC1t2CH(OH)CO), 3.70 (IH, s, 
OCR3), 4.20 (lR, dt, J 8.0, 3.0, TrOCH2CH(OH)CO), 7.13-7.15 (I5H, m, Ph), 
hydrogen couplings were confirmed by a COSY experiment; Oc (IOO MHz. CDC h), 
52.4 (OCH3), 65.1 (CH2), 70.6 (QI), 86.3 (CPh3), 127.0 (Ph), 127.7 (Ph), 128.4 (Ph), 
143.3 (Ph), 173.3 (C 0), carbon signal assignments were confirmed by HMQC 
experiments. eHN: Calculated: C, 76.22; H, 6.12; Found: C, 76.02; H, 6.08; vnur/cm-J 
3537 (O-H), 2971, 2901 (C-H), 1732 (C=O). mlz (ESI) 385.1244 [M+Nar. HRMS 
Calculated for [C23H2203Nar: 385.1410, observed: 385.1410. mp: 88-90°C literature 
value 88-90° C.178 
3-(2-bromoacetyl)furan-2,4(3H,5H)-dione 257203 
To a solution oftetroni~ acid 256 (l.40 g, 14.0 mmol) in dry DCM (60 mL) under argon 
at O°C was added dry pyridine (2.50 mL, 30.0 mmol), followed by bromoactyl bromide 
(1.50 mL, 15.0 mmol) dropwise over 10 minutes. The reaction was stirred at O°C for 1 
hour followed by stirring at ambient temperature for an additional 1 hour. After this 
time the reaction mixture was poured into 3M Hel (50 mL) in ice-water (70 g). The 
organic layer was separated, washed with water, dried with MgS04 and concentrated in 
vacuo to give the product (2.02 g, 9.24 mmol, 66%) as a dark red brown oil, which was 
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used without further purification. 0" (400 MHz, CDC h), 4.02 (2H, s, C/hBr), 4.88 (2H. 
s, COClhO), 6.04 (1H, s, Cli). Oc (100 MHz, CDC h), 24.2 (CH2Br), 68.1 (COCH20), 
101.9 (QI), 162.5 (CO), 168.3 ~O), 171.7 (CO), carbon signal assignments were 
confirmed by HMBC and HMQC experiments. vmo;/cm-l 2956 (C-H), 1778, 1750, 1625 
(C=O), 709 (C-Br). mlz (ESJ) 242.82 C9Br-M+Nar, 244.80 [8 1 Br-M+Nar. HRMS 
Calculated for [C6HsO/9BrNat: 242.9263, observed: 242.9274, (1:1 isotope pattern of 
bromine). 
5-(2-bromoacetyl)-2,2-dimethyl-l,3-dioxane-4,6-dione 229179,203 
Synthetic procedure as for 257 using Meldrum's acid 226 (2.02 g, 14.0 mmol) in place 
oftetronic acid. The product was isolated as a brown oil (2.40 g, 9.10 mmol, 65%). 0" 
(400 MHz, CDC b), 1.76 (6H, s, 2 x C!iJ), 4.67 (2H, s, BrC/hCO), O-H not visible on 
IH NMR spectrum; Oc (100 MHz, CDCh), 26.0 (CH2Br), 27.0 (C(QI3h), 91.9 
(CO(CO)C CO), 105.7 (C(CH3)2), 141.9 (COH), 165.0 ~=O), 188.4 (C=O), carbon 
signal assignments were confirmed by HMBC and HMQC experiments. vmo;/cm-I 2996 
(C-H), 1725, 1659 (C=O), 725 (C-Br). mlz (ESJ) Molecular ion not visible HRMS 
Calculated for [CSH90481BrNat: 286.9526 observed: 286.9521. (1:1 isotope pattern of 
bromine). 
S-tert-butyl 4-bromo-3-oxobutanethioate 231203 
OH 0 
== Br~s--+ 
To a solution of crude Meldrum's acid derivative 229 (7.92 g, 30.0 mmol) in dry DCE 
(120 mL) under argon was added t-butanethiol (3.20 mL, 30.0 mmol). The solution was 
150 
Chapter 7: Experimental 
heated to reflux for 4 hours. After this time the solvent was removed in vacuo, to give a 
red brown oil which was purified by flash column chromatography (10: 1 hexane / ethyl 
acetate). The product was isolated as a dark red oil (4.31 g, 17.10 mmol, 570/0 over 2 
steps from 30.0 mmol of Meldrum's acid). 1:0.6 Keto / enol based on the J H NMR 
spectrum; Ou (400 MHz, CDCh), Keto 1045 (9H, s, 3 x CliJ), 3.81 (2H, s. 
C(O)CHzC(O)), 4.03 (2H, s, ClbBr). Enol 1.49 (9H, s, 3 x CliJ), 3.76 (2H, s. ClhBr), 
5.56 (lH, s, ClJ), 12.67 (lH, s, Oli), hydrogen couplings were conflffiled by a COSY 
experiment. Oc (100 MHz, CDCh), Keto 30.0 (3 x CH3), 34.7 (CH2Br), 49.9 (SC(Me)3), 
5504 (C(O)GhC(O)), 192.5 ~=O), 194.3 (C=O), Enol 3004 (3 x CH3), 29.1 (CH2Br), 
49.3 (SC(Me)3), 101.5 (C(O)CHC(OH)), 167.8 (COH), 197.2 (C=O), carbon signal 
assignments were confirmed by HMQC experiments. vmtvl'cm-1 2962, 2923 (C-H), 1724, 
1670 (C=O), 1620 (C=C conj with C=O), 3072 (O-H), 779 (C-Br). HRMS Calculated 
for [CSH13S1Br02SNat: 276.9697 observed: 276.9684 (1:1 isotope pattern of bromine). 
S-tert-butyl 4-( diethoxyphosphoryl)-3-oxobutanethioate 224169 
a a a 
II II II Eta-r~s-L 
Eta \ 
a a aH 
II II J EtO-r~s-L 
EtO \ 
To a suspension of sodium hydride (NaH) (0.30 g, 12.65 mmol) in dry THF (75 mL). 
under argon, at -10°C was added thioester 231 (2.91 g, 11.50 mmol) in dry THF (10 
mL) dropwise. Meanwhile to a suspension ofNaH (0.33 g, 13.96 rnmol) in dry THF (30 
mL) under argon at -10°C, was added diethyl phosphate (1.63 mL, 12.65 mmol) 
dropwise. The solutions were stirred for 1 hour before the solution of sodium 
diethylphosphite was added dropwise via cannula to the solution of 231. The reaction 
was stirred at O°C for 1 hour before being allowed to warm to ambient temperature over 
24 hours by removing the ice bath. The mixture was poured into a mixture of saturated 
ammonium chloride (200 mL), and ether (300 mL). The organic layer was separated 
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and the aqueous layer re-extracted with ether (2 x 50 mL). The combined organic layers 
were washed with water (2 x 100 mL), brine (100 mL), dried with MgS0
4
• and 
concentrated to give a crude oil which was purified by flash column chromatography 
(1:1 hexane / ethyl acetate) to give the desired product (3.33 g, 10.75 mmol, 85%) as an 
orange oil. Keto / enol 3: 1 based on the 1 H NMR spectrum Ou (400 MHz, CDCh), 1.32 
(6H, m, P(OCH2Clh)2), 1.44 (7H, s, 3 x Clh), 1.48 (2H, s, 3 x Clh), 2.69 (O.4H, d, J 
23.0, PClhCO), 3.22 (1.6H, d, J23.0, PClhCO), 3.77 (1.6H, s, PCH2COClhCO), 4.13 
(4H, m, P(OClhCH3)2), 5.45 (O.4H, d, J 3.0, PCH2COCHCOH), 12.90 (O.4H, br s. 
PCH2COCHCOlf), hydrogen couplings were confirmed by a COSY experiment; Oc 
(100 MHz, CDC b), 16.5 (d, J 6.5, POCH20I3), 16.6 (d, J 6.5, POCH20I3), 29.8 (3 x 
0I3), 30.3 (3 x 0I3), 33.8 (d, J 136.0, P0I2CO) 42.8 (d, J 126.0, P0I2CO), 48.7 
(SC(Me)3), 49.4 (SC(Me)3), 58.7 (-CH2C(=O)0I2-C(=O)-S-), 62.8 (d, J 6.5, 
P00I2CH3), 62.9 (d, J 6.5, P00I2CH3), 102.3 (d, J 8.0, PCH2COOICOH), 166.4 
(COH), 192.5 (d, J 6.5, Cc-O), 194.3 (d, J 6.5, C=O), 196.5 (C=O) , carbon signal 
assignments were confmned by HMQC experiments. vflUlJt"cm-1 2962, 2923 (C-H), 1725, 
1675 (C=O), 1257 (P=O). mlz (ESI) 333.02 [M+Nat, 242.83, 214.76, 168.72, 126.88 
HRMS Calculated for [CI2H230SSIPlt: 311.1077 observed: 311.1085. 
General method for synthesis of JI-keto thioesters170 
To a suspension ofNaH (0.10 g, 4.00 mmol) in dry THF (40 mL) under argon at O°C, 
was added phosphonate 224 (0.50 g, 1.61 mmol) in dry THF (5 mL) dropwise. The 
mixture was stirred for 1 hour at O°C then the corresponding aldehyde (1.30 mmol) in 
dry THF (2 mL) was added dropwise. The mixture was stirred for 1 hour at O°C then 
allowed to warm to ambient temperature overnight. The mixture was poured into 
saturated ammonium chloride (40 mL) and ether (80 mL). The organic layer was 
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separated and the aqueous layer re-extracted with ether (2 x 50 rnL). The combined 
organic layers were washed with water (2 x 50 mL) and brine (50 mL). dried with 
MgS04, and concentrated in vacuo to give the crude product which was purified by 
flash column chromatography. 
S-tert-butyl-( 4E,6E,8E)-6,8-dimethyl-3-oxodeca-4,6,8-trienethioate 222 
The crude residue was purified by flash column chromatography (25: 1 petroleum ether / 
diethyl ether) to give the product as a brown solid (0.23 g, 0.83 mmol, 64%). 1: 1 Keto / 
enol based on 1 H NMR spectrum 08 (400 MHz, CDC h), 1.40 (4.5H, s, SC(Clh)3), 1.53 
(4.5H, s, SC(Clh)3), 1.75 (3H, d, J 7.0, ClhCH=C(CH3)), 1.83 (3H, s, 
CH3CH=C(CH3)CH=), 1.94 (3H, s, CH3CH=C(CH3)CH=C(Clh)), 3.69 (IH, s, 
COClhC(O)), 5.41 (O.5H, s, C(OH)CHC(=O)), 5.62 (0.5H, q, J 7.0, CH3CH=C(CH3)), 
5.68 (O.5H, q, J 7.0, CH3CH:.-C(CH3)), 5.74, (0.5H, d, J 15.5, 
CH3CH=C(CH3)CH=C(CH3)-CH=CH-C(OH)), 6.22 (0.5H, d, J 15.5. 
CH3CH=C(CH3)CH=C(CH3)-CH=CH-C(OH)), 6.23 (0.5H, s, 
CH3CH=C(CH3)CH C(CH3)), 6.32 (0.5H, s, CH3CH=C(CH3)CH=C(CH3)), 7.17 (0.5H, 
d, J 15.5, CH3CH=C(CH3)CH=C(CH3)-CH=CH-C(OH)), 7.32 (0.5H, d, J 15.5, 
CH3CH=C(CH3)CH=C(CH3)-CH CH-C(=O)), 12.60 (0.5H, s, C(OmCHC=O), 
hydrogen coupling was confirmed by a COSY experiment; Oc (100 MHz, CDC h), 13.7 
(CH3CH=C(CH3)CH=C(CH3)), 13.8 14.0 
(CH3CH=C(CH3)), 14.2 (0I3CH=C(CH3)), 16.2 (CH3CH=C(£H3)CH=), 16.4 
(CH3CH=C(0I3)CH=), 29.6 (SC(0I3)3), 30.20 (SC(CH3)3), 48.2 (SC(CH3h). 48.89 
(SC(CH3)3), 56.7 (-CO-CHrCO-SC(CH3)3), 101.4 (-COH-CH-CO-SC(CH3h). 119.5 
123.6 
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129.1 
CH=CH-COH), 131.4 (CH3CH=C(CH3)CH-C(CH3)-CH=CH-COH). 133.8 
(CH3CH C(CH3)CH=C(CH3)-CH=CH-COH), 142.8 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-C(OH)-CH-CO-SC(CH3)3), 144.5 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-CO-
CH2-CO-SC(CH3)3), 146.6 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-COH-CH-CO-
SC(CH3)3), 152.0 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-CO-CH2-CO-SC(CH3h). 
167.5 (-CH=CH-COH-CH-CO-SC(CH3)3), 191.6 (-CH=CH-CO-CHrCO-SC(CH3)3), 
193.0 (-CH=CH-CO-CH2-CO-SC(CH3)3), 195.9 (-CH=CH-COH-CH-CO-SC(CH3)3). 
carbon signal assignments were confirmed by HMBC and HMQC experiments. vmm/ 
cm-1 2960, 2914 (C-H), 1775, 1749 (C=O), 1623 (C=C conj with C=O). mlz (ESI) 
280.96 [M+Ht, 262.94, 206.87, 164.87, 144.91 HRMS Calculated [C 1Ji240 2SINat: 
303.1389 observed: 303.1398 mp: 35-37°C. 
S-tert-butyl-(E)-3-oxo-5-phenylpent-4-enethioate 251 170 
o 0 I/' OH 0 I/' ~s~~~s~ 
The crude residue was purified by flash column chromatography (10: 1 petroleum ether / 
diethyl ether), to give the product as a yellow solid (0.28 g, 1.08 mmol, 830/0). 8: 1 enol/ 
keto based on the 1 H NMR spectrum, Ou (400 MHz, CDC h), 1.39 (1 H, s, C(Clh)3), 1.45 
(8H, s, C(Clh)3), 3.71 (0.2H, s COClbCO), 5.39 (0.8H, s, C(OH)CHC(=O», 6.21 
(0.9H, dd, J 15.5, 1.0, PhHC=CH-COH), 6.72 (O.1H, d, J 15.5, PhHC=CH-CO), 7.21-
7.38 (5.9H, m, Ph and PhHC=CH-COH), 7.52 (O.1H, d, J 15.5, PhHC=CH-CO), 12.60 
(0.9H, d, J 1.0, C(Olt}-CH-C=O), hydrogen couplings were confirmed by a COSY 
experiment; Oc (100 MHz, CDC h), 29.7 (C(gh)3), 30.2 (C(CH3h), 48.8 ~(CH3)3). 
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49.4 (C(CH3)3), 57.2 (COa-hCO), 102.1 (C(OH)CHC(=O), 121.7 (phHC=CH-COH). 
125.3 (PhHC CH-CO), 127.9 (Ph), 128.9 (Ph), 129.14 (Ph), 129.3 (Ph), 129.8 (Ph), 
131.2 (Ph), 134.5 (Ph), 135.7 (Ph), 138.0 (PhHC=CH-COH), 145.2 (PhHC=CH-CO), 
166.7 (COH), 191.8 (COCH2CO), 192.9 (COCH2CO), 196.6 (C(OH)CHC(=O». carbon 
signal assignments were confmned by HMBC and HMQC experiments. v",d'cm- I 2959. 
2920 (C-H), 1637 (C=O) mlz (ESl) 262.90 [M+Ht, 206.80, 190.82, 172.80, 130.99 
HRMS Calculated for [ClsHlsS02Nat: 285.0920 observed: 285.0923, mp 62-64°C. 
S-tert-butyl-(E)-3-oxododec-4-enethioate 252170 
OH 0 1/ 
~ ~ s~ 
The crude residue was purified by flash column chromatography (19: 1 petroleum ether / 
diethyl ether), to give the product as a bright red oil (0.26 g, 0.7 mmol, 70%) 1:1 Keto / 
enol based on IH NMR spectrum Ou (400 MHz, CDCh), 0.85 (3H, t, J 7.0, 
CH3(CH2)4ClbCH2CH=CH), 1.44 (4.5H, s, SC(Clh)3), 1.48 (4.5H, s, SC(Clh)3), 2.20 
(2H, m, CH3(CH2)4CH2ClbCH=CH), 3.67 (lH, s, -(CO)Clb(CO)-), 5.27 (0.5H, s, -
(COH)CH(CO)-), 5.64 (0.5H, dd, J 15.0, 1.0, CH3(CH2)4CH2CH2CH=CH-
(COH)CH(CO», 6.12 (0.5H, dd, J 15.0 1.0, CH3(CH2)4CH2CH2CH=CH-
(COH)CH(CO», 6.67 (0.5H, dt, J 15.0, 7.0, CH3(CH2)4CH2CH2CH=CH-
(COH)CH(CO», 6.88 (0.5H, dt, J 15.0, 7.0, CH3(CH2)4CH2CH2CH=CH-
(CO)CH2(CO», 12.58 (0.5H, d, J 1.0, -(COlDCH(CO)-), hydrogen couplings were 
confirmed by a COSY experiment; Oc (100 MHz, CDCh), 12.5 (CH3), 22.6 (CH2), 22.2 
(CH2), 27.9 (CH2), 28.5 (CH2,), 29.0 (CH2), 29.1 (CH2), 29.1 (CH2), 29.6 (SC(CH3)3), 
31.1 (SC(CH3)3), 31.7 (CH2), 31.8 (CH2), 32.6 (CH2), 32.7 (CH2), 48.2 (SC(CH3)3), 
48.9 (SC(CH3)3), 56.1 (-(CO)CH2(CO)-), 100.2 (-(COH)CH(CO)-). 124.1 
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(CH3(CH2)4CH2CH2CH-CH-(CO)CH2(CO», 129.6 (CH3(CH2)4CH2CH2CH=CH-
(COH)CH(CO», 142.7 (CH3CH2(CH2)4CH2CH=CH-(CO)CH2(CO», 150.7 
(CH3(CH2)4CH2CH2CH=CH-(COH)CH2(CO», 166.8 (CH3(CH2)4CH2CH2CH=CH-
~OH)CH(CO», 191.8 (-~0)CH2(CO)-), 192.7 (-(CO)CH2~0)-). 196.3 (_ 
(COH)CH~O)-), carbon signal assignments were confrrmed by HMBC and HMQC 
experiments. vlHlDl'cm-J 2957, 2924, 2855 (C-H), 1655 (C=O), 1581 (C=C) mlz (ESl) 
285.00 [M+Ht, 228.89, 152.94, 134.98, 107.11, 93.27, 79.39 HRMS Calculated for 
[C16H28Na02St: 307.1702 observed: 307.1707. 
S-tert-butyl-(E)-5-cyclohexyl-3-oxopent-4-enethioate 253 170 
uDJ~ = uMsk 
The crude residue was purified by flash column chromatography (10: 1 petroleum ether / 
diethyl ether) to give the product as a pink oil (0.34 g, 1.27 mmol, 98%). 1:1 Keto / enol 
based on IH NMR spectrum Ou (400 MHz, CDCI), 1.0-1.3 (6H, m, 6 x cyclohexyl 
protons), 1.40 (4.5H, s, SC(Clh)3), 1.45 (4.5H, s, SC(Clh)3), 1.5-1.75 (4H, m, 
cyclohexyl protons), 2.0-2.2 (lH, ffi, CH cyclohexyl proton), 3.69 (lH, s, -CH=CH-
(C=0)Clb(C=0)SC(CH3)3), 5.31 (0.5H, s, -CH=CH-(C=0)CH(COH)SC(CH)3), 5.62 
(0.5H, d, J 15.5, -CH=CH-(C=0)CH2(C=0)SC(CH3)3), 6.10 (0.5H, d, J 15.5, -CH=CH-
(C=0)CH(COH)SC(CH3)3), 6.64 (0.5H, dd, J 15.5, 7.0, -CH=CH-
(C=0)CH2(C=0)SC(CH3)3), 6.81 (0.5H, dd, J 15.5, 7.0, -CH=CH-
(C=0)CH(COH)SC(CH3)3), 12.62 (0.5H, s, -CH=CH-(C=O)CH(COmSC(CH))), 
hydrogen couplings were confirmed by a COSY experiment; Oc (100 MHz, COCI), 
25.6 (Cy), 25.8 (Cy), 29.6 (SC(CH3)3), 30.2 (SC(CH3)3), 31.6 (Cy), 32.1 (Cy), 40.8 
(Cy), 40.9 (Cy), 48.3 (SC(CH3)3), 48.9 (SC(CH3»)), 56.12 (-CH=CH-
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(C=0)CI-h(C=0)SC(CH3)3), 100.4 (-CH=CH-(C=0)CH(COH)SC(CH3)3), 121.8 (_ 
CH CI-I-(C=0)CH2(C=0)SC(CH3)3), 127.1 (-CH CH-(C=O)CH(COH)SC(CH3)3), 
147.7 (-CI-I=CH-(C=0)CH2(C=0)SC(CH3)3), 155.3 (-CH=CH-
(C=0)CH(COH)SC(CH3)3), 167.1 (-CH=CH-(C=0)CH«0H)SC(CH3)3), 192.2 (C 0), 
192.8 (Q 0), 196.3 (Q 0), carbon signal assignments were confinned by HMQC 
experiments. v~cm-l 2923, 2851 (C-H), 1650 (C=O), mlz (ESI) 268.94 [M+H]\ 
250.92,232.86, 194.85, 152.88, 134.98, 119.00 HRMS Calculated for [ClsH2402SNar: 
291.1389 observed: 291.1394 eRN: Calculated: C, 67.12; H, 9.01; S, 1l.95; Found: C 
67.22; H, 9.15; S, 11. 80. 
I-methoxy-l-oxo-3-( trityloxy)propan-2-yl-( 4E,6E,8E)-6,8-dimethyl-3-oxodeca-
4,6,8-trienoate 237170 
o 0 
~o MeO~OTr 
o 
To a solution ofthioester 222 (0.51 g, 1.78 mmol), and ester 236 (0.52 g, l.42 mmol) in 
dry THF (14 mL) under argon, was added silver trifluoroacetate (0.47 g, 2.20 mmol). 
The reaction mixture was stirred at ambient temperature for 16 hours whilst shielded 
from light. The mixture was diluted with ether and passed through a plug of silica and 
concentrated in vacuo. The residue was purified by flash column chromatography (20: 1 
petroleum ether / diethyl ether) to give the product as an off white oil (0.23 g, 038 
mmol, 27%). Enol/Keto 3:2 based on the IH NMR spectrum, Ou (400 MHz, CDCh), 
1.68 (3H, d, J 7.0, CLDCH=C(CH3)), 1.76 (3H, s, CH3CH=C(CLD)CH=), l.87 (3H, m, 
CH3CH=C(CH3)CH=C(CLD)), 3.41 (2H, m, CH30(C=0)-CH(-0-)-ClbOTr), 3.64 (3H, 
s, CLDO(C=O)-CH(-O-)-CH20Tr), 3.69 (1.2H, s, -(CO)Clb(CO)-), 5.18 (0.6H, m, 
CH30(C=O)-CH(-O-)-CH20Tr), 5.20 (O.4H, s, -(COH)CH(CO)-) 5.23 (O.4H, m, 
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CH30(C=0)-CH(-0-)-CH20Tr), 5.55 (1H, m, CH3CH C(CH3», 5.83 (O.4H, d, J 15.5. 
CH3CH=C(CH3)CH=C(CH3)-CH=CH-C(OH», 6.17 (O.4H, s. 
CH3CH=C(CH3)CH C(CH3)-CH=CH-C(OH», 6.28 (0.6H, s. 
CH3CH=C(CH3)CH C(CH3)-CH=CH-C(0H», 7.10-7.40 (16H, m, (Ph). 
CH3CH=C(CH3)CH=C(CH3)-CH CH-C(OH), and 2 X CH3CH=C(CH3)CH=C(CH3)-
CH CH-C(OH», 11.55 (OAH, s, COlf), hydrogen couplings were confirmed by a 
COSY experiment; Oc (100 MHz, CDCh), 13.8 (~l:hCH=C(CH3), 13.8 
~3CH=C(CH3), 14.1 (CH3CH=C(CH3)CH=C(Cl~h», 14.1 
(CH3CH=C(CH3)CH=C(ClI3», 16.2 (CH3CH=C(Clh)CH=), 16.3 
(CH3CH=C~3)CH-), 47.1 (-(CO)ClI2(CO)-), 52.4 (OClI3), 62.8 (CH30 (C=O)-CH(-
0-)-ClI20Tr), 63.3 (CH30(C=0)-CH(-0-)-ClI20Tr), 71.6 (CH30 (C=O)-CH(-O-)-
CH20Tr), 72.7 (CH30(C=0)-ClI(-0-)-CH20Tr), 86.7 (CPh3), 89.9 (-(COH)CH(CO)-), 
119.6 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C(OH», 123.6 
(CH3CH=C(CH3)CH=C(CH3)-CH ClI-CO), 127.2 (Ph), 127.0 (Ph), 128.6 (Ph), 129.1 
(CH3ClI=C(CH3)CH=C(CH3)-CH=CH-C(OH», 131.0 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-CO), 131.1 (CH3CH=C(CH3)CH C(CH3)-CH=CH-CO), 131.4 
(CH3CH=C(CH3)CH C(CH3)-CH=CH-CO), 133.8 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH), 133.8 (CH3CH C(CH3)CH=C(CH3)-CH=CH-CO), 142.7 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-C(OH», 144.8 (CH3CH=C(CH3)CH=C(CH3)-
CH CH-C(OH», 146.3 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-CO), 151.5 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-CO), 167.1 ~OH), 168.2 ~=O), 168.8 ~=O), 
171.3 (C 0),171.9 (C 0),191.3~ 0), carbon signal assignments were confinned by 
HMQC and HMBC experiments. vnuv/cm-J 2915 (C-H), 1777, 1755 (C=O), 1667 
(C=C). mlz (ESl) 575.23 [M+Naf, 331.07, 298.96, 243.95 212.89, 148.95. HRMS 
Calculated for [C3sH3606Nat: 575.2404, observed: 575.2428. 
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I-methoxy-l-oxo-3-(trityloxy)propan_2_yl_( 4E)-3-oxododec-4-enoate 254 170 
o 0 
'-':::: 0 
MeO~OTr 
o 
Synthesised using the same method as for 237 using thioester 252 instead of 222. The 
product was purified by flash column chromatography (I6: 1 hexane / ethyl acetate), to 
give the product (0.12 g, 0.22 mmol, 16%) as a white oil. 11:5 keto / enol based on the 
1 H NMR spectrum. Ou (400 MHz, CDCh), 0.80 (3H, t, J 7.0, C!h), 1.11-1.30 (8H, m, 
CH3(Cffi)4CH2CH2CH=CH), 1.35 (2H, m, CH3(CH2)4ClbCH2CH=CH), 2.15 (2H, m, 
CH3(CH2)4CH2CffiCH=CH), 3.40 (2H, m, CH30(C=O)-CH(-O-)-ClbOTr), 3.64 (3H, 
s, ClhO(C=O)-), 3.66 (0.7H, s, -(CO)Clb(CO)-), 5.11 (O.3H, s, -(COH)CH(CO)-), 5.l8 
(0.7H, t, J 3.5, CH30(C=O)-CH(-O-)-CH20Tr), 5.23 (O.3H, t, J 3.5, CH30(C=O)-CH(-
O-)-CH20Tr), 5.77 (O.3H, dd, J 15.0, 1.0, CH3(CH2)4CH2CH2CH=CH-(COH)CH(CO)), 
6.15 (0.7H, d, J 15.0, CH3(CH2)4CH2CH2CH-CH-(CO)CH2(CO»), 6.63 (O.3H, dt, J 
15.0, 7.0, CH3(CH2)4CH2CH2CH CH-(COH)CH(CO», 6.88 (0.7H, dt, J 15.0, 7.0, 
CH3(CH2)4CH2CH2CH=CH-(CO)CH2(CO», 7.10-7.42 (I5H, m, Ph), 11.65 (O.3H, d, J 
1.0, -(CO)CH(COH)-), hydrogen couplings were confirmed by a COSY experiment; Oc 
(100 MHz, CDCb), 14.4 (gI3), 23.0 (aI2), 29.0 (~fh), 29.0 ~2), 29.4 (aI2,), 29.5 
~2), 29.5 (gI2), 32.1 (aI2), 32.1 (aI2), 33.0 (aI2), 46.8 (-(CO)aI2(CO)-), 52.7 
(aI30(C=O)-CH(-O-)-CH20Tr), 63.1 (CH30(C=O)-CH(-O-)-aI20Tr), 63.4 
(CH30 (C=O)-CH(-O-)-aI20Tr), 71.9 (CH30(C=O)-aI(-O-)-CH20Tr), 73.0 
(CH30(C=O)-CH(-O-)-CH20Tr), 87.1 (CH30(C=O)-CH(-O-)-CH20C(Ph)3), 89.6 (-
(COH)aI(CO)-), 124.5 (CH3(CH2)4CH2CH2CH-aI-(COH)CH(CO», 127.5 (Ph), 
128.9 (Ph), 129.0 (Ph), 129.8 (CH3(CH2)4CH2CH2CH=aI-(CO)CH2(CO», 142.6 
(CH3(CH2)4CH2CH2CH=CH-(COH)CH(CO», 143.7 (Ph), 143.8 (Ph), 151.0 
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(CH3(CH2)4CH2CH2CH=CH-(CO)CH2(CO», 167.2 (C-OH), 168.5 (C=O), 169.1 
(C-O), 171.1 (C 0), 172.3 (C-O), 191.8 (C=O), carbon signal assignments were 
confirmed by HMQC and HMBC experiments. vnuu/cm-1 2925, 2854 (C-H). 1747 
(C=O), 1665 (C=C). mlz (ESI) 579.25 [M+Na]\ 335.09, 303.03, 274.39, 242.91. 
HRMS Calculated for [C35~o06Nar: 579.2717, observed: 579.2717. 
7.4: Experimental- Results and Discussion Chapter 6 
4-methoxy-5-(phenylselenyl)furan-2(5H)-one 273186 
(Zo Meo~ 
SePh 
To a solution of n-BuLi (1.37M solution in hexanes, 2.75 mL, 2.75 mmol) in dry THF 
(20 mL) at -78°C under argon, was added a solution of 4-methoxyfuran-2(5H)-one 269 
(1.14 g, 10.0 mmol) in dry THF (10 mL) dropwise via cannula. The reaction was stirred 
for 1 hour at -78°C. To this solution was added a solution of phenylselenyl chloride 
(1.91 g, 10.0 mmol) in dry THF (10 mL) dropwise via cannula. The reaction mixture 
was stirred at -78°C for 1 hour then allowed to warm to room temperature overnight. 
The reaction was quenched with saturated ammonium sulphate (20 mL), and diluted 
with DCM (50 mL). The organic layer was separated, and the aqueous layer was 
extracted with DCM (5 x 50 mL). The combined organic layers were dried with MgS04, 
and concentrated in vacuo. The product was purified by flash column chromatography 
(2: 1 hexane / ethyl acetate) to give the product (1.40 g, 5.20 mmol, 520/0) as a yellow 
oil. 00 (400 MHz, CDCh), 3.70 (3H, s, OC!h), 4.80 (lH, d, J 1.0, C=ClJ), 6.40 (lH, d, 
J 1.0, SeCm, 7.22-7.53 (5H, m, Ph); Oc (100 MHz, CDCb), 59.5 (Oal)), 76.8 (SeCH), 
89.9 (C CH), 123.9 (Ph), 129.2 (Ph), 129.6 (Ph), 136.8 (Ph), 170.8 (£=0). 179.l 
(COMe). vlnlDl'cm-1 3117, 2940 (C-H), 1770 (C=O), 1744 (O-Me) 1622,1567,1578 
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(C=C, aromatic). mlz (ESI) 292.80 [M+Hr, 270.79, 224.72, 194.76, 182.72. HRMS 
Calculated for [CIlHlONa03Ser: 292.9687, observed: 292.9687. 
4-methoxy-5,5-bis(phenylselanyl)furan_2(5H)_one 275 
Impurity isolated during the synthesis of 273 as an orange crystalline solid. Ou (400 
MHz, CDCb), 3.60 (3H, s, OC!iJ), 4.52 (lH, s, C=ClJ) , 7.18-7.55 (lOH, m, Ph). Oc 
(l00 MHz, CDCb), 59.2 (OCH3), 89.9 (C=CH), 126.1 (Ph), 129.2 (Ph), 130.0 (Ph). 
137.3 (Ph), 168.9 (Q 0), 180.1 (COMe), carbon signal assignments were confinned by 
HMQC and HMBC experiments. vnuu/cm-1 1776 (C=O), 1749 (O-Me), 1621, 1571. 
1453 (aromatic) mlz (ES/) 426.84 [M+Hr, 268.77, 240.74, 188.82, 240.73, 160.88 
HRMS Calculated for [C17HI40 3SeNat: 448.9169, observed: 448.9170 mp 164-1650 C 
5-chloro-4-methoxyfuran-2(5H)-one 276 
o Q 
MeO CI 
Impurity isolated during the synthesis of 273 as a yellow oil Ou (400 MHz, CDCb), 3.93 
(3H, s, OCl!J) , 5.21 (lH, s, C=C!1) , 6.30 (lH, s, -O-CHCI(-COMe)). Oc (l00 MHz, 
CDCb) 60.4 (OCH3), 83.0 (-O-CHCI(-COMe)), 89.1 (C=CH), 168.9 (C=O), 178.7 
(COMe), carbon signal assignments were confirmed by HMBC and HMQC 
experiments. v",o/cm-1 3128, 2961 (C-H), 1781 (C=O), 1635 (C=C). mlz (ES/) 170.97 
[M+Ht, 148.80, 116.88, 112.96, 89.13, 85.24, 71.43 HRMS Calculated for 
[CsHs033sCINat: 170.9819, observed: 170.9812, isotopic pattern for chlorine observed 
3:1. 
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4-methoxy-5-methylfuran-2(5H)-one 279186 
to 
MeoK 
To a solution of 4-methoxyfuran-2(5H)-one 269 (0.57 g, 5.00 mmol) in dry THF (10 
mL) under argon was added n-BuLi (1.37M solution in hexanes, 3.9 mL, 5.50 mmol) in 
dry THF (10 mL) at -78°C dropwise via syringe. The reaction was stirred for 1 hour at 
-78°C. To this mixture was added a solution of methyl iodide (0.78 g, 0.35 mL, 5.50 
mmol) in dry THF (10 mL) dropwise via cannula. The reaction mixture was stirred at 
-78°C for 1 hour then allowed to warm to ambient temperature overnight. The reaction 
was quenched with saturated ammonium sulphate (20 mL), and diluted with DCM (50 
ml). The organic layer was separated, and the aqueous layer was extracted with DCM (5 
x 50 mL). The combined organic layers were dried with MgS04, and concentrated in 
vacuo. The product was purified by flash column chromatography (1: 1 hexane/ ethyl 
acetate) to give the product (0.17 g, 1.45 mmol, 290/0) as a white solid. OH (400 MHz, 
CDCh), 1.33 (3H, d, J 7.0, Cl!J), 3.79 (3H, s, -OCl!J), 4.73 (1H, q, J 7.0, -0-
C(COMe)H-CH3), 4.94 (lH, s, =CH-(CO)); Oc (100 MHz, CDCh), 17.8 (QI3), 59.7 (-
OCH3), 75.30 (-O-CH(COMe)-CH3), 87.9 ( CH-(CO)), 172.6 ~=O), 183.7 (COMe) 
vmaxl'cm-l 3105, 2989 (C-H), 2945 (CH), 1739 (C=O), 1618 (C=C). HRMS Calculated 
for [CJI8Na03t: 151.0366 observed: 151.0371 mp 44-46°C 
4186 4_methoxy_5_methyl-5-(phenylselenyl)furan-2(5H)-one 27 
(ZO 
Meo))<sePh 
Tetronate 273 (0.63 g, 2.40 mmol) was dissolved in dry THF (30 mL) under argon. and 
cooled to -78°C. t-BuLi (l.40 mL) was added dropwise via syringe and the reaction 
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mixture stirred at -78°C for 1 hour. A solution of methyl iodide (0.41 g. 2.90 mmol) in 
dry THF (10 mL) was added dropwise via cannul~ and the reaction mixture was stirred 
for 1 hour at -78°C then allowed to warm to ambient temperature overnight. The 
reaction was quenched with saturated ammonium sulphate (10 mL). The organic layer 
was separated, and the aqueous layer was extracted with OCM (5 x 50 mL). The 
combined organic layers were dried with MgS04, and concentrated in vacuo. The 
product was purified by flash column chromatography (2: 1 hexane / ethyl acetate) to 
give the product (0.53 g, 1.87 mmol, 78%) as a pale yellow oil which crystallised on 
standing at 5°C. Ou (400 MHz, COCh), 1.77 (3H, s, Clh), 3.69 (3H, s, OClh), 4.63 
(lH, s, Cm 7.22, 7.30, 7.49 (5H, m, Ph); Oc (100 MHz, COCh) 24.2 (C(OMe)-CH3), 
59.7 (C(OCH3)-CH3), 88.9 (gI), 126.1 (Ph), 129.5 (Ph), 130.2 (Ph), 137.8 (Ph), 170.1 
(Q 0),182.3 (QOMe). vnuv/cm-1 3125,2951 (C-H), 2854 (O-Me), 1749 (C=O), 1624 
(C=C). mlz (ESI) 284.91 [M+Ht, 306.9 [M+Nat, 322.89, 346.04, 149.88, 167.81 
HRMS Calculated for [C12H1203SeNat: 306.9830, observed: 306.9844 mp 70-73°C 
4-methoxy-5-methylenefuran-2(5H)-one 261 
Method 1186 
Tetronate 274 (0.43 g, 1.51 mmol) was dissolved in dry OCM (20 mL) under argon and 
cooled to O°C. A solution of mCPBA (0.29 g, 1.65 mmol) in OCM (5 mL) was added 
dropwise. The solution turned bright yellow. After 1 hour the reaction had not gone to 
completion as judged by TLC therefore additional mCPBA (0.16 g, 0.90 mmol) in dry 
OCM (5 mL) was added and the reaction stirred at 4°C overnight. The solvent was 
removed in vacuo, the residue dissolved in ether and the white precipitate was removed 
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by filtration. This process was repeated until no white solid precipitated. The filtrate 
was concentrated in vacuo, and the residue was purified by flash column 
chromatography (5:3 hexane / ethyl acetate) to give the product as an off white solid. 
which was further purified by dissolving in ether and washing with saturated sodium 
bicarbonate. The ether layer was dried and concentrated to give the title compound 
(0.14 g, 1.11 mmol 74%) as a white crystalline solid. 
Method 2191 
To a solution of 270 (7.00 g, 41.4 mmol) in DCE (120 mL) was added acetic acid 
(13.80 mL, 207 mmol) and sodium triacetoxyborohydride (43.87 g, 207 mmol). The 
reaction mixture was heated to reflux for 48 hours. After cooling to room temperature 
the reaction was quenched with a solution of NaOH (1M) and the product extracted into 
ether (50 ml). The organic layer was dried with MgS04, and concentrated in vacuo. The 
crude product was purified by flash column chromatography (5:1 hexane / ethyl acetate) 
to give the desired product as a white crystalline solid. This solid was dissolved in EhO, 
and washed with a saturated solution of sodium bicarbonate which removed final traces 
of chlorobenzoic acid and gave the title compound (4.59 g, 36.43 mmol, 880/0) as a 
crystalline white solid. Ou (400 MHz, CDCb), 3.93 (3H, d, J 1.0, -OClh), 5.03 (lH, m, 
C=Clb.), 5.06 (lH, m, C=Clb.) , 5.25 (lH, d, J 1.0, Clf), hydrogen couplings were 
confirmed by a COSY experiment; Oc (l00 MHz, CDCb), 59.3 (g~h), 89.9 (Q-I), 92.3 
(CH2), 149.7 (Q CH2), 167.0 (Q 0), 169.8 (QOMe), carbon signal assignments were 
confirmed by HMBC and HMQC experiments. v1lll»l'cm-1 3109 (C=CH2), 2900 (C-H), 
1760 (C=O), 1598 (C=C conj). mp: 92-93°C. mlz (ESJ) 149.021 [M+Na]\ 126.91 
[M+H]+, 109.01, 81.00. HRMS Calculated for [C6H603Naf: 149.0209, observed: 
149.0211. 
164 
Chapter 7: Experimental 
4-ethoxy-5-methylenefuran_2(5H)_one 304 
Synthesised using method 2 for the synthesis of 261. The residue was purified by flash 
column chromatography (5:3 hexane / ethyl acetate) to give the product (4.75 g, 33.96 
mmol, 89%) as an orange crystalline solid. Ou (400 MHz, CDCb), 1.43 (3H, t, J 7.0, 
Cll3CH20-), 4.11 (2H, q, J7.0 -OClhCH3), 5.01 (2H, m, Clh=C), 5.18 (lH. d, J 1.0, 
Cll), hydrogen couplings were confirmed by a COSY experiment; Oc (l00 MHz, 
168.8 (C=O), 169.0 (COEt), carbon signal assignments were confirmed by HMBC and 
HMQC experiments. vnuo/cm-1 3129 (C=CH2), 2999 (C-H), 1777 (C=O), 1606 (C=C 
conj). HRMS Calculated for [C7H80 3Nat:163.0366, observed: 163.0372. mp: low 
melting point solid. 
5-« dimethylamino )methylene )-4-methoxyfuran-2(5H)-one 270189 
A solution of 4-methoxy-2(5H)furanone 269 (5.00 g, 43.9 mmol) in dimethylformamide 
dimethyl acetal (25 mL) was made up in a 100 mL round bottomed flask fitted with 
distillation apparatus. The mixture was heated in an oil-bath at 110°C overnight 
(temperature not in excess of 120°C) with slow, continuous distillation of methanol. The 
mixture was cooled to room temperature and the excess of solvent-reagent was removed 
under reduced pressure to leave a brown oil, which slowly crystallised. Purification by 
flash column chromatography (ethyl acetate) gave the desired product (7.91 g, 41.22 
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mmol, 94%) as a yellow crystalline solid. OR (400 MHz, CDCb), 3.06 (6H, s, 
-N(Clh)2), 3.81 (3H, s, -OClh), 4.85 (IH, s, -C=CH-CO-), 6.00 (lH, s, -C=CH-NMe2)' 
Oc (100 MHz, CDCI3), 42.4 (-N(Q-I3h), 58.4 (OCH3), 80.6 (=CH(CO)-), 120.1 
(-C=CHNMe2), 122.8 (-C CHNMe2) , 170.0 (Q 0), 171.4 (QOCH3), assignments were 
confirmed using HMQC and HMBC experiments. vnuv/cm-l 2901, 2990, 2822 (C-H), 
1704 (C=O), 1655 (C=C). mlz (ESJ) 169.87 [M+Ht, 154.85, 139.89, 126.90, 110.05, 
83.32. HRMS Calculated for [CSH ll0 3N1Nat: 192.0631, observed: 192.0624 mp: 72-
73°C, literature value 59_65°C.1S9 
5-« dimethylamino )methylene )-4-ethoxyfuran-2(5H)-one 303 
Synthesised using the same procedure as 270. Purified by flash column chromatography 
(1:1 hexane / ethyl acetate) to give the title compound (6.98 g, 38.14 mmol, 89%) as a 
yellow solid. OR (400 MHz, CDCb), 1.23 (3H, dt, J 7.0,2.0, -OCH2Clh), 2.93 (6H, s, -
N(Clh)2), 3.89 (2H, dq, J 7.0, 2.0, -OClhCH3), 4.66 (lH, d, J 2.0, -C=CH-CO), 5.91 
(IH, d, J 2.0, =CH-NMe2). Oc (100 MHz, CDCb) 14.3 (-OCH2CH3), 42.4 (-N(Q-I3)2), 
67.4 (-OCH2CH3), 80.5 ( CH-(CO)), 120.3 (-C-CH-NMe2), 122.8 (-C-CH-NMe2), 
170.1 (C-O), 170.5 (-COCH2CH3), assignments were confmned using an HMQC 
experiment. vnuv/cm-l 2921 (C-H), 1734 (C=O), 1662 (C=C). mlz (ESJ) 205.90 
[M+Nat, 183.92 [M+Ht, 155.89 HRMS calculated for [C9H1303Nlt: 184.0968 
observed: 184.0972 mp: 85-86°C 
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Ethyl-(2E,4E,6E)-4,6-dimethylocta-2,4,6-trienoate 281 172 
o 
~O~ 
To a solution of (2E,4E)-2,4-dimethylhexa-2,4-dienal 219 (9.95 g, 118.0 mmol), in dry 
toluene (250 mL) under argon at ambient temperature, was added phosphorane 280 
(47.40 g, 131.0 mmol). The mixture was heated to reflux for 48 hours then allowed to 
cool to room temperature and concentrated under reduced pressure. E120 was added, 
and the resulting triphenylphosphine oxide precipitate was removed by filtration. The 
yellow filtrate was concentrated in vacuo and purified by flash column chromatography 
(20:1 petroleum ether / diethyl ether), to give the product (15.52 g, 79.61 mmol, 67%) 
as a colourless oil. 00 (400 MHz, CDCh), 1.28 (3H, t, J 7.0, -OCH2Clh), 1.73 (3H, d, J 
7.0, CH3CH=), 1.81 (3H, s, CH3CH=C(Clh)CH=), 1.92 (3H, s, 
CH3CH=C(CH3)CH=C(CH3)), 4.19 (2H, q, J 7.0, -OClbCH3), 5.61 (lH, q, J 7.0, 
CH3CH ), 5.81 (IH, d, J 15.5, CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 6.25 (lH, 
s, CH3CH=C(CH3)CH ), 7.33 (lH, d, J 15.5, CH3CH=C(CH3)CH=C(CH3)-CH CH-
C=O), hydrogen couplings were confirmed by a COSY experiment; Oc (l00 MHz, 
CDC h), 13.4 (CH3CH=C(CH3)CH=C(gh)-CH=CH-C=0), 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 
(CH3CH=C(Q-I3)CH=C(CH3)-CH=CH-C=0), 
14.1 
59.9 
( -OCH2CH3), 
(-OCH2CH3), 
CH=CH-C=O), 130.6 (CH3CH=C(CH3)CH C(CH3)-CH=CH-C=0), 
13.8 
16.0 
115.8 
133.3 
(CH3CH C(CH3)CH=C(CH3)-CH=CH-C=0), 143.5 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-C=O), 150.6 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 167.3 (Q-O), 
carbon signal assignments were confirmed by HMBC and HMQC experiments. 
vma/cm-J 2977 (C-H), 1708 (C=O) 1605 (C=C). mlz (ESJ) 217.87 [M+Na]+, 194.96 
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[M+Ht, 121.10, 93.27 HRMS Calculated for [CI2HIS02Nat: 217.1299, observed: 
217.1299. 
Methyl-(2E,4E,6E)-4,6-dimethylocta-2,4,6-trienoate 301 172 
Synthesised as for 281 using phosphorane 300 in place of phosphorane 280. The 
product was purified by flash column chromatography (20: 1 petroleum ether / diethyl 
ether), to give the product (4.47 g, 24.7 mmol, 83%) as a colourless oil. On (400 MHz, 
CDCb), 1.73 (3H, d, J 7.0, Clt3CH=), 1.82 (3H, s, CH3CH=C(Clt3)CH=), 1.92 (3H, s, 
CH3CH=C(CH3)CH=C(Clt3)), 3.73 (3H, s -OClt3), 5.61 (1H, q, J 7.0, CH3CH ), 5.81 
(1H, d, J 15.5, (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 6.25 (1H, s, 
CH3CH=C(CH3)CH ), 7.33 (1H, d, J 15.5, (CH3CH=C(CH3)CH=C(CH3)-CH=-CH-
C=O), hydrogen couplings were confirmed by a COSY experiment; Oc (100 MHz, 
CDCb), 13.9 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 14.3 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 16.5 (CH3CH=C(gI3)CH=C(CH3)-
CH=CH-C=O), 51.7 (-OCH3), 115.8 (CH3CH=C(CH3)CH=C(CH3)-CH CH-C=O), 
130.0 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 131.1 
CH=CH-C=O), 144.1 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 151.4 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 168.2 (Q-O), carbon signal assignments 
were confrrmed by HMBC and HMQC experiments. v",./cm-1 2948 (C-H), 1716 (C=O) 
1603 (C=C). HRMS Calculated for [C IIH1602t: 181.1223, observed: 181.1224. 
168 
Chapter 7: Experimental 
(2E,4E,6E)-4,6-dimethylocta-2,4,6-trien-l-ol 282 172 
~OH 
To a stirred solution of ester 281 (18.0 g, 107.0 mmol) in dry Et20 (250 mL), under 
argon at O°C, was added DIBAL-H (225 mL, 1M solution in hexanes, 225.0 mmol). 
After 3 hours, the reaction was quenched by the cautious addition of MeOH (10 mL). 
The mixture was diluted with Et20 (100 mL), and a saturated solution of sodium 
potassium tartrate tetrahydrate (300 mL) was added. The mixture was stirred vigorously 
for several hours until the organic and aqueous layers had completely separated. The 
organic layer was extracted, washed with brine (200 mL), dried over MgS04, filtered 
and concentrated under reduced pressure. The resulting oil was purified by flash column 
chromatography (2:1 petroleum ether / diethyl ether). The product was isolated as a 
colourless oil (12.93 g, 84.53 mmol, 79%). On (400 MHz, CDCh) 1.69 (3H, d, J 7.0, 
CltJCH=), 1.76 (3H, s, CH3CH=C(CltJ)CH=), 1.88 (3H, s, 
CH3CH=C(CH3)CH=C(CltJ)), 4.19 (2H, dd, J 5.5, 1.0, -ClbOH), 5.45 (1H, q, J 7.0, 
CH3CH ), 5.76 (1H, dt, J 15.5, 5.5, CH3CH=C(CH3)CH=C(CH3)-CH=CH-CH2-0H), 
5.90 (1H, s, CH3CH=C(CH3)CH), 6.26 (1H, dd, J 15.5, 1.0, 
CH3CH=C(CH3)CH=C(CH3)-CH CH-CHrOH), hydrogen couplings were confirmed 
by a COSY experiment; Oc (100 MHz, CDCI3) 14.2 (CH3CH=C(CH3)CH=C(£fl))-
CH=CH-CH2-0H) and (£H3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 17.0 
(CH3CH=C(Cl-h)CH=C(CH3)-CH=CH-CH2-0H), 64.2 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-Cl-h-OH), 126.4 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-CHr OH), 126.6 
(CH3CH=C(CH3)CH=C(CH3)-CH CH-CH2-0H), 132.0 (CH3CH=C(CH3)CH-C(CH3)-
CH=CH-CHrOH), 133.8 (CH3CH C(CH3)CH=C(CH3)-CH=CH-CHr OH), 136.6 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-CH2-OH), 137.9 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-CH2-0H)), carbon signal assignments were confirmed by HMBC and HMQC 
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experiments. vnuv/cm-1 3305 (O-H), 2915, 2858, (C-H) 1637 (C=C) mlz (ESJ) 152.92 
[M+Ht, 134.99 [M-H20t, 111.09, 93.24, HRMS Calculated for [ClOHI60 INat: 
175.1093, observed: 175.1100. 
(2E,4E,6E)- 4,6-dimethylocta-2,4,6-trienal 234172 
~o 
To a stirred solution of alcohol 282 (2.29 g, 18.10 mmol) in DCM (200 mL) under 
argon was added Mn02 (23.60 g, 271.5 mmol) at ambient temperature. After 72 hours 
the mixture was filtered through celite and the filtrate concentrated in vacuo to give the 
product as a yellow oil, which was used without further purification. (2.62 g, 17.38 
mmol, 96%) On (400 MHz, CDCh), 1.72 (3H, d, J 7.0, ClhCH=), 1.82 (3H, s, 
CH3CH=C(Clh)CH=), 1.93 (3H, s, CH3CH=C(CH3)CH=C(Clh», 5.65 (lH, q, J 7.0, 
CH3CH ), 6.01 (IH, dd, J 15.5, 8.0, CH3CH=C(CH3)CH=C(CH3)-CH=CH-CHO), 6.33 
(IH, s, CH3CH=C(CH3)CH ), 7.09 (lH, d, J 15.5, CH3CH=C(CH3)CH=C(CH3)-
CH CH-CHO), 9.51 (lH, d, J 8.0, CH3CH=C(CH3)CH=C(CH3)-CH=CH-CHO), 
hydrogen couplings were confirmed by a COSY experiment; Oc (l00 MHz, CDCh), 
13.2 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-CHO), 13.6 (QI3CH=C(CH3)CH=C(CH3)-
CH=CH-CHO), 15.5 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-CHO), 126.4 
(CH3CH=C(CH3)CH=C(CH3)-CH CH-CHO), 130.5 (CH3CH=C(CH3)CH C(CH3)-
CH=CH-CHO), 131.0 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-CHO), 133.1 
(CH3CH C(CH3)CH=C(CH3)-CH=CH-CHO), 145.2 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-CHO), 158.7 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-CHO), 193.3 (CHO), 
carbon signal assignments were confirmed by HMBC and HMQC experiments. vnuv/ 
cm-1 2918 (C-H), 1673 (C=O), mlz (ESJ) 150.88 [M+Ht, 132.92, 122.96, 105.00, 
83.31 HRMS Calculated for [ClOHI40INat: 173.0937, observed: 173.0939. 
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Ethyl-(2E,4E,6E,8E)-2,6,8-trimethyldeca-2,4,6,8-tetraenoate 283172 
o 
~o~ 
To a solution of alcohol 282 (3.10 g, 24.6 mmol) was added phosphorane 245 (13.4 g, 
36.9 mmol), and Mn02 (32.0 g, 375 mmol) in dry toluene (150 mL) at ambient 
temperature. The mixture was heated to reflux for 48 hours then allowed to cool to room 
temperature, filtered through celite and concentrated under reduced pressure. Et20 was 
added, and the resulting triphenylphosphine oxide was removed by filtration. The 
yellow filtrate was concentrated in vacuo and purified by flash column chromatography 
(25:1 petroleum ether / diethyl ether), to give the product (3.46 g, 14.76 mmol, 60%) as 
a pale yellow oil. OH (400 MHz, CDCb), 1.28 (3H, t, J7.0, C[hCH2), 1.71 (3H, d, J7.0, 
C[h-CH=C), 1.79 (3H, s, =C(C[h)CH=C(CH3)-CH), 1.95 (6H, s, =C(C[h)-CH=CH-
CH=C(C[h)CO), 4.18 (2H, q, J 7.0, OClbCH~, 5.54 (1H, q, J 7.0, CH3CH'-), 6.06 
(lH, s, CH3CH=C(CH3)-CH) 6.41 (lH, dd, J 15.0, 11.5, =C(CH3)-CH=CH-
CH=C(CH3)CO), 6.55 (lH, d, J 15.0, =C(CH3)-CH=CH-CH=C(CH3)CO), 7.24 (lH, d, 
J 11.5, =C(CH3)-CH=CH-CH C(CH3)CO), hydrogen couplings were confirmed by a 
COSY experiment; Oc (l00 MHz, CDCl3), 13.0 (C=C({}h)C=O), 14.2 
(C(CH3)CH=CH=CH-C(CH3)-CO), 14.3 (CH3-CH=C), 14.7 (OCH2CH3), 16.8 
(CH3CH=C(CH3)-CH), 60.8 (OCH2CH3), 122.6 (C-CH CH-CH=C(CH3)), 126.0 
(=C(CH3)CO-0), 128.3 (CH3CH=CH(CH3), 132.8 (CH3CH=C(CH3)-CH-C(CH3)C-), 
134.1 (CH3CH C(CH3)C-), 139.3 (CCH=CH-CH=C(CH3)), 140.1 (CH3CH=C(CH3)-
CH=C(CH3)C-), 146.0 (=C(CH3)-CH=CH-CH=C(CH3)CO), 168.6 (C-O), carbon 
signal assignments were confirmed by HMBC and HMQC experiments. vllllDl'cm-J 2954 
(C-H), 1697 (C=O), 1606 (C=C). HRMS Calculated for [ClsH2202Naf: 257.1512, 
observed: 257.1504 
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Methyl-(2E,4E,6E,8E)-2,6,8-trimethyldeca-2,4,6,8-tetraenoate 306 
To a stirred solution of ester 283 (0.45 g, 1.90 mmol) in methanol (10 mL) was added 
sodium methoxide (1.10 g, 21.0 mmol) at room temperature. The reaction mixture was 
stirred for 3 hours, quenched with ammonium chloride and the aqueous layer extracted 
with DCM (5 x 50 mL). The organic layer was dried with MgS04 and the solvent 
removed in vacuo. The crude residue purified by flash column chromatography (25:1 
petroleum ether / diethyl ether), to give the product (0.30 g, 1.47 mmol, 74%) as a pale 
yellow oil. On (400 MHz, CDCI3), 1.62 (3H, d, J 7.0, CltJ-CH=C), 1.72 (3H, s, 
=C(CltJ)CH=C(CH3)-CH), 1.88 (6H, s, =C(CltJ)-CH=CH-CH=C(CltJ)CO), 3.65 (3H, 
s, OCltJ), 5.46 (1H, q, J 7.0, CH3-CH ), 5.97 (1H, s, CH3-CH=C(CH3)-CH=-), 6.33 
(IH, dd, J 15.0, 11.5, =C(CH3)-CH=CH-CH=C(CH3)CO), 6.47 (1H, d, J 15.0, 
=C(CH3)-CH CH-CH=C(CH3)CO), 7.19 (1H, dd, J 11.5, 1.0, =C(CH3)-CH=CH-
CH=-C(CH3)CO), hydrogen couplings were confrrmed by a COSY experiment; Oc (100 
MHz, CDCb), 12.7 (CH=CH=CH(QI3)-CO), 14.0 (CH3CH=C(CH3)-CH=C(QI3)), 
14.2 (CH3CH=C(CH3)-CH=C(CH3)), 16.6 (CH3-CH=C(QI3)-CH=C(CH3)), 51.2 
(OCH3), 122.3 (=C(CH3)-CH CH-CH=C(CH3)CO), 125.3 (=C(CH3)-CH=CH-
CH-C(CH3)CO), 128.3 (CH3CH=C(CH3)-CH=C(CH3)), 132.6 (CH3CH=C(CH3)-
CH C(CH3)), 133.9 (CH3CH C(CH3)-CH=C(CH3)), 139.4 (=C(CH3)-CH=CH-
CH=C(CH3)CO), 140.0 (CH3-CH=C(CH3)-CH=C(CH3)C-), 146.0 (=C(CH3)-CH=CH-
CH=C(CH3)CO), 169.0 (C 0), carbon signal assignments were confinned by HMBC 
and HMQC experiments. vmaJt'cm-J 2952 (C-H), 1698 (C=O), 1607 (C-C). HRMS 
Calculated for [CI4H2o(hNat: 243.1356, observed: 243.1360. 
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(2E,4E,6E,8E)- 2,6,8-trimethyldeca-2,4,6,8-tetraen-l-ol 284204,205 
~OH 
To a stirred solution of ester 283 (0.40 g, 1.76 mmol) in dry Et20 (10 mL) under argon 
at -78°C, was added DIBAL-H (1.50 mL of a 1M solution in hexanes, 1.50 mmol). 
After 3 hours, the reaction was quenched by the cautious addition of methanol (2 mL). 
A saturated solution of sodium potassium tartrate tetrahydrate (10 mL) was added and 
the mixture stirred vigorously for several hours until the organic and aqueous layers had 
completely separated. The organic layer was separated, washed with brine, dried over 
MgS04, filtered and concentrated under reduced pressure. The residue was purified on 
florisil (2.5:1 petroleum ether / diethyl ether) to give the product (0.08 g, 0.53 mmol, 
30%) as a colourless oil. 08 (400 MHz, CDCh) 1.64 (3H, d, J 7.0, Clh-
CH=C(CH3)CH=C(CH3)-CH=CH-CH=C(CH3)-CH2OH), 1.71 (3H, s, CH3-
CH=C(Clh)CH=C(CH3)-CH=CH-CH=C(CH3)-CH20H), 1.74 (3H, s, CH3-
CH=C(CH3)CH=C(CH3)-CH=CH-CH=C(Clh)-CH20H), 1.87 (3H, s, CH3-
CH=C(CH3)CH=C(Clh)-CH=CH-CH=C(CH3)-CH20H), 3.99 (2H, s, CH3-
CH=C(CH3)CH=C(CH3)-CH=CH-CH=C(CH3)-ClbOH), 5.41 (lH, q, J 7.0, CH3-
CH C(CH3)CH=C(CH3)-), 5.86 (lH, s, CH3_CH=C(CH3)-CH C(CH3)-), 6.04 (lH, dd, 
J 10.5, 1.0, CH3-CH=C(CH3)CH=C(CH3)-CH=CH-CH=C(CH3)-CH20H), 6.19 (lH, d, 
J 15.0, CH3-CH=C(CH3)CH=C(CH3)-CH CH-CH=C(CH3)-CH20H), 6.34 (lH, dd, J 
15.0, 10.5, CH3-CH=C(CH3)CH=C(CH3)-CH=CH-CH=C(CH3)-CH20H), O-H signal 
not visible on the 1 H NMR spectrum, hydrogen coupling was confmned by a COSY 
experiment; Oc (100 MHz, CDCh), 13.9 (CH3-CH=C(CH3)CH=C(Q-h)-CH=CH-
CH=C(CH3)-CH20H), 14.0 (CH3-CH=C(CH3)CH=C(CH3)-CH=CH-CH=C(CH3)-
CH20H), 14.3 (CH3-CH=C(CH3)CH=C(CH3)-CH=CH-CH=C( CH3)-CH20H), 16.7 
68.8 (CH=CH-
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CH=C(CH3)-Cl-hOH), 122.7 (CH3-CH=C(CH3)CH=C(CH3)-CH-CH-CH=C(CH3)-
CH20H), 125.9 (CH3-CH=C(CH3)CH=C(CH3)-CH=CH-CH=C(CH3)-CH20H), 126.2 
(CH3-CH=C(CH3)CH=C(CH3)-CH=CH-CH=C(CH3)-CH20H), 132.8 (CH3-
CH=C(CH3)-CH C(CH3)C-), 133.7 (CH3-CH C(CH3)CH=C(CH3)-CH=CH-
CH=C(CH3)-CH20H), 136.2 (CH3-CH=C(CH3)CH=C(CH3)-CH=CH-CH-C(CH3)-
CH20H), 136.3 (CH3-CH=C(CH3)-CH=C(CH3)C-), 139.0 (CH3-
CH=C(CH3)CH=C(CH3)-CH CH-CH=C(CH3)-CH20H), carbon signal assignments 
were confinned by HMBC and HMQC experiments vnuv/cm-1 3302 (O-H), 2912, 2856 
(C-H), 1620 (C=C). HRMS Calculated for [M-H20t [C13HI9t: 175.1481, observed: 
175.1482. 
(2E,4E,6E,8E)- 2,6,8-trimethyldeca-2,4,6,8-tetraenal 285172 
To a stirred solution of alcohol 284 (0.10 g, 0.50 mmol) in DCM (10 mL) was added 
Mn02 (0.65 g, 7.50 mmol) at ambient temperature. After 72 hours the mixture was 
filtered through celite and the filtrate concentrated in vacuo to give the product as a 
yellow oil, which was used without further purification. (0.09 g, 0.49 mmol, 98%) OH 
(400 MHz, CDCh) 1.71 (3H, d, J 7.0, ClhCH=), 1.81 (3H, s, CH3CH=C(Clh)CH=), 
1.97 (3H, s, CH3CH=C(CH3)CH=C(Clh», 5.61 (1H, q, J 7.0, CH3CH-), 6.14 (lH, s, 
CH3CH=C(CH3)CH ), 6.59 (2H, m, CH3CH=C(CH3)CH=C(CH3)-CH=CH-CH= and 
CH3CH=C(CH3)CH=C(CH3)-CH=CH-CH C(CH3)-C(=O)H), 6.90 (IH, d, J 11.0, 
CH3CH=C(CH3)CH=C(CH3)-CH CH-CH=), 9.40 (lH, s, CH=CH-CH=C(CH3)-
C(=O)lf), hydrogen couplings were confinned by a COSY experiment. HRMS 
Calculated for [C13HI901t: 191.1430, observed: 191.1432. 
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3-(I-hydroxyoctyl)-4-methoxy-5-methylenefuran-2(5H)-one 286 15 
Tetronate 261 (0.10 g, 0.80 mmol) was dissolved in dry THF (20 mL) under argon and 
cooled to -78°C. LDA (2M, in mixture of tetrahydrofuran, heptane, and 
ethylbenzene, 0.45 mL, 0.88 mmol) was added dropwise via syringe and the reaction 
mixture stirred at -78°C for 1 hoUT. Octanal (0.12 mL, 0.80 mmol) was then added 
dropwise and the reaction allowed to warm to -60°C. The reaction was quenched with 
saturated ammonium chloride and the organic layer separated. The aqueous layer was 
extracted with DCM (5 x 50 mL). The combined organic layers were dried with MgS04, 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(4:1 hexane / ethyl actetate) to give the product (0.08 g, 0.30 mmol, 57%) as a viscous 
white oil. OH (400 MHz, CDCb), 0.86 (3H, t, J 6.5, C!iJ), 1.26 (9H, m, 4 x Clh. and 1 x 
Cll), 1.45 (lH, m, Cll), 1.73 (lH, m, Cll), 1.90 (lH, m, Cll), 3.09 (IH, br s, Oll), 4.12 
(3H, s, 0 C!iJ), 4.79 (lH, t, J 6.5, CHOH), 5.05 (2H, s, C=Clh), hydrogen couplings 
were confirmed by a COSY experiment; Oc (l00 MHz, CDCI3), 12.5 (CH3), 21.6 
(CH3CH2), 25.1 (CH3CH2CH2), 28.2 (CH3CH2CH2CH2), 28.3 (0I2CH2CH2CHOH), 
30.8 (CH2CH2CHOH), 36.7 (0I2CHOH), 59.3 (OCH3), 65.2 (0IOH), 92.2 (C-CH2), 
106.3 (C C(CO)-CH), 148.4 (0 CH2), 159.9 (COMe), 168.3 ~=O), carbon signal 
assignments were confirmed by HMBC and HMQC experiments. v~cm-l 3452 (O-H), 
2924 (C-H), 2854 (O-Me), 1756 (C=O), 1622 (C=C). mlz (ESJ) 531.2 [2M+Nat, 277.1 
[M+Nat, 254.98, 236.92, 180.85, 166.85, 152.86, 138.87, 83.26. HRMS Calculated for 
[C14H2204Nat: 277.1410, observed: 277.1407. 
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(2E,4E,6E)-3-(I-hydroxy-4,6-dimethylocta-2,4,6-trienyl)-4-methoxy-5-
methylenefuran-2(5H)-one 26515 
OH 0 
To a solution of diisopropylamine (0.70 mL) in dry THF (5.4 mL) under argon was 
added n-BuLi (3.90 mL) dropwise at -78°C. The mixture was stirred at this temperature 
for 15 minutes then warmed to O°C and stirred for a further 15 minutes to give a 
solution of LDA. To a solution of 4-methoxy-5-methylenefuran-2(5H)-one 261 (0.25 g, 
2.00 mmol) in dry THF (20 mL) was added the freshly prepared LDA (4.40 mL, 2.20 
mmol) dropwise at -78°C. The mixture was stirred for 30 minutes then aldehyde 234 
was added (2.00 mmol). The reaction was stirred at -78°C for 1 hour then allowed to 
warm to -60°C. The reaction was quenched with saturated ammonium chloride (5 mL). 
The organic layer was separated, and the aqueous layer was extracted with DCM (5 x 50 
mL). The combined organic layers were dried over MgS04 and concentrated in vacuo. 
The crude residue was purified by flash column chromatography (5:1 hexane / ethyl 
acetate) to give the desired product (0.19 g, 0.70 mmol, 35%) as a yellow oil. Ou (400 
MHz, CDC b) 1.64 (3H, d, J 7.0, C[hCH=), 1.70 (3H, s, CH3CH=C(C[h)CH=), 1.82 
(3H, s, CH3CH=C(CH3)CH=C(C[h», 3.19 (lH, d, J 7.5, CH(Oll), 4.10 (3H, s, -
OC[h), 5.02 (2H, m, CH2=C(-COMe)-O), 5.38 (2H, m, CH3CH'- and 
CH3CH=C(CH3)CH=C(CH3)-CH=CH-CH(OH», 5.81 (lH, dd, J 17.0, 7.5, 
CH3CH=C(CH3)CH=C(CH3)-CH=CH-CH(OH», 5.87 (lH, s, CH3CH=C(CH3)CH'-), 
6.17 (IH, d, J 17.0, (CH3CH=C(CH3)CH=C(CH3)-CH'-CH-C=O), hydrogen couplings 
were confirmed by a COSY experiment; Oc (100 MHz, CDCh), 13.3 
(CH3CH=C(CH3)CH=C(Qf3)-CH=CH-C=O), 13.5 (GbCH=C(CH3)CH=C(CH3)-
CH=CH-C=O), 15.9 (CH3CH=C(Qf3)CH=C(CH3)-CH=CH-C=O), 60.1 (-Om3). 66.0 
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(CH=CH-CH(OH)), 92.4 (g-h=C(O)-C(COMe )), 1 05.1 (-CH(OH)-C(CO)-C(OMe)). 
125.9 (CH3CH=C(CH3)CH=C(CH3)-CH CH-CH(OH), 126.3 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-), 130.7 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-), 136.8 and 136.9 (CH3CH=C(CH3)CH C(CH3)-CH=CH-CH(OH), and 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 148.9 (CH2 C(O)-C(COMe)), 160.8 
(C 0), 168.9 ({ZOMe) , carbon signal assignments were confmned by an HMQC 
experiment. vnuv/cm-1 3444 (O-H) 2914, 2857 (C-H), 1760 (C=O) 1668 (C=C). HRMS 
Calculated for [CI6H180~ar: 299.1254, observed: 299.1240. 
(2E,4E,6E)-3-( 4,6-dimethylocta-2,4,6-trienoyl)-4-methoxy-5-methylenefurao-
2(5H)-one 267 
Method 115 
To a solution of 265 (0.07 g, 0.27 mmol) in DCM (5 mL) was added Dess-Martin 
periodinane (0.17 g, 0.40 mmol). The reaction was stirred at room temperature for 30 
minutes. The solvent was removed in vacuo and the crude residue applied to a silica gel 
column. The product was eluted with 5: 1 hexane / ethyl acetate to give the desired 
product (0.01 g, 0.05 mmol, 15%) as a yellow oil. 
Method i 96 
To a solution of diisopropylamine (0.70 mL), in dry THF (5.40 mL) under argon was 
added n-BuLi (3.9 mL) dropwise at -78°C. The mixture was stirred at this temperature 
for 15 minutes then wanned to O°C and stirred for a further 15 minutes giving to a 
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freshly prepared solution of LDA. To a solution of tetronate 261 (0.25 g, 2.00 mmol) in 
dry THF (20 mL) was added LDA (4.40 mL, 2.20 mmol) dropwise at -78°C. The 
mixture was stirred for 30 minutes then the ester 281 was added (0.36 g, 2.00 mmol) in 
dry THF (2 mL). The reaction was stirred at -78°C for 1 hour then allowed to warm to 
-60°C. The reaction was quenched with saturated citric acid (5 mL), the organic layer 
was separated, and the aqueous layer was extracted with DCM (5 x 50 mL). The 
combined organic layers were dried with MgS04 and concentrated in vacuo. The crude 
residue was purified by flash column chromatography (5:1 petroleum ether / diethyl 
ether) to give the title compound (0.03 g, 0.11 mmol, 14%) as a viscous yellow oil. 08 
(700 MHz, CDC h), 1.76 (3H, d, J 7.0, C[hCH=), 1.85 (3H, d, J 1.0, 
CH3CH=C(C[h)CH=), 2.01 (3H, s, CH3CH=C(CH3)CH=C(C[h)), 4.13 (3H, s, 
-OC[h), 5.17 (lH, d, 1.5, C[b=C(COMe)-O-(C=O)), 5.25 (1H, d, 1.5, C[b=C(COMe)-
O-(C=O)), 5.71 (1H, q, J 7.0, CH3CH ), 6.40 (1H, s, CH3CH=C(CH3)CH ), 6.74 (1H, 
d, J 15.5, CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 7.33 (1H, d, J 15.5, 
CH3CH=C(CH3)CH=C(CH3)-CH CH-C=O), hydrogen couplings were confrrmed by a 
COSY experiment; Oc (175 MHz, CDCh), 13.9 (CH3CH=C(CH3)CH=C(0I3)-CH=CH-
C=O), 14.2 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 16.2 
(CH3CH=C( CH3)CH=C(CH3)-CH=CH-C=0), 62.50 (-OCH3), 94.0 (0I2=C(COMe )-0-
(C=O)), 104.5 (C(=O)C (COMe)(C=O)), 124.0 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-C=O), 131.4 (CH3CH=C(CH3)CH-C(CH3)-CH=CH-C=0), 131.5 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 134.0 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-C=O), 147.0 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 149.8 
(CH2 C(COMe)-O-(C=O)), 152.5 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0)), 
165.6 (Q 0), 166.6 (QOMe), 187.4 (Q 0), carbon signal assignments were confirmed 
by HMBC and HMQC experiments. v",.:/cm-J 2922, 2852 (C-H), 1752 (C=O), 1588 
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(C=C). mlz (ESI) 297.11 [M+Na]+, HRMS Calculated for [C16HI80~ar: 297.1097. 
observed: 297.1103. 
(lE,3E,5E)-3-(4,6-dimethyl-7-oxoocta-l,3,5-trienyl)-4-methoxy-5-methylenefuran-
2(5H)-one 287 
o 
Isolated as an impurity during the synthesis of 267 - method 1. The product was eluted 
with 5:1 hexane / ethyl acetate, to give the title compound (0.08 g, 0.03 mmol 10%) as a 
yellow oil. OR (700 MHz, CDCh), 2.03 (3H, s, CH3C(=0)-C(CliJ)=CH), 2.13 (3H, s, 
CH3C(=0)-C(CH3)=CH-C(CliJ)=CH-), 2.37 (3H, s, CliJC(=0)-C(CH3)=CH), 4.24 
(3H, s, -OCliJ), 5.06 (1H, d, J3.0, Clh=C-), 5.09 (1H, d, J3.0, Clh=C-), 6.33 (1H, d, J 
11.5, CH3C(=0)-C(CH3)=CH-C(CH3)=CH-CH=CH-), 6.61 (1H, d, J 15.0, CH3C(=0)-
C(CH3)=CH-C(CH3)=CH-CH=CH-), 7.03 (1H, s, CH3C(=0)-C(CH3)=CH-
C(CH3)=CH-CH=CH-), 7.69 (1H, dd, J 15.0, 11.5, CH3C(=0)-C(CH3)=CH-
C(CH3)=CH-CH CH), hydrogen couplings were confrrmed by a COSY experiment; Oc 
(175 MHz, CDCh), 13.6 (CH3C(=0)-C(0I3)=CH), 17.6 (CH3C(=0)-C(CH3)=CH-
C(0I3)=CH-), 26.1 (0I3C(=0)-C(CH3)=CH), 60.8 (-0(1-1), 93.6 (0I2=C-), 104.4 
(C=C-C(=COMe)-C(=O», 119.0 (CH3C(=0)-C(CH3)=CH-C(CH3)=CH-CH=CH-), 
120.3 (CH3C(=0)-C(CH3)=CH-C(CH3)=CH-CH CH-), 129.7 (CH3C(=0)-
C(CH3)=CH-C(CH3)=CH-CH=CH-), 135.6 (CH3C(=0)-C(CH3)=CH-C(CH3)=CH-
CH=CH-), and (CH3C(=0)-C(CH3)=CH-C(CH3)=CH-CH=CH-), 142.4 (CH3C(=0)-
C(CH3) CH-C(CH3)=CH-CH=CH), 148.2 (CH2 C-), 158.4 (C=C-C(-COMe)-C(=O», 
166.4 (C=C-C(=COMe)-C(=O)), 199.5 (CH3C(=0)-C(CH3)=CH-C(CH3)=CH-
CH=CH), carbon signal assignments were confrrmed by HMBC and HMQC 
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experiments. vmm/cm-J 2951 (C-H), 1762 (C=O) 1614 (C=C). HRMS Calculated for 
[CI6Hls04Nat: 297.1097, observed: 297.1095. 
3-acryloyl-4-hydroxy-5-methylene-IH -pyrrol-2(5H)-one 293196 
To a stirred solution of diisopropylamine (0.70 mL) in dry THF (5.40 mL) at -78°C 
under argon was added n-BuLi (1.6M in hexanes, 3.90 mL) dropwise. After 15 minutes 
the solution was warmed to room temperature and stirred for a further 30 minutes to 
give a 0.50 M solution of LDA. To a stirred solution of 261 (0.20 g, 1.59 mmol) in dry 
THF (20 mL) at -78°C under argon was added a freshly prepared solution of LDA 
(0.5M in THF, 4.40 mL, 2.20 mmol) dropwise. After stirring for 1 hour a solution of 
methyl acrylate 289 (0.71 g, 4.77 mmol) in dry THF (2 mL) was added dropwise. The 
reaction mixture was allowed to warm to ambient temperature, quenched with saturated 
ammonium chloride (20 mL), and the organic layer separated with DCM (5 x 50 mL). 
The combined organic layers were dried with MgS04 and the solvent removed in vacuo. 
The crude residue was purified by flash column chromatography (5: 1 hexane / ethyl 
acetate) to give the title compound (0.03 g, 0.l7 mmol, 11%) as a white solid. 0" (700 
MHz, Acetone) 5.l7 (lH, d, J 3.0, CH2=C(NH)(COH», 5.49 (1H, d, J 3.0, 
CH2=C(NH)(COH), 5.59 (lH, d, J 10.5, CH2=CH-CO), 6.22 (IH, d, J 17.0, CH2=CH-
CO), 7.38 (lH, dd, J 17.0, 10.5, CH2=CH-CO), 8.36 (lH, br s, NH or OH), 8.94 (1H, br 
s, NH or OH), hydrogen couplings were confmned by a COSY experiment; Oc (175 
MHz, Acetone) 94.0 (CH2=C(NH)(COH», 94.8 (-(C=O)-C(CO)(COH)-), 126.3 
(CH2=CH-CO), 132.9 (CH2 CH-CO), 147.9 (CH2-C(NH)(COH», 162.8 
(CH2=C(NH)(COH», 166.l (-(C=O)-C~O)(COH)-), 184.7 (CH2=CH-CO), carbon 
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signal assignments were confmned by HMBC and HMQC experiments. vnuv/cm-1 3377 
(N-H), 3217 (O-H), 2987 (C-H), 1735 (C=O) 1647, 1601 (C=C). mlz (ES/) 165.85 
[M+H]\ 155.83, 137.86 HRMS Calculated for [CgH70 3NNat: 188.0318 observed: 
188.0318. 
Methyl 5-hydroxy-2-methoxy-3-oxo-5-vinylcyclopent-l-enecarboxylate 292 
OH 0 55l.oMe o OMe 
Second product from method for 293. The crude residue was purified by flash column 
chromatography (5:1 hexane / ethyl acetate) to give the title compound (0.02 g, 0.11 
mmol, 7%) as a white solid. On (700 MHz, CDCb), 2.57 (1H, d, J 19.0, C(O)-Clh-
CH(OH)), 2.67 (1H, d, J 19.0, C(O)-Clh_C(OH)), 3.75 (1H, s, OH), 3.80 (3H, s, -C-
(C=O)-OClh), 4.10 (3H, s, =C(-OClh)), 5.10 (1H, d, J 11.0, Clh=CH-C(OH)), 5.20 
(lH, d, J 17.0, Clh=CH-C(OH)), 5.95 (1H, dd, J 17.0, 11.0, CH2=CH-C(OH)), 
hydrogen couplings were confirmed by a COSY experiment; Oc (175 MHz, CDCb), 
49.0 (C(O)-ClhC(OH)), 52.1 (COMe)=C-(C=O)-OCl-I)), 59.4 (-OCR3), 73.7 
(CH2=CH-C(OH)), 113.9 (CR2=CH-C(OH)), 131.7 (COMe)=C-(C=O)-OCH3), 141.2 
(CH2 CR-C(OH)), 156.1 ( C(-OCH3)), 165.0 (C-(Q O)-OCH3), 200.1 (CHrC(=O)-
C(OMe)), carbon signal assignments were confmned by HMBC and HMQC 
experiments. HRMS Calculated for [ClOH120SNat: 235.0577 and for [C IOH 110 4t loss 
of water: 195.0652, observed: 235.0575 and 195.0651 respectively. 
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(2E,4E)-3-(2,4-dimethylhexa-2,4-dienoyl)-4-methoxy-5-methylenefuran-2(5H)-one 
297196 
o 0 ~o 
I 1MeO'J---\.. 
To a stirred solution of dry diisopropylamine (0.70 mL) in dry THF (5.40 mL) at -78°C 
under argon was added n-BuLi (3.90 mL) dropwise. After 15 minutes the solution was 
warmed to room temperature and stirred for a further 30 minutes to give a 0.50 M 
solution of LDA. To a stirred solution of 4-methoxy-5-methylenefuran-2(5H)-one 261 
(0.20 g, 1.59 mmol) in dry THF (20 mL) at -78°C under argon was added freshly 
prepared LDA (0.5M, in THF, 4.40 mL, 2.20 mmol) dropwise. After stirring for 1 hour 
a solution of ester 247 (0.71 g, 4.77 mmol) in dry THF (2 mL) was added dropwise. The 
reaction mixture was stirred at -78°C overnight and quenched with a solution of 
saturated citric acid (20 mL). The organic layer was separated, and the aqueous layer 
was extracted with DCM (5 x 50 mL). The combined organic layers were dried with 
MgS04 and the solvent removed in vacuo. The crude residue was purified by flash 
column chromatography (5:1 hexane / ethyl acetate) to give the title compound (0.04 g, 
0.16 mmol, 11%) as a viscous yellow oil. 00 (300 MHz, CDCb), 1.78 (3H, d, J 7.0, 
ClhCH=), 1.92 (3H, s, 2.07 (3H, s, 
CH3CH=C(CH3)CH=C(Clh», 3.19 (3H, s, -OC!h), 5.14 (2H, m, Clb=C(COMe)-O-
(C=O», 5.91 (IH, q, J 7.0, CH3CH ), 6.89 (lH, s, CH3CH=C(CH3)CH-), hydrogen 
couplings were confirmed by a COSY experiment; Oc (75 MHz, CDCb), 12.7 
(CH3CH=C(CH3)CH=C(CH3)-C=O), 14.4 (Qf3CH=C(CH3)CH=C(CH3)-C=O), 15.8 
(CH3CH=C(Qf3)CH=C(CH3)-C=O), 60.9 (-OCH3), 94.0 (CH2=C(COMe)-O-(C=O», 
105.0 «C=OhC COMe), 133.8 (CH3CH=C(CH3)CH=C(CH3)-C=O), 134.6 
(CH3CH C(CH3)CH=C(CH3)-C=O), 135.9 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-
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C=O), 149.0 (CH2 C(COMe)-O-(C=O)), 151.3 (CH3CH=C(CH3)CH=C(CH3)-C=0), 
165.2 «C=0)2C COMe), 166.2 (Q 0), 192.0 (CH3CH=C(CH3)CH=C(CH3)-C-0)), 
carbon signal assignments were confirmed by HMBC and HMQC experiments. 
vttuD!'cm-1 2948, 2858 (C-H), 1764 (C=O) 1613 (C=C). HRMS Calculated for 
[CI4HI604Nat: 271.0941, observed: 271.0937. 
(2E,4E)-3-(2,4-dimethylhexa-2,4-dienoyl)-4-ethoxy-5-methylenefuran-2(5H)-one 
298196 
o 0 ~o 
I I EtoK 
Isolated as a by-product of the reaction for the synthesis of 297. The crude residue was 
purified by flash column chromatography (5:1 hexane / ethyl acetate) to give the title 
compound (0.03 g, 0.12 mmol, 9%) as a viscous yellow oil. OR (300 MHz, CDCh), 1.36 
(3H, t, J 7.0, ClhCH20-), 1.79 (3H, d, J 7.0, ClhCH=), 1.93 (3H, s, 
CH3CH=C(Clh)CH=), 2.07 (3H, s, CH3CH=C(CH3)CH=C(Clh)), 4.14 (2H, q, J 7.0, 
-OClbCH3), 5.05 (lH, d, J 2.5, CllrC(COEt)-O-(C=O)), 5.15 (lH, d, J 2.5, 
Clb=C(COEt)-O-(C=O)), 5.91 (IH, q, J 7.0, CH3CH), 6.91 (lH, s, 
CH3CH=C(CH3)CH ), hydrogen couplings were confirmed by a COSY experiment; Oc 
(75 MHz, CDCh), 12.7 14.4 
14.7 15.8 
(CH3CH=C(QH3)CH=C(CH3)), 70.0 (-OCH2CH3), 93.9 (QH2=C(COMe)-0-(C=0)), 
104.7 «C=0)2C COMe), 133.8 (CH3CH=C(CH3)CH C(CH3)-), 134.3 
(CH3CH=C(CH3)CH=C(CH3)-), 136.0 (CH3CH=C(CH3)CH=C(CH3)-), 149.2 
(CH2 C(COEt)-O-(C=O)), 151.2 (CH3CH=C(CH3)CH=C(CH3)-), 164.4 (QOEt), 166.4 
(C 0), 192.2 (CH3CH=C(CH3)CH=C(CH3)-C-0), carbon signal assignments were 
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confmned by HMBC and HMQC experiments; vrruv/cm-1 2949, 2856 (C-H), 1766 
(C=O) 1610 (C=C). HRMS Calculated for [ClsHlS04Nat: 285.1097, observed: 
285.1097. 
General method for the synthesis of 291, 299, 305 and 268 
To a stirred solution of 2,2,6,6-tetramethylpiperidine (TMP) (0.84 mL) in THF (5.50 
mL) at -78°C under argon was added n-BuLi (1.6M in hexanes, 3.70 mL) dropwise. 
After 15 minutes the solution was warmed to room temperature and stirred for a further 
30 minutes to give a 0.50 M solution of LTMP. To a stirred solution of 304 or 261(1.4 
mmol) in THF (20 mL) at -78°C under argon was added a solution of LTMP (0.5M, in 
THF, 4.40 mL, 2.20 mmol) dropwise. After stirring for 1 hour a solution of ester 281 or 
283 or 306 or 289 (0.70 mmol) in THF (2 mL) was added dropwise. The reaction 
mixture was stirred at -78°C overnight and quenched with saturated citric acid (20 mL). 
The organic layer was separated, and the aqueous layer was extracted with DCM (5 x 50 
mL). The combined organic layers were dried with MgS04 and the solvent removed in 
vacuo. 
3-acryloyl-4-methyoxy-5-methylenefuran-2(5H)-one 291 196 
JJlo 
Meok 
The product was purified by flash column chromatography (1.5:1 hexane / diethyl ether) 
to give the desired product (0.03 g, 0.13 mmol, 18%) as a white crystalline solid. OH 
(400 MHz, CDCI3), 4.15 (3H, s, -OC!h), 5.23 (lH, d, J3.0, Clb=C(COMe)-O-(C=O)), 
5.28 (IH, d, J 3.0, Clb=C(COMe)-O-(C=O)), 5.93 (lH, d, J 10.5, Clb=CH-CO), 6.36 
(lH, d, J 17.5, CH2=CH-CO), 7.04 (IH, dd, J 17.5, 10.5, CH2=CH-CO), hydrogen 
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couplings were confinned by a COSY experiment; Oc (175 MHz, CDCh), 63.0 
(-OC1I3), 95.8 (Q-h=C(COMe)-O-(C=O», 104.5 «C=O)2C COMe), 130.8 (Qi2=CH-
CO), 135.0 (CH2 C1I-CO), 148.3 (CHrC(COMe)-O-(C=O», 166.3 (C=O), 168.6 
(CH2=C~OMe)-O-(C=O», 186.0 (CH2=CH-CO), carbon signal assignments were 
confinned by HMBC and HMQC experiments. v~cm-J 3014, 2974 (C-H), 1769 
(C=O) 1681, 1664 (C=C). HRMS Calculated for [C9Hg0 4Nat: 230.0315, observed: 
203.0320. mp: 69-70°C 
(2E,4E,6E)-3-(4,6-dimethylocta-2,4,6-trienoyl)-4-ethoxy-5-methylenefuran-2(5H)-
one 299196 
The crude product was purified by flash column chromatography (5:1 hexane / ethyl 
acetate) to give the title compound (0.05 g, 0.18 mmol, 25%) as a viscous yellow oil. Ou 
(700 MHz, CDCI3), 1.38 (3H, t, J 7.0, CH3CH20-), 1.74 (3H, d, J 7.0, CH3CH=), 1.84 
(3H, s, CH3CH=C(CH3)CH=), 1.99 (3H, s, CH3CH=C(CH3)CH=C(CH3», 4.42 (2H, q, 
J 7.0, -OClbCH3), 5.17 (1H, d, 1.5, Clb=C(COMe)-O-(C=O», 5.25 (1H, d, 1.5, 
Clb=C(COMe)-O-(C=O», 5.69 (1H, q, J 7.0, CH3CH), 6.38 (1H, s, 
CH3CH=C(CH3)CH ), 6.73 (lH, d, J 15.0, CH3CH=C(CH3)CH=C(CH3)-CH=CH-CO), 
7.32 (1H, d, J 15.0, CH3CH=C(CH3)CH=C(CH3)-CH CH-CO), hydrogen couplings 
were confmned by a COSY experiment; Oc (175 MHz, CDCh), 12.9 
(CH3CH=C(CH3)CH=C(gI3)-CH=CH-C=O), 13.2 (Q-hCH=C(CH3)CH=C(CH3)-
CH=CH-C=O), 13.8 (-OCH2CH3), 15.2 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 
70.6 (-OCH2CH3), 95.5 (gI2=C(COMe)-O-(C=O», 104.5 «C=O)ill COMe), 122.9 
(CH3CH=C(CH3)CH=C(CH3)-CH CH-CO), 130.3 (CH3CH=C(CH3)CH=C(CH3)-
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CH=CH-C=O), 130.5 (CH3CH C(CH3)CH=C(CH3)-CH=CH-C=0), 133.0 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 148.4 (CH2 C(COEt)-O-(C=O», 145.9 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=0), 151.3 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-CO), 165.0 (COEt), 165.9 (Q 0), 185.1 (CH3CH=C(CH3)CH=C(CH3)-
CH=CH-C-O», carbon signal assignments were confmned by HMBC and HMQC 
experiments. vnuv/cm-1 2950, 2857 (C-H), 1768 (C=O) 1608 (C=C). mlz (ESJ) 311.06 
[M+Nat, 289.04 [M+Ht, 270.96, 242.90, 214.88, 172.88 HRMS Calculated for 
[C17H2004Nat: 311.1254, observed: 311.1260. 
(2E,4E,6E,8E)-3-(2,6,8-trimethyldeca-2,4,6,8-tetraenoyl)-4-ethoxy-5-methylene 
furan-2(5H)-one 305196 
The crude residue was purified by flash column chromatography (5:1 hexane / ethyl 
acetate) to give the desired product (0.07 g, 0.19 mmol, 27%) as a yellow oil. Ou (400 
MHz, CDCh), 1.34 (3H, t, J7.0, -OCH2Clh), 1.74 (3H, d, J7.0, CH3CH=), 1.83 (3H, s, 
CH3CH=C(Clh)CH=), 1.99 (3H, s, CH3CH=C(CH3)CH=C(Clh», 2.02 (3H, s, 
CH3CH=C(CH3)CH=C(CH3)CH=CH-CH=C(Clh)-(C=0», 4.14 (2H, q, J 7.0, 
-OC[bCH3), 5.13 (1H, d, J 1.0, C[b=C(COEt)-O), 5.17 (1H, d, J 1.0, Clb=C(COEt)-
0), 5.61 (1H, q, J 7.0, CH3CH ), 6.16 (1H, s, CH3CH=C(CH3)CH-), 6.55 (1H, dd, J 
15.0, 11.0, =C(CH3)CH=CH-CH=C(CH3)-(C=0», 6.67 (1H, d, J 15.0, 
=C(CH3)CH CH-CH=C(CH3)-(C=0», 7.04 (1H, d, J 11.0, =C(CH3)CH=CH-
CH C(CH3)-(C=0», hydrogen couplings were confirmed by a COSY experiment; Oc 
(175 MHz, CDCh), 11.6 (CH3CH=C(CH3)CH=C(CH3)CH=CH-CH=C(CH3)-(C=0», 
14.0 (CH3CH=C(CH3)CH=C(QH3)CH=CH-CH=C(CH3)-(C=0», 14.2 (OCH2CH3), 
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14.9 (CH3CH=C(CH3)CH=C(CH3)CH=CH-CH=C(CH3)-(C=0)), 16.6 
(CH3CH=C(Q-h)CH=C(CH3)CH=CH-CH=C(CH3)-(C=0)), 70.1 (OCH2CH3), 93.9 
((fh=C(COEt)-O-(C=O)), 104.8 (CH2-C(COMe)-0-(C=0)), 122.4 
(CH3CH=C(CH3)CH=C(CH3)CH=CH-CH=C(CH3)-(C=0)), 129.6 
(CH3CH=C(CH3)CH=C(CH3)-), 132.6 (CH3CH=C(CH3)CH-C(CH3)-), 134.0 
(CH3CH C(CH3)CH=C(CH3)-), 135.4 (CH3CH=C(CH3)CH=C(CH3)CH=CH-
CH C(CH3)-(C=0)), 142.4 (CH3CH=C(CH3)CH=C(CH3)CH=CH-CH=C(CH3)-
(C=O)), 146.9 (CH3CH=C(CH3)CH=C(CH3)CH=CH-CH=C(CH3)-(C=0)), 149.4 
«C=0)2C-COEt), 149.5 (CH3CH=C(CH3)CH-C(CH3)CH=CH-CH=C(CH3)-(C=0)), 
164.4 «C=0)2C COEt) , 166.6 (C 0), 190.6 (CH3CH=C(CH3)CH=C(CH3)CH=CH-
CH=C(CH3)-(C 0)), carbon signal assignments were confirmed by HMBC and HMQC 
experiments. vltUDl'cm-1 2921 (C-H), 1768 (C=O), 1667 (C=C). HRMS Calculated for 
[C2oH2404Nat: 351.1561, observed: 351.1573. 
(2E,4E,6E,SE)-3-(2,6,S-trimethyldeca-2,4,6,S-tetraenoyl)-4-methoxy-5-methylene 
furan-2(5H)-one 26S196 
The product was purified by flash column chromatography (5: 1 hexane / ethyl acetate) 
to give the desired product (0.05 g, 0.16 mmol, 23%) as a yellow oil. Ou (400 MHz, 
CDCh), 1.67 (3H, d, J 7.0, CH3CH=), 1.76 (3H, s, CH3CH=C(CLD)CH=), 1.92 (3H, s, 
CH3CH=C(CH3)CH=C(CLD», 1.95 (3H, s, CH3CH=C(CH3)CH=C(CH3)CH=CH-
CH=C(CLD)-(C=O), 3.85 (3H, s -OCLD), 5.08 (2H, m, Clt2=C(COMe)-O-(C=O», 5.55 
(lH, q, J7.0, CH3CH ),6.09 (lH, s, CH3CH=C(CH3)CH:.-), 6.48 (lH, dd, J 15.0, 11.0, 
=C(CH3)CH=CH-CH=C(CH3)-(C=0», 6.61 (lH, d, J 15.0, 
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CH3CH=C(CH3)CH=C(CH3)CH CH-CH=C(CH3)-(C=0)), 7.21 (1H, d, J 11.0, 
CH3CH=C(CH3)CH=C(CH3)CH=CH-CH C(CH3)-(C=0)), hydrogen couplings were 
confirmed by a COSY experiment; Oc (175 MHz, CDCh), 11.5 (=C(CH3)-
CH=CH=CH(Q-I3)-C=0), 13.9 (CH3CH=C(CH3)CH=C(Cfh)-CH=CH=CH(CH3)-
C=O), 14.1 (Q-I3CH=C(CH3)CH=C(CH3)-CH=CH=CH(CH3)-C=0), 16.4 
(CH3CH=C(Q-I3)CH=C(CH3)-CH=CH=CH(CH3)-C=0), 60.8 (-OCfb), 94.0 
(Clh=C(COMe)-O-(C=O)), 104.9 «C=OhC-COMe), 122.2 
(CH3CH=C(CH3)CH=C(CH3)CH CH=CH-C(CH3)-(C=0)), 
(CH3CH=C(CH3)CH-C(CH3)CH=CH-CH-C(CH3)-(C=0)), 
133.9 
129.5 
132.4 
CH=CH=CH(CH3)-CO), 135.3 (CH3CH=C(CH3)CH=C(CH3)CH=CH-CH C(CH3)-
(C=O)), 142.4 (CH3CH=C(CH3)CH=C(CH3)-CH=CH=CH(CH3)-CO), 146.9 
(CH3CH=C(CH3)CH=C(CH3)CH=CH CH-C(CH3)-(C=0)), 149.0 (CH2=C(COMe)-O-
(C=O)), 149.4 (CH3CH=C(CH3)CH=C(CH3)CH=CH-CH-C(CH3)-(C=0)), 165.0 
(COMe), 166.3 (Q 0), 190.3 (CH3CH=C(CH3)CH=C(CH3)CH=CH=CH-C(CH3)-
(C 0)), carbon signal assignments were confmned by HMBC and HMQC experiments. 
vmaxfom-1 2917, 2857 (C-H), 1766 (C=O) 1667 (C=C). HRMS Calculated for 
[CI9H22Na04t: 337.1416, observed: 337.1417. 
198 4-ethoxyfuran-2(5H)-one 302 
io 
/'0 
A solution oftetronic acid 256 (5.00 g, 50.0 mmol),p-toluenesulfonic acid (0.50 g, cat.) 
and ethanol (10 mL, 200 mmol) in toluene (150 mL) was heated to reflux in a flask 
equipped with a reflux condenser and Dean-Stark separator. The reaction was heated to 
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reflux for 24 hours then cooled to ambient temperature. The solvent was removed in 
vacuo and the product purified by flash column chromatography (I: 1 ethyl acetate / 
hexane) to give the title compound (5.50 g, 42.97 mmol, 86%) as an off white oil. 011 
(400 MHz, CDCh) 1.38 (3H, t, J 7.0, -OCH2C[h), 4.07 (2H, q, J 7.0, -OCli2CH3), 4.58 
(2H, s, -OCli2C(OEt», 5.03 (lH, s, C=CH-(C=O)O-), hydrogen couplings were 
confirmed by a COSY experiment; Oc (100 MHz, CDCh), 14.2 (-OCH2CH3), 68.1 
«C=O)OCH2C(OEt», 68.9 (-OCH2CH3), 88.8 (C-CH-(C=O)O-), 173.9 (Q-O), 179.6 
(QOEt), carbon signal assignments were confirmed by an HMQC experiment. vmm/cm-1 
2986 (C-H), 1772 (C=O), 1737, 1617 (C=C). mlz (ES/) 150.90 [M+Nat, 129.01 
[M+Ht, 168.84. HRMS Calculated for [C6Hs0 3t: 129.0546, observed: 129.0544. 
General method for the synthesis of 206 and 207 
To a solution oftetronate 267 or 268 (15 mg, 0.06 mmol), in ~-DMSO (0.75 J.1L) was 
added LiCI (24 mg, 0.60 mmol) and the reaction was heated at 50°C for 16 hours after 
which time a 1 H NMR spectrum confirmed the consumption of the starting material. 
Water (40 ml) was added and the solvent removed by freeze drying. The product was 
dissolved in 80:20 acetonitrile / water and purified by HPLC. 
(2E,4E,6E)-3-( 4,6-dimethylocta-2,4,6-trienoyl)-4-hydroxy-5-methyleoefurao-2(58)-
ooe 20615 
100% conversion judged by the IH NMR spectrum, 2 mg purified by HPLC (see Table 
11). Ou (700 MHz, CDC h), 1.82 (3H, d, J 7.0, C[hCH=), 1.92 (3H. s, 
CH3CH=C(CLD)CH=), 2.09 (3H, s, CH3CH=C(CH3)CH=C(CLD», 2.41 (1 H. s, -OH). 
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5.15 (1H, s, CH2=C-(O)-COH), 5.41 (1H, s, CH2=C-(O)-COH), 5.90 (1H, q, J 7.0. 
CH3CH), 6.58 (IH, s, CH3CH=C(CH3)CH), 7.04 (IH, d, J 15.5. 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 7.78 (1H, d, J 15.5 
CH3CH=C(CH3)CH=C(CH3)-CH CH-C=O), hydrogen couplings were confmned by a 
COSY experiment; Oc (175 MHz, CDCh), 13.4 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-
C=O), 13.8 (0I3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 15.6 
(CH3CH=C(0I3)CH=C(CH3)-CH=CH-C=O), 95.3 (CH2=C-(O)-COH), *carbon at 
about 104 not visable, 114.8 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 132.3 
(CH3CH=C(CH3)CH C(CH3)-CH=CH-C=O), 134.0 (CH3CH-C(CH3)CH=C(CH3)-
CH=CH-C=O), 136.0 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 150.1 (CH2-C-
(O)-COH)), 151.5 (CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), 156.2 
(CH3CH=C(CH3)CH=C(CH3)-CH=CH-C=O), *(C=O) not visible, 180.6 
assignments were confirmed by HMBC and HMQC experiments. HRMS Calculated for 
[ClSHI604t: 261.1121, observed: 261.1121. 
(2E,4E,6E,8E)-3-(2,6,8-trimethyldeca-2,4,6,8-tetraenoyl)-4-hydroxy-5-
O IS methylenefuran-2(5H)-one 2 7 
o 0 
100% conversion judged by IH NMR spectroscopy, 2 mg purified by HPLC (see Table 
11). Ou (700 MHz, CDCh), 1.77 (3H, d, J 7.0, ClhCH=C(CH3)CH=C(CH3)CH=CH-
CH=C(CH3)-C=O), 1.86 (3H, s, CH3CH=C(Clh)CH=C(CH3)CH=CH-CH=C(CH3)-
C=O), 2.03 (3H, s, CH3CH=C(CH3)CH=C(Clh)CH=CH-CH=C(CH3)-C=O), 2.07 (3H, 
s, CH3CH=C(CH3)CH=C(CH3)CH=CH-CH=C(Clh)-C=O), 5.21 (1H, br s, C/h=C(-
190 
Chapter -. Experimental 
O)-(COH», 5.45 (1H, br s, Clb=C(-O)-(COH), 5.68 (1H, q, J 7.0, 
CH3CH C(CH3)CH=C(CH3)-CH=CH-CH=C(CH3)C=0), 6.28 (1H, s, 
CH3CH=C(CH3)CH C(CH3)-CH=CH-CH=C(CH3)C=0), 6.62 (IH, dd, J 14.5, 11.5, 
CH3CH=C(CH3)CH=C(CH3)-CH=CH-CH=C(CH3)C=0), 6.89 (1H, d, J 14.5 
CH3CH=C(CH3)CH=C(CH3)-CH CH-CH=C(CH3)C=0), 8.28 (1H, br s 
H3CH=C(CH3)CH=C(CH3)-CH=CH-CH-C(CH3)C=0), O-H signal not viable on 
spectrum, hydrogen couplings were confIrmed by a COSY experiment; Oc (175 MHz, 
CDCI3), 12.1 (CH3CH=C(CH3)CH=C(CH3)CH=CH-CH=C(CH3)-C=0), 13.9 
(CH3CH=C(CH3)CH=C( CH3)CH=CH -CH=), 14.3 (CH3CH=C(CH3)CH=C( CH3)CH=), 
16.5 (CH3CH=C(CH3)CH=C(CH3)CH=), 95.5 (gh=C(-O)-(COH», *Carbon at appro x 
105 not visible, 122.7 (CH3CH=C(CH3)CH=C(CH3)CH=CH-CH=C(CH3)-C=0), 128.6 
(=C(CH3)CH=CH-CH C(CH3)-C=0), 130.4 (CH3CH=C(CH3)CH=C(CH3)CH=CH-
CH=C(CH3)-C=0), 132.6 (CH3CH=C(CH3)CH-C(CH3)CH=CH-CH=C(CH3)-C=O), 
134.0 (CH3CH C(CH3)CH=C(CH3)CH=CH-CH), 143.6 
(CH3CH=C(CH3)CH=C(CH3)CH=CH-CH=C(CH3)-C=0), 149.2 (CH2=C( -O)-(COH», 
149.3 (=C(CH3)CH=CH-CH=C(CH3)-C=0), 152.1 (=C(CH3)CH=CH-CH=), 164.8 
«C=O)-C(C O)(COH», 185.8 (CH2=C( -O)-((OH», 190.2 (-CH=CH-
CH=C(CH3)C 0), carbon signal assignments were confmned by HMBC and HMQC 
experiments. HRMS Calculated for [C19HlS04r: 299.1278, observed: 299.1280. 
Time (mins) Solvent A (H20 + 0.1 % Solvent B (Acetonitrile + 
TFA),% 0.1 % TFA), 0/0 
0 25 75 
-
15 20 80 
.- - -- - - ---- - -
20 20 
- -4 80 - - _._-----
25 0 
- -I 100 -- - ----- - ----
30 25 75 
--t----.. _.- ------------
40 25 75 
Table 11: HPLC method for purification of 206 and 207 
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Column: 100 x 21 mm, 5J-lm, Agilent Xorbax C18 column equipped with a 10 x 21 mm 
guard column 
Flow Rate: 5.0 mL / min 
Temperature: room temperature 
Detection wavelength: 210 nm 
Total run time: 40 minutes 
Retention time 20 to 21 minutes 
Biomimetic Experiments 
Biomimetic conditions 1 
A solution oftetraene 305 (5 mg, 0.02 mmol) and 267 (4 mg, 0.02 mmol) was heated to 
100°C in dry toluene (3 mL) for 72 hours. Aliquots (l00 J-ll) were taken after 24, 48 and 
72 hours and analysed by LC-MS (LC-MS conditions are shown in Table 14). No 
product was observed by LC-MS over the 72 hour period. 
Biomimetic conditions 2 
A solution of tetraene 305 (5 mg, 0.02 mmol) and triene 267 (4 mg, 0.02 mmol) was 
heated in a sealed tube at 100°C in dry toluene (3 mL) for 72 hours. After this time the 
temperature was increased to 125°C and the reaction heated for a further 15 days. 
Aliquots (100 f.1L) were taken after 1,2,3, 5, 7, 11, 14 and 18 days and analysed by LC-
MS. LC-MS conditions shown in Table 14, results shown in Table 12. 
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Timea mlz 
1 549,603,823 
2 549,603,803 
3 549,603,657,823 
5 549,603,657,823 
7 549,603,657,823 
11 549,603,657.823 
14 549,603,657,823 
18 549,603,657,823 
Table 12: Dimers observed by LC-MS in toluene 
at different time intervals from sealed tube reaction 
a:Time in days 
Biomimetic conditions 3 
A solution oftetraene 305 or 268 (5 mg, 0.02 mmol) and triene 267 (4 mg, 0.02 mmol) 
was heated in a microwave tube at 250°C in dry toluene (3 mL), nonane (3 mL), 
isopropanol (3 mL) or water/toluene (l: 1, 3 mL). Aliquots (l00 ilL) were taken after 
0.5, 1.5, 3.5 and 7.5 hours and analysed by LC-MS as shown in Table 13. LC-MS 
conditions shown in Table 14. 
Solvent Timec mJz Timec mlz Timec mlz Timec m/z 
Toluenea 0.5 549, 1.5 549, 3.5 549, 7.5 549, 
603 603 603,657 603, 
657 
Nonaneb 0.5 549, 1.5 549, 3.5 549, 7.5 nlao 
589, 589, 589,629 
629 629 
Iso- 0.5 n/de 1.5 n/de 3.5 nlad 7.5 nlad 
propanolb a--
Toluene/ 0.5 549, 1.5 549, 3.5 549, 7.5 nla 
water 589, 589, 589,629 
mixb 629 629 
Table 13: Dimers observed by LC-MS in various solvents at different time intervals in microwave 
a:Uses ethyl protected tetraene 305 and methyl protected triene 267.b Uses methyl protected tetraene 268 
and methyl protected triene 267. Ctime in hours. d not attempted; enJd none detected, 
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Time (mins) Solvent A (H20 + 0.10/0 Solvent B (Acetonitrile + 
TFA), % 0.1 % TF A), 0/0 
0 20 i 80 
---+--- --~ -------
5 20 80 
--
20 5 I 95 I 
. .1- ------
40 5 I 95 I 
_. -
55 0 100 
--
60 0 100 
---
62 20 80 
Table 14: LC-MS method for analysis ofbiomimetic experiments 
Column: 4.6x 150 mm Agilent Xorbax C8 column 
Flow Rate: 1.0 mL / min 
Temperature: room temperature 
Detection wavelength: 210 nm 
Total run time: 75 minutes 
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